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Abstract
In atherosclerosis disease, macrophages present intra-plaque antigens in the form of 
peptides on major histocompatibility (MHC) class II molecules to T lymphocytes. 
Macrophages stimulated by low density lipoprotein (LDL) may present differential 
peptide profiles on MHC complex molecules resulting in an altered immune response. 
The main aim of this study was to stimulate macrophages with LDL in vitro, to induce 
expression of novel patterns of MHC-associated peptides to be subsequently 
identified by LC-MS analysis. Then, to complete the study, the aim was to elucidate 
the affect of these identified peptides on macrophage function. To achieve this, J774.2 
mouse macrophages were treated with human native and oxidized LDL. Peptides 
were extracted from macrophage MHC complexes using citrate-phosphate buffer (pH 
3, 4 and 5). Samples were fractionated and then analyzed by LC/MS/MS. MASCOT 
analysis, lEDB and NetMHCII I.O bioinformatics platforms were used to predict 
peptide-binding affinity to MHC complexes. We also aimed to evaluate the effect of 
novel identified peptides (Pep4 & Pep5) on macrophages and ox-LDL functions using 
flow cytometry analysis. In addition, the metabolite profiles derived from 
macrophage pre-treated with ox-LDL and n-LDL were assessed. Results showed that 
135 peptides from 100 proteins with 27 overlapping proteins and 40 overlapping 
peptides among the different groups were identified. Based on predictive MHC 
binding analysis algorithms, 22 of these peptides were found to be MHC class I 
peptides and 24 were MHC class II peptides. Importantly, 66.1% of these peptides 
had high promiscuity values. Flow cytometry analysis showed a clear inhibition in 
the expression of TLR-2, TLR-4 and CD 14 by macrophages pre-treated with ox-LDL 
and then with Pep3, Pep4 and Pep5. Moreover, different metabolite profiles were 
induced by each condition, and different types of triglyceride were identified in ox- 
LDL which were missing in n-LDL conditions. These findings may contribute to 
future identification of disease-associated markers and may also facilitate the potential 
development of therapeutic tools to treat atherosclerosis.
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Chapter 1 ; General Introduction
1. General Introduction
1.1 Cardiovascular disease and atherosclerosis
The term heart disease is a broad term used to describe a variety of different 
diseases affecting the heart. Cardiovascular disease (CVD) refers to diseases that 
involve the heart or blood vessels (arteries and veins). Problems that occur inside the 
heart muscle, within arteries delivering blood to the heart muscle, or in valves within 
the heart that pump blood in the correct direction are responsible for angina (chest 
pain), heart attack, and heart failure (Stanner; 2005). The ability to distinguish 
between these sub-diseases provides an opportunity to explain the mystery of the term 
heart disease (Kumar and Clark, 2002).
Coronary heart disease (CHD), otherwise known as coronary artery disease 
(CAD), is a condition where the walls of the arteries supplying blood to the heart 
muscle become thickened and narrow due to the buildup of a waxy fatty substance 
called plaque. This muscle thickening and vessel narrowing known as atherosclerosis, 
is an inflammatory process, which gained its name from the lipid rich material 
(atheroma) and connective tissue (sclerosis) involved (Ross, 1999).
Atherosclerosis is the most common type of heart disease that causes death in 
both genders all over the world. The buildups of intracoronary thrombus in patients 
with atherosclerosis cause an important symptom known as angina (Hallenbeck et al, 
2005). Certain sites in the arteries known as ‘sites of predilection’ are known to be 
more prone to the development of atherosclerotic plaques (Feldman et al, 1984; 
Stary, 1987) than others. The carotid bifurcations, coronary arteries and vessels 
supplying the lower extremities have the greatest risk of developing atherogenesis, 
and within these areas, branches and curvatures are at the highest risk of developing 
atherosclerotic lesions (Cornhill et al, 1985, Hallenbeck et al, 2006; Libby, 2002). 
The reason for these differences is that the local haemodynamic environment differs 
from location to location in the blood vessel (Yamamoto et al 1996; Friedman et al, 
1993; Nguyen and Haque, 1990).
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Plaques cause a reduction of blood flow and result in inadequate oxygen 
delivery to the heart muscle. This limited blood and oxygen flow can cause angina 
and lead to a heart attack. The imbalance between oxygen supply and other necessary 
myocardial nutrients leads to myocardial ischemia (Kumar and Clark, 2002; 
Hallenbeck et ah, 2005) and the initiation of CVD is linked to the presence and rate of 
some risk factors, which are discussed below.
1.2 Risk factors in CHD
The term ‘risk factor’ is widely used to describe those characteristics found in 
individuals who have been shown in observational epidemiological metabolic and 
genetics studies, to be linked to the subsequent incidence of CHD (Lindsay and Gaw,
2004). There are many risk factors that contribute to the development of 
atherosclerosis. High blood pressure (> 140/90 mmHg) and low levels of high density 
lipoprotein (HDL) in combination with high levels of low density lipoprotein (LDL) 
are considered crucial factors in the development of atherosclerosis (Bryan and Silvia, 
2003; He and Whelton, 1999). Other important factors include age, previous family 
history of CHD, lack of physical activity, smoking and gender. Until recently, it was 
believed that men were more susceptible to develop complications of the disease 
compared tofemales. This assumption was attributed to the protective role of 
estrogens in women (Glass and Witztum, 2001). However, a recent set of guidelines 
published by the European Society of Cardiology shows that women may have the 
same, or even higher, risk levels as men (Graham et al, 2007).
Unhealthy habits such as a lack of exercise, smoking and a diet high in 
cholesterol and other fats accelerate the deposit of fat and calcium within the inner 
lining of coronary arteries. This process leads to hardening of the arteries and results 
in the formation of lesions and then the plaque. The plaque is composed of fat-filled 
macrophages locally located within the arterial intima, which cause narrowing of the 
blood vessel and results in restricted blood flow (Virmani et al, 2000).
1.3 Atherosclerosis and inflammation
Atherosclerosis is a pathological process affecting large and medium sized arteries, 
and is the main underlying cause of CVD. The term arteriosclerosis was first coined 
by Jean Lobstein in 1829 and recent investigations have suggested that atherosclerosis
is an inflammatory disease (Galkina and Ley, 2009). Atherosclerosis is now defined 
as a chronic inflammatory disease with a strong immunological involvement (Sherer 
and Shoenfeld, 2006; Hansson and Libby, 2006). The first description of 
atherosclerosis as a disease was given by Ross and Glomset in 1973 (Ross and 
Glomset, 1973; Ross and Marker, 1976). They proposed that in human arteries there 
are four stages in the development of the atherosclerotic plaque. These stages have 
been identified as: endothelial injury, relocation of LDL across the endothelial layer 
into the intima and modified intima, an inflammatory response and finally, the 
formation of a fibrous cap (Ross, 1995). The plaque develops via a close interaction 
between inflammatory cells within the arterial wall and molecular components 
derived from the serum that cause the growth of complex lesions, which extend 
beyond the arterial lumen (Libby, 2008; Glass and Witztum, 2001).
As fatty deposits accumulate and the inflammatory process progresses, the 
elasticity of the blood vessels decreases and the plaques become prone to rupture. 
When rupture occurs luminal clots (thrombus) arise that may partially or totally block 
the artery (Libby and Theroux, 2005; Hallenbeck et ah, 2005; Lucas and Greavas, 
2001; Mayr et al, 2004). Thrombus formation leads to acute ischemia and angina, 
which are the most common clinical symptoms associated with ischemic heart disease 
(Hallenbeck et al, 2005; Libby, 2008). The consequences of atherosclerosis are many 
and include kidney damage, CHD and stroke caused by decreased blood circulation to 
the brain.
1.4 Atherosclerosis and immunity
Atherosclerosis is an inflammatory disease in which the immune system plays 
a critical role (Galkina and Ley, 2009). Atherosclerotic plaques contain different types 
of immune cells such as macrophages, lymphocytes, monocytes and dendritic cells, 
and other extracellular matrix components implicated in plaque formation (Hansson, 
2001; Hansson and Libby, 2006). Other cell types and molecules involved include 
endothelial cells (ECs) and smooth muscle cells (SMCs), heat shock proteins (HSP 
60/65), oxidised low density lipoprotein (ox-LDL) and collagen (Ohashi et a l, 2004). 
Lymphocytes and monocytes are important because they are present within 
atherosclerotic lesions at all stages of the disease (Hansson, 2001; Nilsson and 
Hansson, 2008). Monocytes and macrophages are among the most important cell 
types as they participate in the maturation of atherosclerotic plaques by directly
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contributing to lipid accumulation and plaque growth (Thusen et ah, 2003). 
Monocytes and macrophages are able to stimulate an immune response without 
antigenic specificity and secrete different signals to generate stimulated T cells in 
damaged tissue (Boyle, 2005). The co-localization stage of these cells to the artery 
wall is the initial step of plaque development, SMC proliferation and fibrous cap 
formation (Libby, 2002). Macrophage colony-stimulating factor (M-CSF), is 
expressed in atherosclerotic plaques and mediates the transformation and proliferation 
of monocytes into macrophages as well as causing the over-expression of scavenger 
receptors leading to the engulfment of modified lipoproteins (Libby, 2006; Glass and 
Witztum., 2001). Importantly, several inflammatory mediators such as IL-1, IL-6, IL- 
8, P- and E-selectins, ICAM-1 and VCAM-1, are implicated in atherosclerosis 
development via macrophages (Glass and Witztum, 2001). In addition, macrophages 
are largely controlled by ATP binding cassette protein A1 (ABCAl), which mediates 
the formation of HDL by regulating the efflux of cholesterol to form apolipoproteins 
Macrophages are remarkable and versatile cells, with various associated effector 
functions that implicate them in several features of atherosclerosis including lipid 
phagocytosis, plaque repair and plaque ruptures.
It is known that a diet rich in cholesterol can trigger the formation of a special 
subset of macrophages within the arterial wall, known as foam cells which are the 
hallmark of early atherosclerotic lesions (Ross, 1993; Hansson et al, 2002; Glass and 
Witztum, 2001). In plaque formation, LDL migrates from the blood into the 
endothelial cells of the artery and is then modified to ox-LDL. Biologically active 
lipids are released that activate and influence endothelial cells to induce adhesion 
molecules such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular 
adhesion molecule-1 (ICAM-1). Monocytes then adhere to endothelial cells via trans- 
endothelial migration into the vessel wall (Figure 1.2a) (Wick et al, 2004; Glass and 
Witztum, 2001). The continuing entry of monocytes and the replication of monocyte 
and macrophage cells in lesions depends, in part, on factors including macrophage 
colony-stimulating factor (MCSF) and granulocyte-macrophage colony-stimulating 
factor (G-MCSF) for monocytes and interleukin-2 (IL-2) for lymphocytes (Kharbanda 
and MacAllister, 2005). Monocyte-derived macrophages occur in tissues under the 
endothelial monolayer, and macrophages start to accumulate ox-LDL particles via 
scavenger receptors (i.e. SR-A and CD36) to form foam cells. This stage of the 
process results in the formation of a simple fatty streak (Figure 1.1a).
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The second step in the process involves the formation o f more complex lesions 
and starts by the migration o f SMCs from the medial to the intima o f the artery wall 
(Figure 1.1b). SMCs cooperate with macrophage cells to form more foam cells by 
accumulating ox-LDL particles leading to the development o f the fibrous cap around 
the foam cells. Moreover, the communication and interaction between monocytes, 
macrophages and T cells causes a huge affect on the immune system that also triggers 
inflammatory responses (Glass and Witztum, 2001; Kharbanda and MacAllister, 
2005). It appears that the T cells in the atherosclerotic lesions are able to be activated 
and induce both T hl and Th2 cytokines (i.e. IL-2, IL-4 and IL-13) at the same time 
(Glass and Witztum, 2001; Hansson and Libby, 2006). All o f these cells that are 
involved in lesion formation are able to induce MHC class 11 molecules and 
inflammatory cytokines, when in the activated state (Hansson, 2001; Glass and 
Witztum, 2001).
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Figure 1.1a: The first step in the formation of the fatty streak The migration of LDL 
particles and monocyte cells from the blood stream into the artery wall causes a modification 
for both species. Monocytes differentiate into macrophage cells under the endothelial cell 
monolayer and LDL is modified to ox-LDL. Monocyte/macrophage cells engulf ox-LDL via 
scavenger receptors (SR-A, B and CD36) and are transformed in to foam cells containing lipid 
droplets.
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Figure 1.1b: Formation of the fibrous cap.Conversion of the fatty streak to the more fibrous 
lesion involves the migration of smooth muscle cells (SMGs) from the media into the intima. 
The fibrous cap covers a mixture of foam cells, lipid and debris which may form a necrotic 
core during the rupture stage.
1.5 Cells and factors implicated in the development o f atherosclerosis
1.5.1 T cells
T cells are lymphocytes that defend the body against virus-infected cells, 
cancer cells, parasites, and single-cell fungi. T-cells are unable to recognize antigens 
independently, unless the antigen is presented by a special type o f cell called an 
antigen presenting cell (APC), and these include macrophages and dendritic cells 
(Thomas and Lipsky, 1996; Taams et a l, 2005).
The term ‘T ’ in T cells arises from the word thymus, which is the gland in 
which they grow and mature (Wood, 2006; Nairn and Helbert, 2002). Generally, only 
2% o f T cells will survive and become mature T cells (Maddox and Schwartz, 2002; 
Abbas and Lichtman, 2004). T cells can be distinguished from the other lymphocytes 
including B cells and natural killer (NK) cells by the existence o f a special receptor on 
their surface, which is called the T-cell receptor (TCR). TCRs include the cluster o f 
differentiation (CD) glycoproteins CD3, CD4 and CDS (Abbas and Lichtman, 2004; 
Kuby, 1997; Nairn and Helbert, 2002). CD4^ T cells are known as T-helper (Th) cells, 
which upon antigen recognition secrete cytokines that modulate immune responses 
(Maddox and Schwartz, 2002; Gotsman et a l, 2008). Th cells can be classified in to 
two different functional groups: Thl cells are characterised by the secretion o f
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interferon gamma (IFN)-y and interleukin 2 (IL)-2, while Th2 cells secrete IL-4, IL-5, 
IL-10 and IL-13. Thl cells have been classified as pro-inflammatory and pro- 
atherosclerotic due to the effects observed in human and animal models of 
atherosclerosis, whereas Th2 cells are known as anti-inflammatory and athero- 
protective (Gotsman et al, 2008; Neurath et al, 2002). CD4^ T cells can recognise 
atherogenic antigens presented by MHC class II molecules on the surface of APCs. 
Some of these antigens include apoliprotein (apo) B-lOO and microbial antigens 
(Nordin et al, 2005, Ross, 1993). These antigens are ultimately responsible for 
driving the balance between athero-protective and atherogenic cytokines.
This balance may be also controlled by a special type of T cell named a 
regulatory T cell (T r) . The main function of Tr  cells is to inhibit effector T cell- 
mediated reactions and re-establish homeostasis once the antigenic stimuli is 
eliminated (Oufella et al, 2006; Stephens et al, 2007). T r cells also contribute to 
maintaining the immunological tolerance against self antigens (Oufella et al, 2006, 
Stephens et al, 2007).
Finally, T cells play an important role in atherosclerosis. Naïve T cells bind 
cell-surface adhesion molecules expressed by endothelial cells at the artery wall and 
then enter the plaque (Glass and Witztum, 2001). Within the plaque, macrophages 
express MHC class II molecules that may present antigen to these T cells causing 
further activation. Macrophages internalize ox-LDL particles by the scavenger 
receptor pathway. Ox-LDL fragments (the protein components of LDL and apo-B) 
presented in peptide forms are then displayed by MHC class II molecules to CD4^ T 
cells. This interaction between T cells and macrophages induces the production of IL- 
18, IL-12, IFNy and TNF and induces expression of CD40 ligand, which together 
stimulate foam cells and fibrous cap formation and SMC migration. The interface of 
CD40 and CD40 ligand (CD40L) between T cells and macrophages, SMCs, vascular 
endothelial cells or platelets, proliferates inflammatory activation in all the main cell 
types involved in atherogenesis (Glass and Witztum, 2001; Baidya and Zeng, 2005).
1.5.2 Dendritic cells
Dendritic cells (DCs) are immune cells that play a central role in the immune 
system. They were first described in 1973 by Steinman and Cohn as a novel myeloid 
cell type (Steinman and Cohn, 1973). DCs are low density cells that can be obtained 
from murine spleens and are easily distinguished from macrophages (Steinman and
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Cohn, 1973; McKenna et al, 2005). They represent around 1% of total spleen cells 
and were considered to derive from the thymus, independently from bone marrow 
derived cells. It has been reported that DCs are one of the most potent APCs (Thomas 
and Lipsky, 1996; Male et al, 2006), which is mediated by mannose receptors on 
their surface (on the clathrin coated region) that are able to internalize antigens (Tan 
et al, 1997; Engering et al, 1997; McKenna et al, 2005).
DCs exist as four different types: lymphoid, myeloid, plasmacytoid and 
follicularlmmediately upon activation, DCs migrate to lymphoid tissues where they 
cooperate with B and T cells and start the immune response (Galkina and Ley, 2009). 
Several markers have been identified as positive differentiation markers for human 
DCs. The mature DCs, called APCs, express different types of markers with each 
marker indicating a different differentiation stage. CD llc and CD45RO are the 
earliest-stage markers, with CMRF-44 and CD86 being expressed at the final stages 
of differentiation (Thomas and Lipsky, 1996; O'Doherty et al, 1994). More recently, 
additional DC surface markers have been identified including Mac-1, Pgp-1 (CD44), 
LFA-1, BDCA-2 and BDCA-4 (Dzionek et al., 2002; Ardavin and Shortman, 2005), 
which may also indicate cell maturity.
The function of DCs in humans is thought to be slightly different from that in 
other species including mice and rats (Auffray et al, 2009; Reid et al, 1992). 
Differences between mouse and human DCs were noticed when their precursor cells 
(monocytes) were compared. In the mouse, monocytes account for 4% of leukocytes 
and the cells do not express CDllc or MHC class 11 antigen on their surface. In 
contrast, in humans, 10% of leukocytes are monocytes and the cells are able to 
express both CDllc and MHC class 11 antigen (Auffray et al, 2009). In the 
experimental arena, differences between rodent and human DCs appeared when 
isolated mouse CD8  ^DCs and human DCs (DC2 cells: lymphocyte system dendritic 
cell) were compared. In humans, the DC2 population is normally generated from a 
culture system while in mice, DC2 is presented from freshly isolated CD8+ DCs, and 
DCl (myeloid system dendritic cells) generated in vivo (Shortman and Liu, 2002).
In addition, different surface phenotype markers are induced by human and 
mouse DCs (e.g. CD86, CD40, CD4 and MHC class 11) when interferon used in 
culture to generate a plasmacytoid dendritic cell population. Following interferon 
stimulation, mouse dendritic cells obtain CDl Ic^ CD45RA^°^ MHC 11^ ' and CD4'°^ 
CD8+ markers, while human DCs obtain CDl lc+ CD45RA'“"' MHC 11^ ' and CD4'™
CDS' markers. On the other hand, freshly isolated human and mouse thymus 
populations showed no differences in response to interferon (Vandenabeele et al, 
2001). Depending on the surface antigen markers expressed, DCs are heterogeneous 
in humans and mice, which may indicate a different function in the antigen 
presentation process.
1.5.2.1 Dendritic cells and atherosclerosis
Within non-diseased arteries, a small number of DCs mainly restricted to a 
small area of endothelium in the subendothelial layer are present in the intima 
(Bobryshev and Lord, 1995; Bobryshev et al, 1997; Auffray et al, 2009). The 
healthy arterial intima contains a special subtype of the DC family presenting a unique 
ultrastructural feature. In addition, vascular DCs form focal networks in some intimai 
areas during their processes (Millonig et al, 2001). It has been demonstrated that in 
the normal intima, DCs are a main component of the so-called vascular-associated 
lymphoid tissue (VALT), which is composed of a collection of vascular DCs, T cells, 
and resident macrophages and is spread in the subendothelial layer (Waltner-Romen 
et al, 1998; Galkina and Ley, 2009).
Moreover, several studies have measured the numbers of vascular DCs in the 
intima of atherosclerosis-prone and atherosclerosis-resistant areas of the non-diseased 
aorta. They found that more DCs were found in the atherosclerosis-prone areas than in 
the atherosclerosis-resistant areas (Lord and Bobryshev, 1999). Vascular DCs residing 
in the intima become activated in the early phases of atherosclerosis. These DCs are 
initially resident in the vascular tissue but atherosclerotic plaques might also be 
populated by blood-derived DCs or by monocytes that infiltrate the intima during the 
early stages of atherosclerosis, leading to an increased DC population within the 
vessel wall (Ross, 1999; Ross, 1993; Nilsson and Hansson, 2008). Histopathological 
studies of human arterial tissue confirmed that only some DCs relocate to the lymph 
nodes while other DCs may activate T cells directly in the intima (Auffray et al, 
2009). DCs cluster with T cells and express lCAM-1, VCAM-1 and CD40. Some DCs 
express CD83, which is a marker of DC activation (Bobryshev and Lord, 1998). 
Within atherosclerotic lesions DCs express high levels of MHC class 11 molecules and 
also CDl molecules on their surfaces. CDl molecules are another group of antigen- 
presenting molecules similar to the classical MHC class 1 and 11 molecules 
(Bobryshev and Lord, 2002; Bobryshev and Lord, 2000). The CDl molecule is
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responsible for lipid and glycolipid (non-peptide) antigen presentation to NK and T 
cells (Brigl and Brenner, 2004). So though the role of CDl is similar to MHC class 1 
and 11 molecules, the antigen presentation route is different. Although CDl molecules 
are structurally similar to MHC class 1 molecules, they behave like MHC class 11 
molecules, using the endosome-lysosomal pathway (Moody and Porcelli, 2003; Brigl 
and Brenner, 2004). DC-T cell clusters have also been observed in rupture-prone 
regions making contact with NKT cells (Bobryshev and Lord, 1998; Nilsson and 
Hansson, 2008). Formation of such DC-T cell clusters is associated with plaque 
destabilization (Yilmaz et al, 2004; Bobryshev and Lord, 2005).
1.5.3 Mast cells and basophiles
Mast cells can be defined as bone marrow-derived cells present in a variety of 
tissues (Abbas and Lichtman, 2004; Male et al, 2006). Two types of mast cells have 
been discovered: mucosal mast cells and connective tissue mast cells. Mast cells 
appear to be key players in the initiation of the inflammatory response. Under 
inflammatory conditions, mast cells are able to present higher levels of high affinity 
IgE receptor (FcsRI), CD40L and Th2-type cytokines, IL-4 and IL-13 (Abbas and 
Lichtman, 2004 Wood, 2006). Basophils and mast cells are able to release basic 
inflammatory mediators, such as histamine, heparin, proteolytic enzymes and 
different types of cytokines (IL-4, IL-5, IL-6 and Tumor necrosis factor (TNF-a) 
(Galkina and Ley, 2009). The increased number of basophils and mast cells at sites of 
inflammation results in accelerated elimination of the cause of tissue injury that may 
have lead to a chronic inflammatory response. Because of their role in the 
inflammatory response, mast cells play a critical role in the development of 
atherosclerosis lesions (Hansson, 2002).
1.5.4 Endothelial and Smooth muscle cells (SMC)
Endothelial cells (ECs) are found throughout the whole circulatory system 
including in the chambers of the heart, blood vessels and lymphatics. ECs appear as a 
permanent and constant monolayer on a basement membrane called the endothelium 
(Ross, 1993; Severs and Robenek, 1992). Endothelial cells play a crucial role in the 
development of atherosclerotic disease. Atherosclerosis occurs as a result of lipid
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accumulation in the vessel wall, the initiation of an inflammatory response, SMC 
proliferation and endothelial dysfunction.
Endothelial dysfunction has been implicated in atherosclerosis and the 
precipitation of acute ischaemia (Kharbanda and MacAllister, 2005). The damage of 
endothelial cells affects the cell-surface expression of molecules including VCAM-1 
and ICAM-1 (Falk, 2006). Subsequently, mononuclear cells transmigrate into the 
vessel wall across the endothelium as a result of endothelial injury and activation 
(Kharbanda and MacAllister, 2005). This injury leads to the formation of thrombin 
and the expression of selectins, which promote thrombosis, leukocyte infiltration, 
inflammation and vascular fibrosis (Endemann and Schiffrin, 2004; Caramori and 
Zago, 2000).
Within the vascular system, connective tissue cells that form a coating around 
the endothelial tube are called smooth muscle cells (SMCs). SMCs are mainly found 
in the tunica media of arteries and in the adventitia of larger veins. They are slender, 
spindle shaped cells and their size varies depending on their position in the body 
(Faller and Schuenke, 2004). The proliferation and migration of SMCs plays an 
important role in the development of atherosclerotic plaques (Ross, 1993, Glass and 
Witztum, 2001; Hallenbeck et al, 2006). SMCs can induce the expression of effective 
leukocyte chemo-attractants, including monocyte chemotactic protein-1 (MCP-1) and 
IL-8 . At the same time, they are capable of inducing the secretion of pro- 
inflammatory cytokines such as TNF-a and IL-1, which activate endothelial cells to 
induce adhesion molecules and leukocyte chemo-attractants (Rainger and Nash, 
2001).
1.6 Monocytes and macrophages
Monocytes are members of the leukocyte family and have a diameter of 12 -20 
pm. Monocytes protect the body against pathogens and move quickly to sites of 
infection. They originate from stem cells called monoblasts in the bone marrow and 
circulate in the bloodstream for several days before naturally moving into tissues. 
When monocytes mature and migrate from the bloodstream to the tissues they 
differentiate into macrophages (Severs and Robenek, 1992, Abbas et al, 2007).
Macrophages are responsible for protecting tissues from foreign substances, 
and are long lived cells found concentrated in the liver and lung tissues. Macrophages 
are one of the most important APCs (Purcell and Gorman, 2004; Shashkin et al,
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2005) and play a major role in triggering atherosclerosis at the first step of plaque 
formation (Taams et al, 2005).
Monocytes adhere to endothelial cells and transendothelial migration follows. 
This relocation triggers the differentiation of monocytes into macrophages. These 
macrophages ingest lipid (ox-LDL) and become laden with fat and turn into foam 
cells, which are the hallmark of early atherosclerotic lesions (Glass and Witztum, 
2001; Li and Glass, 2002). Following this activation, macrophages start to produce 
and secrete a variety of cytokines including IL-1 and TNF, proteolytic enzymes (i.e. 
MMPs), and reactive oxygen intermediates (Auger and Ross, 1992). These cytokines 
trigger SMCs to migrate into the intima to form the fibrous cap surrounding foam 
cells.
1.6.1 M acrophage cells
Macrophages can be divided into two groups: normal and inflammatory 
macrophages. Though they all share the same function, normal macrophages can be 
further divided depending on their location within the body (Table 1.1) (Abbas and 
Lichtman, 2004; Kruth, 2001). Macrophages are found widely distributed all over the 
body and they participate in the immune responses, via adaptive immunity through 
antigen presentation and lL-1 production and via non specific immunity (innate 
immunity) against bacterial, viral, and fungal infections (Abbas et al, 2007; Wood,
2004).
Table 1.1. The classification o f macrophages. Ten different types of macrophages 
presented in ten different areas of the human body (Abbas etal., 2007; Kruth, 2001).
Location M acrophage name
Liver kupffer's cells
Spleen Free and fixed macrophages (lining cells)
Bone marrow Fixed macrophages (osteoclasts)
Lung Alveolar macrophages
Kidney Mesangial cells
Skin Langerhans's cell
Lymph nodes Free and fixed macrophages
Neural tissue Microglial cells
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1.6.2 M acrophages as antigen presenting cells
Antigen presenting cells (APCs) are specialized cells that are produced to give 
a snapshot of the protein environment which is later presented through specialized 
molecules (MHC complex) to T cells (Nilsson and Hansson, 2008). During infection, 
macrophages are able to take up foreign antigens by phagocytosis while triggering T 
cell immunity by the release of pro-inflammatory cytokines (IFN-y and IL-6) 
(Kropshofer and Vogt, 2005). These inflammatory cytokines are frequently presented 
at infected sites and stimulate macrophages, thus improving their capacity to function 
as APCs. DCs, macrophages and B cells are known as professional APCs due to their 
capacity to present antigens. The uptake of antigen by DCs and macrophagesutilizes 
phagocytosis, pinocytosis and receptor-mediated uptake mechanisms, while B cells 
depend on receptor-mediated endocytosis to internalize antigen (Chaperot et al, 2000; 
Burgdorf et al, 2007). Pinocytosis is a cytoskeleton-dependent type of fluid-phase 
endocytosis and is limited to DCs and macrophages (Burgdorf et al, 2007). In DCs, 
pinocytosis is important in their maturation, while in macrophages it can be induced 
by cytokines and growth factors.
Phagocytosis is a crucial mechanism for both the host’s defense against 
microbial pathogens and the clearance of apoptotic or necrotic cells (Hansson et al, 
2002). APCs are able to phagocytose bacteria, yeast cells or cell debris. Phagocytosis 
of apoptotic bodies mainly relies on a surface complex composed of the scavenger 
receptor CD36 (Taylor et al, 2005; Nilsson and Hansson, 2008). Both microbes and 
apoptotic cells are transported to the cell surface of macrophages or DCs in 
phagosomes and finally to lysosomes for degradation.
1.6.3 Co-stimulatory molecules and antigen presenting cells
All APCs serve to stimulate T cells at different points in the immune system. 
These cells present co-stimulatory signals through B7.1 and B7.2 (CD80 and CD86  
respectively) molecules (Kropshofer and Vogt, 2005) (Figure 1.2). Two different 
signals are involved in the activation of T cells. The first signal occurs when a T cell 
binds to the epitope via T cell-receptors (TCRs), and the second signal is received 
from APCs and is called the co-stimulation signal (Abbas et al, 2007). The binding of 
CD28 to B7 provides the actual signal required to stimulate the T cell (Nilsson and 
Hansson, 2008). With regards to atherosclerosis, these molecules (B7.1, B7.2 and 
CD28) are found near areas densely populated with macrophages with higher amounts
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in the superficial layers of fibrous cap than in the lipid core (Boer et ai, 1997). This 
finding illustrates a complete picture of antigen presentation by macrophage cells and 
the activation of T cells in atherosclerotic plaques via these co-stimulation molecules.
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Figure 1.2: Co-stimulatory m olecules and APCs. B7.1 and B7.2 (CD80 and CD86) 
molecules are normally expressed by APCs such as B cells, DCs and macrophages. Their 
ligand is CD28 and is usually expressed by T cells. T cells require signal one (MHC class I or 
II) and signal two (co-stimulatory molecules) for full and complete activation in the immune 
system.
1.6.4 Scavenger receptors
The transformation of macrophages to foam cells, that contain substantial 
amounts of cholesterol esters, is a hallmark of both early and late atherosclerotic 
lesions. The uptake and conversion of fully oxidized LDL are mediated by a relatively 
large family of receptors called scavenger receptors. These scavenger receptors are 
pattern recognition receptor proteins play a significant role in host defense and also 
mediate the uptake of a wide variety of bacteria, cellular breakdown products and 
other harmful molecules such as ox-LDL (Abbas et al, 2007). Scavenger receptors 
were first discovered as ‘cell surface proteins capable of binding and internalizing 
modified lipoproteins’ (Rigotti, 2000). Macrophages express several different types of 
scavenger receptors that can contribute to foam cell formation in atherosclerosis 
(Taylor g/rz/., 2005; Shashkin etal, 2005).
Different types of macrophage scavenger receptors have been discovered in 
humans and mice (Table 1.2). These include the class A scavenger receptors (SR-AI, 
SR-AII, SR-AIII), class B scavenger receptors (CLA-l/SR-Bl, SR-BII, CD36), and 
the class D receptor CD68 (Figure 1.3). More recently, other new members of the SR 
family have been identified including Lectin-Like Ox-LDL Receptor-1 (LOX-1) in 
class E, SREC-I, and SREC-II in class F and SR-PSOX (known as CXCL16) in class 
G (Figure 1.3) (Taylor et ai, 2005; Matsuura and Lopez, 2008). Most of these types.
14
such as SR-AI and II, LOX-1 and CD36 are thought to be implicated during the 
uptake of modified LDL and the formation of foam cells within atherosclerotic lesions 
(Matsuura and Lopez, 2008; Moore and Freeman, 2006).
Table 1.2. The classification o f macrophage scavenger receptors. Scavenger receptors 
are classified depending on their structure and functions 
hhttoV/users.oath.ox.ac.uk/-areaves/index.htmh. (Greaves, 2005)).
Scavenger Receptor Type Funetion Reference
Murine and Fluman 
SR-AI/II
A
Expressed by foam cells in 
atherosclerotic lesions, binds 
acetylated and ox-LDL
(Gough et at., 199; Villiers et 
at., 1998)
Murine and Human 
CD36
B
Binds ox-LDL, expressed by foam 
cells in atherosclerotic lesions
(Pearce et at., 1998; Boullier 
et al., 2000; Huszar et al, 
2 0 0 0 )
Mouse SR-Bl B
Mediates reverse cholesterol 
transport
(Krieger, 1999)
Murine and Human 
CD6 8
D
Binds to ox-LDL on macrophages 
(i.e. in atherosclerosis plaques)
(Villiers e? a/., 1998; 
Ramprasad e? a/., 1995)
Human LOX-1 E
Binds ox-LDL, expressed by 
endothelial cells and macrophages
(Matsuura and Lopez, 2008; 
Taylor et al, 2005)
A structurally related molecule expressed by murine macrophages is called 
MARCO (MAcrophage Receptor with COllagenous structure). MARCO shows the 
same overall domain structure as the SR-A type I receptor but with some functional 
differences; it binds bacteria but not acetylated or ox-LDL (Moore and Freeman, 
2006; Taylor et al, 2005). Despite binding a similar range of ligands including 
modified LDLs, other macrophage scavenger receptors contain very different 
structures to SR-A and MARCO (Moore and Freeman, 2006; Hansson et al, 2002).
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Figure 1.3: The structure of scavenger receptors. All scavenger receptors are located on 
cell surface except SRA-ll I and SRD which are both located inside the cell (Moore and 
Freeman, 2006).
1.7 M ajor hisocompatability molecules (MHC)
1.7.1 Antigens and antigen presentation in atherosclerosis
1.7.2 Structure and basic function of MHC molecules
MHC class I molecules contain a heteromeric glycoprotein complex with a 
polymorphic heavy a chain and a monomeric non-covalently coupled light chain 
called p2-microglobulin (Abbas et al, 2007). The main structure of MHC class I 
molecules is represented in Figure 1.4. The a-chain contains 3 globular extracellular 
domains (al, a l and a3) and connects to the cell plasma membrane through a 
transmembrane domain that is followed by a very short cytoplasmic domain. The al 
and al extracellular domains are located on the antigen-binding cleft, which is able to 
accommodate peptides of 8 to 11 amino acids in length. The base of the antigen- 
binding cleft is made of an eight-stranded anti-parallel p-plated sheet containing the 
polymorphic residues responsible for specific antigen binding (Oviedo-Orta and 
Bermudez-Fajardo, 2008; Kropshofer and Vogt, 2005). In addition, other polymorphic 
residues are displayed in the clefts and play an important role in the recognition of this 
complex by the TCR. The a3 domain is non-polymorphic and contains the binding 
site for the TCR co-receptor molecule, CD8 (Kropshofer and Vogt, 2005) (Figure 
1.4).
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Figure 1.4: The main structure of the major histocompatibility complex m olecules 
(MHC) in the plasma membrane. Globular domains of MHC structure a l, a2, o3 and p1-P3 
are presented in different colours. The antigen (peptide) binding cleft between a l and p i in 
MHC class II molecules, and between a l and a2 in MHC class I molecules are both shown 
(Oviedo-Orta and Bermudez-Fajardo, 2008).
MHC class II complexes are mainly expressed by phagoeytic antigen- 
presenting cells sueh as macrophages, DCs and B-cells and are also heteromerie like 
MHC class I, MHC class II molecules eontain two different chains called a and p and 
eaeh of them has two extracellular globular domains called al/a2 and pl/p2 (Abbas 
and Lichtman, 2004; Oviedo-Orta and Bermudez-Fajardo, 2008) (Figure 1.4). The 
extracellular globular domains al and pi are responsible for forming the peptide 
binding eleft, whieh is comprised of polymorphic residues that have the capacity to 
accommodate peptides of 10 to 30 amino acids in length. The structure of the peptide 
binding cleft of MHC class II molecules is similar to that of MHC class I (Abbas et 
al, 2007). However, x-ray erystallography studies showed that the side ends of the 
binding cleft in MHC class II molecules are more open, and therefore can 
accommodate peptides with more amino acids than the groove in MHC class I 
molecules (Oviedo-Orta and Bermudez-Fajardo, 2008; Abbas and Lichtman, 2004). It 
has also been suggested that peptide-MHC class II binding specificity is more 
promiscuous than MHC class I interactions, which occasionally makes it more 
difficult to clearly predict the binding speeificity of certain peptides within the MHC- 
II antigen binding groove (Oviedo-Orta and Bermudez-Fajardo, 2008; Pureell and 
Gorman, 2004).
1.7.3 MHC molecules and antigen processing
1.7.3.1 MHC Class I  molecules and peptide presentation
MHC class 1 molecules typically present endogenous antigens including the 
protein produets of cytosolic replicating viruses and bacteria. Cytosolic antigens are
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processed by multi-catalytic protease complexes called proteasomes as discussed 
below. The proteasome is responsible for the generation of peptides within the 
cytoplasm (Figure 1.5). The proteosome is a large proteolytic complex that contains 
many subunits, including LMP-2 and LMP-7. LMP-2 and LMP-7 and plays a critical 
role in the generation of class I-binding peptides (Rammensee et al, 1993; Hansen 
and Bouvie, 2009).
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Figure 1.5: The antigen presentation pathway of c lass I MHC. The source of antigen can 
be derived from bacterial phagosytosis or from cytoplasm virus. Both antigens are processed 
by MHC class I molecules by the same mechanism and are presented on the cell surface. 
Cytosolic and nuclear proteins are degraded by the proteosome into peptides. This antigen 
translocates into the lumen of the endoplasmic reticulum (ER) by TAP. MHC class I 
hetrodimer is presented in the ER for a peptide to bind and then transported from the ER to 
the plasma membrane to be presented to CDS'" T cells.
Proteasome proeessing of antigens causes the formation of short peptides 
which are transferred to the endoplasmic reticulum (ER) by the transporters 
(TAP1/TAP2) associated with antigen processing (Figure 1.5). Within the ER, newly 
synthesized MHC class I molecules are folded, chaperoned and retained by tapasin 
proteins. Peptides delivered into the ER by TAP are loaded onto class I molecules, 
and these MHC class 1-peptide complexes are exported to the cell surfaee for display 
to CD8  ^ T cells (Hansen and Bouvie, 2009; Kropshofer and Vogt, 2005). Different 
proteins play crucial roles in MHC class I presentation and the bloeking process such 
as tapasin, TAP and ATP. For example, tapasin protein is a central part of the peptide- 
loading complex, it has a structural role by connecting MHC class I molecules to TAP
(Brocke et al, 2002; Hansen and Bouvie, 2009). In addition, tapasin is responsible for 
TAP stability by protecting the professional peptide transporter in the ER (Garbi et 
al, 2003; Tan et al, 2000). Scientists have demonstrated that the surface of MHC- 
I/peptide complexes was decreased by around 90% and the half-life of this complex 
was also declined in tapasin knockout mice (Garbi et al, 2000; Garbi et al, 2005).
Briefly, when the peptide is linked to TAP via the protein tapasin the MHC 
class I molecules are synthesized in the ER at the same time. Appropriate breakdown 
of the emerging chains is carried out by various ER chaperone proteins (Figure 1.5). 
The "empty" class I dimers stay attached to the TAP complex by tapasin. The peptide 
is trimmed to a suitable size after entering the ER by ER-resident aminopeptidase 
(ERAP), and is then able to bind to the MHC class I cleft (Purcell and Gorman, 2004; 
Hansen and Bouvie, 2009 ). The peptide-class I complex is then released from tapasin 
and transported to the cell surface. The MHC cleft is degraded if no peptide binds 
(Kropshofer and Vogt, 2005, Wiliams, 2005; Hansen and Bouvie, 2009).
1.7.3.2 MHC Class II molecules and peptide presentation
The majority of class Il-associated peptides are derived from protein antigens 
that are captured and internalized into endosomes by specialized APCssuch as DCs, B 
cells and macrophages. Antigen processing can start in endosomes and may increase 
upon delivery to lysosomes. Acidic proteases such as cathepsins (Cat) S, L, and F are 
able to cleave an antigen to obtain smaller peptides (Abbas et al, 2007).
The peptide in the MHC class II pathway is normally derived from the uptake 
of exogenous antigens in APCs for presentation to CD4+ T cells. MHC class II ap 
heterodimers connect with invariant chains (li) in the ER and generate (apii)] 
complexes (Figure 1.6). A MHC molecule containing (apli)3 complexes is 
translocated to the endosomal network where li is degraded by Cat S, and L or F 
(Abbas et al, 2007; Rocha and Neefjes, 2008). The type of cathepsin used for this 
step is different from cell to cell. Cat S protease is responsible for the later stages of li 
proteolysis in B cells and DCs, while in macrophage cells; Cat S and Cat L as well as 
Cat F may contribute in this process (Wood, 2006; Beers et al, 2005; Villadangos, 
2005). The degradation of invariant chains li results in 3 intermediates (Villadangos,
2005): a) LeuPeptin-induced proteins (LIP) b) Small leuPeptin-induced proteins 
(SLIP) and c) Class Il-associated invariant chain peptide (CLIP).
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Figure 1.6: The antigen presentation pathway of c lass If MHC. MHC class II is mainly 
presented on the ER and is occupied by invariant chains (li). The MHC molecule with li travels 
to the lysosome net and is degraded by Cat S and L resulting in a CLIP protein in the MHC 
groove. CLIP protein is replaced by HLA-DM in MHC class II groove and finally DM is 
replaced by mature peptide to present on the cell surface to CD4^ T cells.
The only protein of li that is implicated in MHC class II presentation is CLIP. 
CLIP binds to the peptide groove in the MHC class II cleft, which prevents the 
loading of premature peptide. The degradation of CLIP is controlled by DM (Lazarski 
et al, 2006; Wood, 2006). DM is another MHC-encoded dimer complex known as 
HLA-DM that combines class II a and (3 to release residual li fragments from the class 
II ligand binding groove (Figure 1.6). Moreover, HLA-DM prevents peptide 
aggregation and allows the MHC groove to switch peptide and then choose a high- 
affinity-binding peptide (Lazarski et al, 2006), This step allows mature peptide to 
bind to class II molecules. The peptide-class II complexes wait on the surface of 
APCs for display to CD4^ T cells (Rocha and Neefjes, 2008; Villadangos, 2005). The 
major differences between class I and II MHC molecules are shown in Table 1.3.
Table 1.3. A summary of MHC class I and II features (Abbas eta l. ,  2007).
Characteristics MHC class I MHC class II
Locations of polymorphic 
residues
al and a2 domains (Kropshofer and 
Vogt, 2005) al and fl domains (Beers et a l, 2005).
Binding site for T cell 
co-receptor
a3 region binds CDS (Kropshofer and 
Vogt, 2005)
P2 region binds CD4 (Oviedo-Orta and 
Bermudez-Fajardo, 2008).
Size of peptide-binding cleft
Accommodates peptides of 8-11 
residues (Oviedo-Orta and Bermudez- 
Fajardo, 2008).
Accommodates peptides of 10-30 
residues or more (Oviedo-Orta and 
Bermudez-Fajardo, 2008).
Peptide motifs involved in 
binding 
to MHC molecule
Anchor residues at both ends of 
peptide normally hydrophobic 
carboxyl-terminal anchor
Anchor residues distributed along the 
length of the peptide (Beers et a!., 
2005).
Nature of bound peptide
Extended structure in which both ends 
interact with MHC cleft but middle 
arches up away from MHC molecule
Extended structure that is held at a 
constant elevation above the floor of 
the MHC cleft
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1.8 Lipoproteins
Lipoproteins are macromolecules that are composed of a neutral lipid core 
(triglycerides and cholesterol ester) surrounded by a monolayer of phospholipids and 
free cholesterol and specific proteins (Figure 1.7). Lipoproteins originate primarily 
from specialized cells in the liver (Alonzi et al, 2008). The physical and chemical 
properties of plasma lipoprotein differ depending on the source of synthesis. The 
protein component of the lipoprotein consists of a mixture of apolipoproteins which 
usually contribute to their function and structural position (Glass and Witztum, 2001).
Integral apo-protein (apo- 
A or apo-B)
P hospholipids monolayer 
and cholesterol
Cholesterol es te
Triglyceride
apo-E
Peripheral apo-protein 
(apo-C and apo-E)
apo-C
Figure 1.7: The structure of lipoprotein. The core of a lipoprotein particle is full of 
triglyceride and cholesterol ester. The lipoprotein surface contains a phospholipid monolayer, 
unesterified cholesterol and apolipoproteins (i.e. apoA, apoB and apoE).
Several classes of lipoproteins have been identified. They were first classified 
according to their hydrated density, which mainly reflects their lipid to protein ratio. 
The lipoprotein classes are high-density (HDL), low-density (LDL), very low-density 
(VLDL), intermediate density (ILDL) and chylomicrons (dietary triglyceride-rich 
carriers synthesized in the intestines) (Alonzi et al, 2008). These lipoprotein classes 
contain different proteins called apolipoproteins with different physiological activities 
such as apoB-100, apoB-48, A-1 and apo-E (Table 1.4) (Krieger, 1994; Goldstein and 
Brown, 1989). The function of apolipoproteins is not only the transport of lipids but 
also the regulation of enzymes involved in lipid metabolism, and communication with 
cellular receptors that are implicated in the uptake of lipoproteins (Eckardstein et al, 
1994; Alonzi et al, 2008).
Though water is the main solvent for most chemicals in the body, some 
substances require lipid volatilization. Lipid transport within the blood occurs via a 
special system named the "lipoprotein distribution system". Lipoprotein appears to be 
the unit component which provides and presents lipids as a soluble phase within our 
blood. These tiny little molecules (lipoproteins) attack cholesterol, bonds are formed
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between the cholesterol and lipoproteins and they are carried through the blood 
(Alonzi et al, 2008; Lewis and Rader, 2005).
Table 1.4. Different types of apo-iipoprotein. The main source of each lipoprotein is shown 
(Eckardstein etal., 1994; Krieger, 1994).
Apo-lipoprotein Main source
ApoA-1 Liver and Intestine
ApoB-48 Intestine (gut)
ApoB-100 Liver
Apo-E Different tissues
1.8.1 The classification o f lipoproteins
Firstly, HDLs are small molecules that are recognized as the "good" 
cholesterol because a high level of HDL is associated with a protective effect against 
heart attack (Breslow, 1996; Barter, 2005). It is synthesised in the liver as a complex 
of lipoproteins and phospholipids and is able to distinguish cholesterol molecules and 
transmit them from body tissue to the liver (Steinberg, 1996; Alonzi et al, 2008). The 
primary apolipoproteins of HDL are apoAI and apoAII, with smaller amounts of 
apoCI, apoCH, apoCIIl, apoE and apoAIV (Tall and Small, 1978, Tall, 1990; Cohn et 
al, 2003). Moreover, HDL is believed to be involved in the recycling of cholesterol 
from extra-hepatic tissues to the liver, in a process called "reverse cholesterol 
transport" (Fielding and Fielding, 1995; Lewis and Rader, 2005). For this reason, 
HDL plays a significant role in protecting individuals from atherosclerotic disease 
(Breslow, 1996; Barter, 2005).
Secondly, LDL is a type of lipoprotein molecule that varies in size and 
contents and is also produced by the liver. It is produced from VLDL once VLDL has 
lost lots of triglycerides (TGs). The major components of LDL are apolipoproteins B- 
100 which are synthesized in the liver, Apo-B48 molecules, which are synthesized in 
the gut, and an antioxidative vitamin (vitamin E) (Eckardstein et al, 1994; Krieger, 
1994). LDL is normally considered as “bad” cholesterol since high LDL levels have 
been associated with cardiovascular disease (Havel, 1995; Alonzi et al, 2008). LDL 
is a major target of cholesterol lowering therapy. Many studies have reported that a 
high concentration of LDL in serum is the most important risk factor for CHD 
(Grundy et al, 2004).
Finally, there are other lipoprotein types which have more or less the same 
function as HDL and LDL. Chylomicron and VLDL are both rich in trigglycerides 
and function to deliver triglycerides to body cells to be used as fuel (Alonzi et al, 
2008; Glass and Witzum, 2001).
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1.8.2 LDL as a key antigen for plaque formation
In a normal situation native LDL does not stimulate immune responses 
whereas in an oxidized state, LDL can trigger inflammation causing atherosclerotic 
disease (Glass and Witztum, 2001; Libby, 2006).
LDL oxidation steps start from VLDL produced by the liver. In the plasma, 
VLDL is converted to LDL by and enzyme called Lipoprotein Lipase (LPL) that 
hydrolyzes triglycerides) (Beisiegel, 1995). LPL enzymes remove triglycerides from 
VLDL and leave a larger amount of cholesterol, thus increasing the density of the 
particle and converting it into LDL. Plasma LDL is moved across the endothelium 
and becomes trapped in the extracellular matrix of the subendothelial space where it is 
subjected to oxidative modifications to create highly oxidized LDL (ox-LDL) (Heeren 
and Beisiegel, 2001; Beisiegel, 1995). Several cellular and biochemicals mediators are 
believed to be implicated in this process including: Myeloperoxidase lipase (MPO), 
Reactive Oxygen Species (ROS) and Sphingomyelinase (SMase) (Heeren and 
Beisiegel, 2001; Deigner et al., 2110). Moreover, catalytically active copper and iron 
(e.g. Cu^  ^or Fe^ "^ ) have been found in atherosclerotic lesions, and the copper-carrying 
protein of plasma (ceruloplasmin) can catalyze LDL oxidation (Chisolm et al., 1999; 
Roland et al., 2001).
Ox-LDL is considered a neo-antigen, a term used to describe modified self 
antigens which are normally tolerated by the immune system but upon modification 
have the potential to exert auto-reactive immune responses. Ox-LDL is therefore, 
implicated in several different diseases (i.e. cancer and atherosclerosis) (Table 1.5) 
(Hansson, 2001; Glass and Witztum, 2001). Several mechanisms are implicated in 
LDL modification including enzymatic degradation, aggregation and oxidation 
(Alonzi et al, 2008), resulting in the induction of pro-inflammatory genes including 
leukocyte adhesion molecules and chemokines (Hansson, 2001; Wick et al, 2004). 
LDL oxidation is responsible for foam cell formation and the production of chemo- 
attractants for SMCs and mononuclear cells that make up the inflammatory core of the 
atherosclerotic plaque (Alonzi et al, 2008; Glass and Witztum, 2001). ApoB-100 is 
captured and processed by macrophages and DCs within the sub-endothelial space. 
The peptides derived from this degradation are then presented by MHC class II 
molecules for recognition by specific CD4^ T cells. These T cells then undergo clonal 
proliferation and expansion with the consequent production of cytokines and 
immunoglobulins (Hansson et al, 2002). However, apparently not all apoB-100-
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derived epitopes induce pro-inflammatory or pro-atherogenic immune responses. A 
protective role against atherosclerosis has been recently proposed in experimental 
animals immunized with whole ox-LDL or with selected peptides derived from the 
polypeptide sequence of apoB-100 (Zhou et al, 2001).
Several important pieces of evidence have been previously reported that ox- 
LDL occurs within human atherosclerotic plaque but not in a healthy arterial wall 
(Steinberg, 1991). High levels of ox-LDL antibodies have been detected in the plasma 
of human patient’s with therosclerosis and in experimental studies using diseased 
animal models (Witztum and Steinberg, 2001; Chisolm and Steinberg, 2000). The 
existence of ox-LDL in atherosclerotic lesions in both human and animal studies has 
been confirmed using monoclonal antibodies against oxidation-specific epitopes in 
oxidized LDL (Witztum and Steinberg, 2001; Chisolm and Steinberg, 2000; Hansson 
and Libby, 2006; Steinberg, 1991). Additionally, LDL that is isolated from animal 
and human lesions represents physical and chemical functions as ox-LDL particles. 
These lesions also positively stained with anti-ox-LDL antibody while normal arterial 
wall negatively stained (Steinberg, 1991; Leake, 1993).
Table 1.5. The implication of ox-LDL in the process of different d iseases. The effect of 
ox-LDL on different interleukins (IL-1 and IL-8), monocytes, adhesion molecule VCAM-1 and 
metalloproteinase is shown. A clear relationship exists between the existence of ox-LDL and 
the immune system (Steinberg, 2002).
Ox-LDL Function References
Induce monocyte binding to endothelial cells (Watson e/nr/., 1997)
Mimic effects of platelet activating factor (Marathe et a/., 1999)
Increase tissue factor activity (Marathe et a/., 1999)
Increase expression of monocyte colony-stimulating factor and 
monocyte chemoattractant protein 1
(Navab er ût/., 1991)
Increase expression of vascular cell-adhesion molecule 1 (Cybulsky and Gimbrone,1991)
Induce Fas-mediated apoptosis (Sata and Walsh, 1998)
Induce expression of interleukins 1 and 8 (Terkeltaub er a/., 1994)
Increase collagen synthesis in smooth muscle cells {Yimi e ta l, 1995)
Increase intracellular calcium (Thorin er a/., 1995)
Activate nuclear factor-xB (Brand et a/., 1997)
Induce expression of type I metalloproteinase (Rajavashisth et al 1999)
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1.9 Proteomics
1.9.1 A brief background o f ‘’om ics”
The term ‘proteome’ (the proteins expressed by a genome or tissue) has been 
attributed to Mare Wilkins (Wilkins et al, 1997; Wasinger et al, 1995, Plebani,
2005). Proteomics is known as the quantitative and qualitative assessment of 
proteomes under different conditions. The genomics methodology supported by 
bioinformaties has now expanded in to other fields such as proteomics, metabolomies 
(concentration and flow of cellular metabolites), and metabonomics (systematic 
profiling and analysis of biological fluids) (Righetti, 2003). Genomics, proteomics, 
and metabolomies have the capacity to provide technological solutions for 
understanding biological processes. For example, these techniques can be linked 
together to study molecular mechanisms of diseases and also to characterise the 
association between genes, proteins and metabolites with diseases (Figure 1.8) 
(Chambers et al, 2000; Nicholson and Wilson, 2003).
Gene expression Transcnptomic
P rote in
e x p re ss io n
ProteomicsMetabo ism
Metabo omics
Figure 1.8: Schematic representation of the link between genom ics, proteomics and 
metabolomies. Protein expression is the central key for all these technologies which are 
involved in gene, metabolomic and proteomic analysis.
Clinical proteomics is recognised as the systematic comprehensive large-scale 
identification of protein patterns (fingerprints) in disease states with the purpose of 
improving patient care and public health (Thongboonkerd and Malasit, 2005; Granger 
et al, 2004). Generally, proteomic approaches have been divided into three different 
categories (Plebani, 2005, Witzmann and Li, 2002): 1) protein expression proteomics: 
a quantitative study of protein expression 2 ) functional proteomics: analysis of protein 
profiles and 3) structural proteomics: identification of the structure of protein 
complexes.
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Proteomic techniques can be carried out using different types of instruments, 
including MALDI-TOF (matrix-assisted laser desorption ionisation-time of flight) and 
ESI (electrospray ionisation) (Plebani, 2005). Sequencing of the detected peptides 
can then be performed in order to obtain sequence information using existing 
databases (Griffin et al, 2005; Savitski et al, 2005).
1.9.2 Ion source and mass spectrometry
1.9.3 M S/M S tandem and database search
A mass spectrometer is a type of analytical instrument used to analyze 
different kinds of samples sueh as manufactured materials, foods, poisons, body fluids 
and medicines. The tandem-MS is used to structurally characterize carbohydrates, 
lipids and peptides (Jungblut and Thiede, 1997; Wilkins et al, 1995; Arrell et al,
2001).The main aim of tandem MS (MS/MS) is the identification of a particular 
mass/charge (m/z) value (or ion collection) from other ions entering a mass analyzer. 
The identified ions are disassociated and the m/z values are then determined by the 
second mass analyzer. In peptide analysis, the majority of fragmentation events or 
covalent bond breakage occurs around the amide bond. Thus, a series of peptide 
fragment ions are observed which represent the amino acid sequence of a given 
peptide (Coon et al, 2005; Frohlich and Arnold, 2006).
Different strategies are available for the interpretation of MS/MS data and the 
identification of peptide sequences (Frohlich and Arnold, 2006). Most methods use 
search algorithms to identify peptides by associating experimental and theoretical 
MS/MS data together (Fenyo, 2000). MS/MS peptide identification search algorithms 
have substantial benefits including their availability, speed and scoring system, as 
well as their relative sensitivity and specificity. A tandem mass spectrometer consists 
of two mass spectrometers linked by a chamber that can break a molecule into pieces 
(ions). This chamber is known as a collision cell and the process is called collision- 
induced dissociation (CID) (Figures 1.9A and B).
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Figure 1.9: Components of a tandem m ass spectrometer. Panel A: the collision-induced 
dissociation (CID) chamber transfers an ion resulting in smaller fragments (MSI). Panel B: an 
overview of CID in tandem containing infrared multi-photon photodissociation (IRMPD) and 
surface-induced dissociation (SID). After sample separation in MSI, ions are fragmented by 
CID and sorted by MS2 then detected by different software as in panel A. Panel B reproduced 
from (Glish and Vachet, 2003).
In the first mass spectrometer the sample is arranged, weighed and then 
broken into ions in the collision cell. In the second mass spectrometer ions are 
arranged first and then weighed and send to the detector (Coon et al, 2005; Dalle- 
Donne et al, 2006).
1.10 Peptidomics
The term “peptidomics” is a new name in the ‘omies’ family, which has only 
recently been coined and discussed in the literature (less than five years ago) 
(Soloviev and Finch, 2006). Peptidomics is a new approach to identify and study 
potential therapeutic targets. The nature of peptides is different from proteins as they 
are more active and dynamic since they are normally derived from precursor proteins 
(Soloviev and Finch, 2006).
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The technical term ‘peptidome’ is a theoretical concept describing a pool of 
different peptides at a given time in a given sample. Peptidomic analysis has a major 
advantage of being able to recognize native small peptides which may act as excellent 
markers for the sample under investigation (Soloviev and Finch, 2006). The most 
suitable system that is normally used as a peptideomic system is capillary 
electrophoresis merged to mass spectrometry (CE-MS). It produces high standard 
results that provide many advantages for peptide analysis, including fast separation 
with high resolution. The only limitation known about this system is that the volume 
of loaded sample is normally very low, which may affect the detection sensitivity 
(Ziirbig and Mischak, 2008).
Defining peptide epitopes recognized by CD8  ^ and CD4^ T lymphocytes 
involved in immune responses has generated tremendous interest (Oviedo-Orta and 
Bermudez-Fajardo, 2008; Germain, 1994a; Ziirbig and Mischak, 2008). Identification 
of such immunogenic epitopes, which are recognized by T and B lymphocytes, would 
advance peptide-based therapies and vaccine development immensley. However, a 
potential difficulty in the development of peptide-based therapies is the fact that the 
human HLA gene is very polymorphic (Doolan et al, 2000).
1.11 M etabolomies
In order to investigate and understand biological systems in both human and 
animal models to include disease mechanisms and drug and food metabolism, it is 
necessary to examine and understand the small organic molecules involved in these 
processes. These small organic molecules include vitamins, cellular metabolites, 
hormones and co-factors that may control the physiological functions. Modifications 
in the levels or the structure of some of these molecules are important indicators and 
markers of disease development and drug effects. Metabolomic systems are powerful 
tools that enable the study of all these molecules and allow the differentiation of 
changes in metabolomic patterns and components. In 1998 Olivier and his group used 
the term “metabolome” to describe the set of metabolites synthesized by an organism 
for the first time (Oliver et al, 1998). Metabolomies is a rapid and sensitive method 
that provides researchers with a powerful tool to discover and screen cellular 
biomarkers of disease. It also enables the measurement of the levels of physiological 
biomolecules in highly complex samples (Ryan and Robards, 2006). Metabolomies is 
the main and most important tool applied currently in the study of nutrition as it
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allows the discovery and measurement of metabolite concentrations in humans and 
the association of these metabolites to specific disease.
1.11.1 M etabolomic systems
Although metabolomic studies have the same level of importance as other 
‘omic’ studies, this method has lagged behind the other technologies, especially as 
there is no specific instrument platform able to analyze all metabolites (Dettmer et al,
2006). Other ‘omics’ such as genomics, transcriptomics and proteomics have made 
major progress in instrument development while metabolome analysis is still growing 
(Bino et al, 2004). The most popular metabolomic analysis tools are mass 
spectrometry (MS) and nuclear magnetic resonance spectroscopy (NMR). NMR- 
based methods provide a strong and reproducible outcome. The measurement of 
chemical shift under each peak is obtained by NMR and the unit observed is as parts 
per million. However, the employment of MS in the study of metabolomies has 
increased dramatically because of the accuracy and sensitivity over the NMR method 
(Mayr, 2008).
Liquid and gas chromatography is normally used for metabolomic analysis, 
LC/MS and LC/MS/MS have been extensively used for metabolite profiling and 
identification (Kostiainen et al, 2003; Prakash et al, 2007). Furthermore, a new 
chromotographic tool has been employed to analyze metabolites providing high 
sensitivity and a high quality results. Ultra performance liquid chromatography 
(UPLC) involves the use of a high pressure fluidic binary pump able to work up to 
1000 bar, whereas a conventional HPLC pump has a maximum operating pressure of 
about 400 bar. The high pressure along with special small-particle (-1.7pm) analytical 
columns provides better chromatographic resolution, resulting in faster analysis and 
better sensitivity. The application of UPLC in pharmaceutical studies, especially in 
the field of metabolism has been reported (Johnson et al, 2005; O’Connor et al,
2006).
In the case of metabolite profiling, high resolution and a sharp peaks are more 
important than high speed to allow sensitive and selective metabolite identification 
(Watkins and German, 2002; Ryan and Robards, 2006). Metabolomic investigation 
normally depends on two different methods, metabolic profiling and metabolic 
fingerprinting (Dettmer and Hammock, 2004). Metabolic fingerprinting is used to
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compare metabolite patterns in disease and normal conditions and is a useful means of 
diagnosis. This approach can be utilized with different types of samples including 
saliva, plasma, serum, urine, cells and culture media. However, the analysis of culture 
media is called foot-printing (Allen et al, 2003; Allen et al, 2004). Metabolic 
profiling involves analyzing groups of metabolites that correlate to a specific 
metabolic pathway or a class of compounds (e.g. quantitative analysis of fatty acids as 
fatty acid methyl esters) (Dettmer et al, 2007; Dunn and Ellis, 2005).
Despite all this progress in the development of metabolomic studies, the 
requirement to develop specific metabolomic instrument is still required. This type of 
instrument would need to overcome the problems of metabolite complexity and offer 
deeper analysis of the metabolome presented by the system. In addition, the 
arrangement and combination of chromatographic separation with MS or NMR 
analysis is required to produce maximal output of both systems (Griffiths et al,
2007). Nevertheless these analytical methods both lack reproducibility due to batch 
variability, or when performed in different laboratories (Ulrich-Merzenich et al,
2007).
1.11.2 Achievements accomplished by metabolomic analysis
The advantages of the metabolomic method are obvious in the development of 
different studies including toxicology, genetic modification of specific organisms, 
drug discovery and cardiovascular diseases. In cancer research, metabolomies has 
been employed as an advanced approach to characterize and screen the development 
of cancer in mouse models (Griffin, 2006). Moreover, it has been used to study tumor 
metabolism in animal models of human brain tumors, liver tumors and colon cancers 
(Griffin and Kauppinen, 2007). The identification of novel xenobiotic metabolites in 
drug and chemical toxicology research has been reported also (Chen et al, 2007). The 
combination of LC-MS-based metabolomies and genetically modified mouse models 
has proved to be an important system in the study and identification of drug 
metabolites (Chen et al, 2007; Chen et al, 2007).
Metabolic fingerprinting is also a powerful method when used as a diagnostic 
tool to assess the difference between healthy and diseased samples. It can be used in 
qualitative and quantitative analyses in clinical and research areas. Both metabolic 
fingerprinting and profiling are able to identify new biomarkers applied to diagnose 
health and disease types, or outcomes of pharmacological treatment. Moreover, the
30
concept of individual health including diet and nutrition implicated with 
pharmacological treatment is based on metabolic analysis (Watkins and German,
2002). When metabolomic tools such as LC/MS are linked to metabolome databases 
they provide useful structural information for each metabolite and present a powerful 
way to identify and detect different metabolites. These tools make the discovery and 
analysis of small molecules at low concentrations in biological fluids possible. 
However, identification of the metabolites in complex biological samples is still 
challenging because of the existence of interfering endogenous material.
1.12 Hypothesis
Our hypothesis is that LDL particles can stimulate differential macrophage 
immune responses which can be identified by the production of specific peptide 
patterns that could potentially serve as a signature (biomarker) to study atherogenesis.
1.13 Aims and objectives
i. To establish and test the acid elution method to extract MHC class I and II 
epitopes from the surface of macrophages. This method utilises synthetic 
peptides (with similar characteristics to those expected to be found in vitro 
after macrophage activation) to first optimise the detection conditions using 
HPLC analysis. These conditions will be then applied to the analysis of 
peptide samples derived from the in vitro stimulation studies.
ii. To investigate whether an acid elution method using citrate phosphate buffer 
can be used for peptide extraction and analysis. A pH range (pH 3, 4 & 5) will 
be used, based on the findings of previously published studies, to determine 
the optimum conditions and to carry out in vitro assays.
iii. To identify potential MHC-derived peptides produced by macrophages treated 
in vitro with ox-LDL. These experiments will be performed using a mouse- 
derived J774.2 monocyte-macrophage cell line as a model. The peptides will 
be extracted using the above mentioned acid elution methodology followed by 
analysis and identification using LC/MS and sequence prediction using 
software available on-line, respectively.
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iv. To assess the effect of LDL treatment on the generation of different protein 
and peptide profiles using three different culture conditions. We will attempt 
to group the peptides and proteins profiles identified by completion of 
objective three with each culture condition used in order to identify key 
differences among the different groups. Of particular interest, within the total 
number of proteins produced by each condition, is the identification of 
proteins that may serve as unique markers of any particular condition.
V . To study whether treatment of macrophages in vitro with some of the peptides 
identified above has an effect on cell immune regulatory functions. To achieve 
this, selected peptides will be chemically synthesized and both J774.2 cells 
and mouse peritoneal macrophages will be used to assess response to peptide 
treatment. Immune response will be analysed by detecting the surface 
expression of makers such as CD 14, MHC class II, TLR-2 & TLR-4 using 
flow cytometry analysis. These markers were specifically selected to provide 
pro- vs. anti-inflammatory response profiles that will help us interpret the 
potential effect and/or role of the peptides (or the proteins where they are 
derived from) during immune responses. The assessment of the profile of 
immune responses will also aid to decide whether the peptides can be used in 
future studies as potential therapies to target atherosclerotic plaque 
development.
vi. To perform a preliminary investigations to evaluate the effect of LDL 
treatment on macrophage lipid metabolism. Experiments will be carried out 
using the same experimental methodology explained above. Cells will be 
collected and the study of the effect on the lipid metabolite profile will be 
studied using the Human Metabolomics DataBase (HMD). Data derived from 
this analysis will not only allow us to correlate the effects with those obtained 
in the previous objectives, but will also help to identify specific pathways 
and/or metabolites that may be targets for future in-depth characterisation.
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Chapter 2; General Materials and
Methods
2.1 Materials
Materials Suppliers
Acetonitrile (ACN) grade Fisher scientific
Ammonium acetate Sigma, UK
BCA protein assay kit Thermo Fisher Scientific
Citric acid +99.5% ALDRICH
Coomassie brilliant blue BioRad
DMEM media Gibco-Invitrogen, UK
Foetal calf serum PCS Gibco
Formic acid (FA) grade Fisher scientific
HBSS media Gibco- Invitrogen, UK
J774.2.2 cells Europe Collection of Cell Cltures (ECACC)
Lysing kit R&D System
Methanol Fisher scientific
Miniprotean II electrophoresis system BioRad
Oil red 0 Sigma, UK
Para formaldehyde (37%) Sigma, UK
Penicillin-streptomycin-glutamine (PSG lOOx) Sigma, UK
Phosphate buffer solution tablets (PBS) Sigma
Phosphate citrate Sigma
Propanol Fisher scientific
RPMI medium Gibco-Invitrogen, UK
Serum-free medium Gibco-Invitrogen, UK
Sodium azide Sigma, UK
Sodium citrate Sigma, UK
Sodium phosphate Sigma, UK
Thioglycollate medium Sigma, UK
Tris/ glycne/ SDS running buffer BioRad
Trypan blue solution (0.4%) Sigma, UK
Zymogram development buffer BioRad
Zymogram sample buffer BioRad
10% Zymogram Ready Gel BioRad
60% Optiprep Fresenius Kabi Norge, AS
Bridged Ethyl Hybrid (Gig BEH column) Waters, Milford, MA
ClSSepPak column Waters, Milford, MA
Centricon-10 filter Milllipore
Centrifuge Beckman GPR
eLica Qween system and soft ware Syngene
Fine filter paper Whatman
Flow cytometry Canto (BD Biosciense, UK)
Flow cytometry tube BECTON DICKINSON
Freeze Dryer Modulyo Edwards
GeneGenius Biolmaging System Syngene, Germany
Hemacytometer slide Horsham
HPLC system ACQUITY UPLC®’ Water
Micro centrifuged Biofuge Pico, Heraeus
Micro con Centrifugal Filter Devices Amicon
Nano-drop spectrophotometer Lab Tech
Onyx monolithic C,g silica column Waters, Milford, MA
Optima XL 100 Ultracentrifuge Beckman
33
Permanent Mounting Medium VECTA MOUNT ™
Polycarbonate tubes Beckman Coulter™ tubes, lot no: A70802
Polypropylen vial Phenomenex
Sonnicate KERRY
Spectrophotometer BIO-TEK, ELx800
T175, 75 & 25 cm^ tissue culture flasks Nunclon
UltiMate 3000 Intelligent LC System Dionex, USA
Ultimate micro-capillary HPLC system Dionex, USA
vortex IKA®
0.2 and 0.45pm filter unit Millipore, Millex^^ G^P
2.2 Buffers and solutions
Buffers and Solutions Preparation
Acitonitrile 60% v/v in water
Ammonium acetate lOmM, pH 4.6
Bovine serum albumin (BSA) 1% (w/v) in PBS
Citrate phosphate buffer pH3,4&5(Table 2.1)
Citric acid O.IM in water
Cooper sulphate (CUSO4) lOmM in water
Destain buffer 10% Methanol, 5% acetic acid
Dialysed solution for LDL isolation ILPBS
Fixative solution 1-2% paraformaldehyde in PBS
Flow cytometry staining buffer 1%BSA, 0.05% Sodium Azide in PBS, pH 7.4
Flow cytometry washing buffer 0.5% BSA, 0.05 Sodium azide in PBS, pH 7.4
Mobile phases
Al) 100% water + 0.1% formic acid (FA) 
Bl) 100% acetonitrile (ACN) + 0.1 % FA
A2) 100% water + 0.1% FA
B2) 100% rnethanol + 0.1 FA
A3): 2% acetonitrile, 0.1% formic acid in H2O
B3): acetonitrile, 0.1% formic acid
ox-LDL 10% of lOM CUSO4 (v/v) on n-LDL to provide ox-LDL
Oil red 0 staining 0.5g of oil red 0 (w/v) in 200 ml isopropanol
Optiprep 12% (v/v) in PBS
Optiprep 6 % (v/v) in PBS
Phosphate buffer solution (PBS) One tablet in 500ml detailed water
Sodium azaid 0.05g (w/v) in PBS
Sodium phosphate 0.2M in water
Thioglycollate 3% Thioglycollate, v/v in PBS
Tris/ glycne/ SDS running buffer 25mMTris, 192mM Glycine and 0.1% (W/V) SDS, PH 8.3
Zymogram development buffer Tris-HCl 63.Og, NaCl: 117g CaC12: 7.4g and distilled water to 1 L
Zymogram sample buffer 62.5 mM Tris-HCl, pH 6.8,25%, glycerol 4% SDS, 0.01% Bromophenol Blue
2% Para formaldehyde Para formaldehyde in PBS
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2.3 Isolation o f LDL from human plasma
Blood samples from healthy human volunteers were collected in 50ml tubes 
containing 10% sodium citrate (Sigma, UK) to prevent blood clotting, and then 
centrifuged at 2772xg for 45min at 4°C (Beckman GPR, UK). A two phase gradient 
containing Optiprep 6% and 12% was prepared using a master solution of 60% 
Optiprep (Fresenius Kabi Norge AS) and the plasma sample (Davies et al, 2003). The 
6% Optiprep solution was transferred into Beckman polycarbonate tubes, (Beckman 
Coulter UK) and 5ml of the 12% mixture was added carefully and slowly to the 
bottom of the tube, which was centrifuged at 200xg for 4h at 16”C using a Beckman 
70 iT rotor and a Beckman Optima XL 100 Ultracentrifuge. The LDL band was 
identified as an orange coloured ring at the interface between the two layers. The LDL 
bound was collected and dialysed against PBS for 48h using a cellulose membrane 
(SOkDa pore size) and stored at 4°C.
For oxidation, the LDL was incubated overnight with 10% CUSO4 (stock 
lOmM) and filtered through a 0.45pm filter unit (Millipore GP, UK). Finally, the ox- 
LDL was dialysed against PBS for 24h twice at 4°C with constant stirring (Davies et 
al, 2003; Galle and Wanner, 1999).
The detection of LDL oxidation was performed by nano-drop 
spectrophotometry (Lab Tech) using an absorbance range of 200-600nm to confirm 
the difference between n-LDL and ox-LDL patterns. 2pl of each sample was injected 
into the spectrometer and the patterns of each condition presented were compared to 
demonstrate the differences between n-LDL and ox-LDL (result presented in 
appendix 2 ).
Protein concentration of the LDL particle was measured using a nano-drop 
spectrophotometer at a wavelength of 280nm (http://www.nanodrop.com/). The 
260/280 ratio of sample absorbance at 260 and 280 nm was used to assess sample 
purity on the basis of the Warburg-Christian method. This was developed to correct 
for nucleic acids contamination in protein absorbance. Nucleic acids absorb radiation 
at 260 nm, while proteins at 280; thus the method uses a correction factor calculated 
from the ratio of the absorbance at 280 nm to that at 260 nm. Due to the nature of 
hydrophobic and hydrophilic proteins in the sample, surface tension of the liquid 
varies gives rise to changeable sample volumes. This difficulty was overcome using a 
large sample volume (2 pi) for protein measurements. In our experiment, a blank
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sample containing 2pl of PBS solvent was used to zero the instrument at 280nm. To 
measure protein concentration, each sample (2 pl) was injected into the spectrometer 
to record absorbance. Protein concentration measured using the following equation:
(A280) (Correction factor = 0.67) = mg/ml protein.
2.3.1 M icro BCA protein Assay
The protein concentration of n-LDL and ox-LDL was determined using a BCA 
protein assay reagent kit (Thermo Fisher Scientific) following the manufacturer’s 
recommendations. Bovine serum albumin (BSA) (a BSA standard provided in the kit) 
at a concentration of 2 mg/ml was used to prepare the standard curve ranging between 
0.5pg/ml to 200pg/ml. The assay was performed using flat bottom 96-well microtitre 
plates (NUNC, Thermo Fisher Scientific Inc., U.K.) in which 150pl of sample was 
mixed with 150pl of working buffer (the standards were treated in the same way) and 
incubated at 37°C for two hours. Finally, absorbance was measured at 490nm using a 
spectrophotometer (BIO-TEK, ELx800).
2.4 Cell culture
2.4.1 J774.2 cell line
J774.2 murine macrophages were obtained from the European Collection of 
Cell Culture (ECACC, Sigma). J774.2 cells are isolated from tumor tissue in BALB/c 
mice that do not express the product of the apo-E gene (Kruth, 2001). BALB/c mice 
are prone to TH2-type immune responses and are resistant to atherogenesis, which 
makes them useful for this study (Hansson and Libby, 2006; Kruth, 2001). Cells were 
grown in two different types of media. First group: J774.2 cells were grown in 10ml 
of DMEM media (Dulbecco’s modified Eagle’s media) (Gibco-Invitrogen, UK) 
containing 10% foetal calf serum (FCS), 5ml PSG [penicillin lOOu/ml, streptomycin 
lOOpg/ml, glutamine 2mM] (GIBCO Invitrogen, UK)]. Second group: cells were 
cultured in 10ml serum-free medium (HyQ® ADCF-MAb™ without L-glutamine; 
Gibco-Invitrogen, UK) containing 5ml PSG [penicillin lOOu/ml, streptomycin 
lOOpg/ml, glutamine 2mM)]. Cells were maintained at 37°C in 5% CO2 atmosphere 
(Hera cell 240, Heraeus). The culture medium was replaced every three days prior to 
the beginning of the treatment. Cells were initially seeded at a density of 
IxlO^cells/ml. Two different types of media were used to determine the optimal 
conditions for LC/MS analysis and to consider the effect of serum in DMEM media 
on LC/MS analysis.
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2.4.2 JY cells
JY cells are a human B lymphoblastoid cell line used as a control for antigen 
presentation (kindly provided by Professor Stefan Stevanovic, Institute for Cell 
Biology Department of Immunology Tübingen, Germany). These cells have been well 
studied by other groups (Szollosi et al, 1996; Bodnar et al, 2003). JY cells were 
seeded at a density of I x 10^  cells/ml and grown in two types of media. Cells were 
either grown in RPMI medium (Gibco-Invitrogen, UK), containing 10% FCS or in 
serum-free-medium (HyQ® ADCF-MAb™ without L-glutamine) containing 5ml 
PSG [penicillin lOOu/ml, streptomycin lOOpg/ml, glutamine 2mM)]. Cells were 
incubated at 37°C in a 5% CO2 atmosphere for three days before treatment.
2.4.3 Isolation and culture o f mouse peritoneal macrophage cells
Peritoneal macrophages were isolated from 10 to 12-week-old female mice 
(C57BL/6). Three days before the experiment, mice were injected with 300pl of 3% 
of thioglycollate medium (Sigma, B255I) (Shaw and Griffin, 1982). Mice were 
euthanized by cervical dislocation and the skin cleaned with 70% ethanol. The skin 
was cut carefully avoiding the peritoneal membrane, and 8-10 ml RPMI medium 
containing 5ml PSG were injected in the peritoneal cavity. Cells were detached from 
the peritoneal cavity by shaking the mouse belly for I-2min. Detached cells were 
collected using a 10ml syringe and the cells were immediately transferred to ice.
Cells were collected by centrifugation at 400g for 5-lOmin at 4°C (Beckman 
GPR, UK). Red blood cells were lysed using M-LYSE buffer (xIO) (R&D System, 
UK), 2-3 ml lyse buffer were added to the pellets and incubated for 5min at room 
temperature. Cells were washed once with 40-50ml RPMI media and centrifuged at 
400g for 5min at 4°C. Cells were counted using a hemacytometer (Horsham) and 
suspended in RPMI medium containing 10% FCS and 5ml PSG. Peritoneal 
macrophages were cultured and used in further experimental analysis (described in 
each chapter).
In this study mouse cells were used as a model, because they are more readily 
available than other types of cells. In addition, these cells have been successfully used 
in the past to study immunological pathways/processes that are similar in humans and 
mice (Jong et al, 2000; Mori et al, 2001; Mills and Finlay, 1998). Moreover, J774 
cells and peritoneal macrophage cells are both reported as good models for antigen 
presentation via MHC molecules (Koberne et al, 2001; Yuki et al, 2006, Lennon-
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Duménil et al, 2002; Rhodes et al, 1989; Harding and Geuze, 1998). Finally, the 
present study confirmed the ability of these cells to act as antigen presenters by 
detecting 22 MHC class I and 24 MHC class II peptides from the J774.2 cell surface.
2.5 Cell culture for zymogram, Oil red O and flow cytometry studies
A group of isolated peritoneal macrophages (untreated cells) at a seeding 
density of IxlO^cells/ml was cultured on a 2cm  ^ chambered slides in six well plates 
(Nunclon^™^) with 3ml advance RPMI medium containing 10% FCS and 5ml PSG. 
Cells were incubated at 37°C in a 5% CO2 atmosphere (Hera cell 240, Heraeus). A 
second group of cells was seeded at a density of IxIO^cells/ml in six well plates with 
3ml RPMI containing 10% FCS and 5ml PSG and incubated at 37°C in a 5% CO2 
atmospher (Hera cell 240, Heraeus). After 24h, different concentrations (20pg/ml, 
40pg/ml, 80pg/ml and lOOpg/ml) of n-LDL and ox-LDL were added separately and 
with 5pg/ml of LPS, cells were incubated for 72h at 37°C in 5% CO2. The selection of 
ox-LDL and n-LDL concentrations was based on what others had previously reported 
(Bjorkerud and Bjorkerud, 1996; Yang et al, 1996; Han and Pak, 1999). In addition, 
some cells were treated with different concentrations (20pg/ml, 40pg/ml, 80pg/ml 
and lOOpg/ml) of Pep I, 2 and 3. (Pep I and 2 are apo-BIOO derived peptides, 
discussed in more detail in chapter 3 section 3.5). Cells were incubated for 72h at 
37°C in a 5% CO2 atmosphere and supernatants were collected and stored at -20°C for 
zymography, and cell pellets were immediately used for flow cytometry analysis. 
Cells on chambered slide were immediately stained with ORO stain. Same 
experimental and culture conditions used for peritoneal macrophages were also 
carried out with J774.2 cells.
2.6 Cell culture and peptide extraction
2.6.1 Cell culture
Cells were cultured using two different methods. Firstly, cells 
(~50xI0^cells/flask) were grown in three T175cm^ tissue culture flasks with 50ml 
DMEM (Dulbecco’s modified eagle’s media) containing 10% FCS and 5ml PSG 
Alternatively, cells (-50x1 O^cells/fiask) were cultured in three TI75cm^ flasks with 
50ml serum-free media (HyQ® ADCF-MAb™ without L-glutamine) containing 5ml 
PSG After 24h incubation, 50pg/ml of n-LDL and ox-LDL were added. MHC class II 
bound peptides were extracted after a further 24h of culture.
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IFN-y was not used in this research because the aim was to investigate the role 
of LDL on macrophages in the absence of any other stimulation factors.
2.6.2 Peptide extraction
Peptides were extracted from J774.2 cells using the method previously 
reported by Storkus in 1993 (Storkus et ai, 1993). Briefly, cells were used for peptide 
extraction when they reached 80-90% of confluence (Figure 2.1). The supernatant was 
removed and cells were gently washed with 10ml of HBSS (Hank’s balanced salt 
solution) (Gibco) three times at room temperature. 5ml of citrate-phosphate buffer 
(pH 3, 4, and 5 (Table 2.1)) was added to the adherent cells and incubated for Imin at 
room temperature. The supernatant was collected and centrifuged at 400g for 5min at 
4°C (Beckman GPR, UK), and stored at -80°C until further analysis. Cells were then 
washed with 10ml HBSS and re-cultured using the same media supplemented with 
50pg/ml of n-LDL o ox-LDL. The procedure was repeated daily for five consecutive 
days and cells were re-cultured each time in the same media with new treatment.
Table 2.1. Citrate phosphate buffer. The preparation of three different solutions of citrate 
buffer at three different pHs.
pH 0.2M NaiHPO^ O.IM citric acid
3 20.5ml 79.5ml
4 37.0ml 63.0ml
5 49.3ml 50.7ml
J77-4 cells
Purification
•Acetonitrile (CAN) 
•C18 Sep Pak 
•0entericon-10
Peptide extraction 
Citrate P hosphate  Buffer 
pH 3, 4
4
/n vritro o r  //> i//Vo 
a c tiv ity  A s s a y s
Peptide selection Sequencing
Figure 2.1. Summary of the protocol used for peptide extraction from macrophage 
MHC-class II com plexes.
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2.6.3 Peptide fractionation
Samples containing peptides were pooled and loaded onto a ClSSepPak 
column (Waters, Milford, MA). Peptides were eluted using acetonitrile (60%, v/v in 
water) and then lyophilized (Freeze Dryer Modulyo, Edwards). Samples were then 
reconstituted in 500|xl of ammonium acetate buffer (lOmM ammonium acetate at pH 
4.6) and fractionated using a Centricon-10 filter (Milllipore, UK) before HPLC 
analysis (ACQUITY UPLC®, Water). Two solutions were used as mobile phase for 
HPLC analysis: Solution A: water / 0.1% formic acid (FA) and solution B: 
acetonitrile (ACN) / 0.1% formic acid (FA). Analysis was carried out using a sample 
flow rate of 0.4ml/min (greater detail of this method is given in chapters three and 
four).
2.7 Conditions for LC/M S/M S
For analysis of peptide sequences, two types of LC/MS system and two 
versions of the Mascot program were used. The first method ultilised an UltiMate 
3000 Intelligent LC System (Dionex, USA) coupled to a Bridged Ethyl Hybrid (BEH) 
particles Cig BEH column. To identify the source of the peptides sequences. 
Mascot™ (Matrix Science, USA; http://www.matrixscience.com) software was used. 
The second method employed an Ultimate micro-capillary HPLC system (Dionex) for 
reversed phase separation using an Onyx monolithic Cig silica column (100pm x 
15cm, Phenomenex). Additionally, Mascot™ script (VI.6b23), Mascot™ Daemon 
(V2.2) or Mascot™ (V2.2, Matrix Science) were used for peptide identification. More 
details of this software are provided in the following chapters.
2.8 Animals
Animals were purchased from Laboratory Animal Science (B&K, UK). 
Animals were housed in the Exeperimental Biology Unit (EBU) with controlled 
environmental conditions (22°C temperature, 50% humidity, and I2hr light/dark 
photoperiod). All procedures where authorised by the local animal research committee 
and approved by the Home Office under a project licence to Dr. Ernesto Oviedo-Orta 
and my personal licence number 70/20132.
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2.9 Statistical analysis
Values are expressed as an average (mean) plus and minus standard deviation (±SD). 
Treatment group values were compared with the control (PBS or ox-LDL depending 
on the particular experiment) using GraphPad Prism v.5 Software. For the comparison 
of each condition mean, an F-test was first performed to test for equal variance. If the 
standard deviations could be considered equal, a I-way ANOVA with Bonferroni 
post-hoc test was carried out. When the variances were significantly different, a 
Kruskal-Wallis test was carried out. Results were considered statistically significant 
when the probability (P) was P < 0.05.
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Chapter 3: Optimisation of Liquid 
Chromatography-Mass Spectrometry 
System
Abstract
Liquid chromatography is a method used to separate different components in a mixed 
sample. Separation relies on the different properties of each component, mobile phase 
and stationary phase and how they interact together. The inside system parameters 
includes capillary voltage, sample cone voltage, column types and the properties of 
solvents, mobile phases and each sample definitely affects the analysis quality. 
Optimisation of the LC-MS/MS platform is required before any major experiments 
are performed in order to standardise all conditions that may interfere with the results. 
The optimisation step was essential for this study in order to minimize the effects of 
different factors that were not derived from the samples under investigation that could 
interfere with, or produce false results. Cig reverse-phase columns and control 
peptides (peptides derived from apo-BIOO protein) were used to achieve optimisation. 
Ammonium acetate, citrate phosphate buffer, methanol and Millipore water were 
tested as different solvents, and two mobile phases and three different capillary 
voltages and sample cones were assessed also. The acid elution method (citrate 
phosphate buffer, pH3) for peptide extraction was tested to isolate MHC-associated 
peptides from the surface of two different cell types [J774.2 mouse macrophages and 
human JY cells (B-lymphoblastoid)]. In addition, the new optimisation conditions 
were assessed to analyse the identified peptides eluted from J774.2 and JY cells. The 
results of this study showed that all solvents under investigation were able to detect 
peptide peaks. Ammonium acetate produced the best analysis pattern with a clear 
background, though acetonitrile mobile phase, 2KV capillary with 35V sample cone 
and an optimal flow rate of 0.4ml/min also resulted in an excellent analysis pattern. 
Seven different proteins were detected from J774.2 and JY cells using acid elution 
extraction protocol and LC/MS analysis. This result indicates that the acid elution 
method can be used to identify MHC-associated peptides. In addition, the LC/MS 
optimisation conditions can be also used to identify these types of peptides.
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3.1 Introduction
The main aim of this chapter was to set up and optimise the LC/MS system; an 
essential step in order to minimise interference from factors other than those in the 
samples under investigation and to avoid the emergence of false positive results. 
Understanding each part of the LC/MS process was a necessity to facilitate system 
optimisation. Each stage of LC/MS is described in more detail below.
3.2 The components o f HPLC
A standard HPLC system consists of four main parts: a pump and sample 
valve, a stationary phase, amobile phase and a detector(s) (MacNair et al, 1997). The 
pump is required to generate a constant flow rate for each specific column. A high 
level of consistency and reliability is necessary, because most HPLC detectors are 
flow sensitive and errors will result from changes in flow rate. This precise flow rate 
produces the total ion count (TIC) trace required for the interpretation of spectral 
analyses (Lemière, 2001). Since sample valves are situated between the pump and the 
column (Figure 3.1) valves must also be able to tolerate pressures of up to 10,000 
p.s.i.
Sample Solvent
Reservoir Reservoir
S a n ip le ^ ^  Sample Sample
Valve Pump Resei-voir
Column 
(stationary phase) /  D e îe c t« r \ Programmer
Figure 3.1. Basic com ponents of Liquid Chromatography. The diagram represents the 
main tools for a LC system. Each of these components is an essential part of the analysis.
The mobile phase is usually water in combination with organic solvents such as 
methanol or acetonitrile, moving through a stationary phase. The HPLC column 
represents the stationary phase and is packed with very fine particles, usually a few 
microns in diameter. These particles are regularly monoliths packed into a thin tube 
(column) (MacNair et al, 1997), but the most commonly used columns contain a 
chemically modified silica stationary phase, where the particular chemical determines 
the polarity of the column (e.g. C]g BEH, C,g Monolethic, C4 and Cg columns) (Kim 
et al, 2007). These columns vary in diameter, length and packing materials. Each of
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these columns has its own benefits and disadvantages and must be chosen to suit the 
properties of the analyte and requirements of the analysis
The hydrophobic interaction between reversed phase liquid chromatography 
(RP-LC) and the alkyl chains of the column material (Cig, Cg and C4) is a crucial step 
for the analysis (Frohlich and Arnold, 2006). Another important interaction occurs 
between the sample under investigation and both the stationary and mobile phases. 
These interactions will vary in strength/affinity depending on the nature of each 
sample (MacNair et al, 1997; Nunez et al, 2005). In a reversed-phase 
chromatography (RP-C) system, columns contain more polar mobile phase than 
stationary phase, and analytes with greater polarity elute faster than the less polar ones 
(Yamane, 2002).
3.3 Peptide identification using LC/M S/M S
Mass spectrometry (MS) is a general technique used for determining atomic 
composition, and plays a crucial role in protein, peptide and carbohydrate 
identification from biomolecules. MS strategies are employed routinely in the 
characterisation of products ranging from small synthetic peptides to conjugated 
antibody molecules. Several types of MS techniques can be used in protein and 
peptide analysis. The most commonly used ionization techniques are electro spray 
ionisation (ESI) and matrix-assisted laser desorption ionization (MALDI) (Vestling, 
2003). ESI-MS is a powerful tool when coupled to LC allowing the separation and 
detection of complex mixtures (Griffiths et al, 2001; Coon et al, 2005).
3.3.1 The effect o f LC/M S parameters on peptide identification
Each part of the LC/MS system plays an important and different role in the 
separation and identification of peptides. However, they have some common features 
such as solvent, mobile phase, voltage cone and sample concentration usage. The 
choice of solvent and mobile phase is a fundamental issue because their composition 
may affects not only the chromatographic flow, but also the spectral characteristics 
and sensitivity of the analyte (Chakraborty and Berger, 2005). Therefore, the 
selection of these parameters must be carefully considered depending on the 
differences of the ionization process, the reversed-phase column and the properties of 
the analyte with respect to the ion detection mode of the LC/MS system (Garcia et al, 
2002; Chakraborty and Berger, 2005).
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Capillary voltage (Cap V) and sample cone are also normally chosen 
depending on the instrument manufacturer’s handbook or on personal experience 
rather than specific experimental optimisation (Marginean et al, 2009). Cap V is the 
voltage applied to a capillary tube from which liquid sample is sprayed to form 
scattered charged droplets. This type of capillary tube is normally applied in reverse 
phase liquid chromatography (Lytle et al, 2000). The normal, and highest Cap V 
ranges between 3-5kV (Lim and Lord 2002). A suitable Cap V within this range 
should be tested for each experimental condition. Sample concentration is also an 
important factor likely to affect the analysis and has been considered in previous 
studies (Quekelberghe et al, 2008).
In this chapter the main objective was to test and optimise the choice of 
solvent, mobile phase, capillary voltage and sample concentration to give specific 
chromatographic conditions. For this purpose the effect of solvents such as 
ammonium acetate, citrate phosphate, methanol and Millipore water were assessed. 
Acetonitrile and methanol were also tested as mobile phases and several sample 
concentrations and capillary voltages were also tested. The methodology for this 
optimisation is presented in the following section.
3.4 Aims and objectives
3.4.1 Aims
To optimise (test and design system and experiment performance) the 
methodology for the identification of MHC-derived peptides from macrophages.
3.4.2 Objectives
• To identify the optimal cycle time for each sample
• To assess different mobile phases and solvents
• To use and assess different voltages and sample cones to detect peptides
• To evaluate several sample concentrations
• To use and assess acid elution method and LC/MS analysis to extract and 
identify MHC-associated peptides respectively
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3.5 M aterials and Methods
3.5.1 Sample preparation
3.5.1.1 Peptide preparation using different solvents for LC-MS analysis
In order to validate the conditions for the LC-MS peptide detection analysis 
control peptides previously identified by Chicz and his group were used (Chicz et al, 
1993; Verreck et al, 1996). These peptides (Pep I and Pep2) are derived from the 
apolipoprotein B-lOO polypeptide sequence. Pep3 is a scrambled peptide derived from 
the sequences of Pepl and Pep2 (Sigma, UK) (Table 3.1). These three peptides all 
share similar characteristics to those expected to be detected in this study.
Table 3.1. Peptide information
Peptide
name
Sequence Homology to 
mouse
Length
(aa) MW
Pep 1 KSSVITLNTNAELFNQSD 94% 18 1981.15
Pep 2 FPKSLHTYANILLDRRVPQ 68% 19 2269.65
Pep 3 STVLDSNAFQKITNLESN 0% 18 1981.15
Peptides (Pep2 and Pep3) were dissolved in water, while Pepl was dissolved 
in a water and DMSO (as recommended by Sigma), which mixed until solutions were 
a homogenous mixture. The effect of four different solvents (methanol, Millipore 
water, ammonium acetate and citrate phosphate buffer pH 3) on peptide identification 
by HPLC was assessed. The three peptides (3pi at I.5mg/ml) were mixed with 8 8pl 
of each solvent. Peptide and solvent mixes were incubated for I5min on ice and then 
centrifuged for lOmin at I3.8xg (4°C). The supernatants were collected in 
polypropylene vials and analysed using LC-MS with 5 or lOmin linear flow (see 
below for more details).
3.5.1.2 Assessment o f peptide concentration
Different dilutions of peptide were made (ranging from 750ng to 24,000ng) 
and added to a mixture of 800pl acetonitrile with 200pl of Millipore water. Samples 
were incubated for 15min on ice and centrifuged for lOmin at 13.8xg (4°C). The 
supernatant was collected into fresh tubes and freeze-dried. Before the analysis, 
samples were reconstituted in lOOpl of Millipore water, vortexed for 15sec and
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centrifuged for 5min at 13.8xg (4°C). Supernatants were transferred (80pl) to 
polypropylene vial tubes for LC-MS analysis.
3.6 Cell culture
3.6.1 J774.2 and JY Cells
The cell culture procedures for J774.2 and JY cells are both presented in 
chapter 2, sections 2.4.1 and 2.4.2 respectively.
3.6.2 Cell treatment and peptide extraction
To optimize HPLC conditions for the cell type under investigation, J774.2 
cells were treated with n-LDL and ox-LDL (50pg/ml) every 24h for five days (as pilot 
study). Peptide extraction was carried out using the acid elution method at pH 3.0 
(section 2.6 chapter two for more details). Untreated J774.2 and JY cells were used as 
control samples.
3.7 Optimisation o f the HPLC system
3.7.1 UPLC Analysis.
The Ultra Performance Liquid Chromatography (ACQUITY UPLC®, Waters) 
system produces a separation of better quality, quantification and characterization of 
samples over the traditional HPLC. The UltiMate 3000 Intelligent LC System 
(Dionex, USA) used in this study has a double delivery pump (P22000 pumps) and 
detectors (ThermoFinnegan, UK), chromatography management software and a lOpl 
loop. ACQUITY UPLC™ BEH columns, containing Bridged Ethyl Hybrid (BEH) 
particles (1.7pm), allow maximum sensitivity and resolution at high flow speeds. 
Furthermore, BEH contains a tri-functional ligand bond which allows superior low pH 
stability. This low pH stability, combined with the high pH stability of the 1.7 pm 
BEH particles, allows a wider pH range (I-I2), enhancing detection capabilities.
In this study, the injection volume was 5pl on a Cig BEH column and the flow rate 
was decreased from Iml/min to 0.4ml/min to allow for the narrow bore (1.7pm) of the 
column. Sample temperature was maintained at 4°C to prevent any temperature- 
dependent degradation and column temperature was 40°C with an m/z ratio up to 
3000. Two mobile phases were assayed:
• First mobile phase: A) 100% water + 0.1% formic acid (FA)
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B) 100% acetonitrile (ACN) + 0.1 % FA 
• Second mobile phase: A) 100% water + 0.1% FA
B) 100% methanol + 0.1 FA 
Formic acid was used in both conditions because it produces an excellent linear 
response (R^= 0.999).
Mascot™ script (V1.6b23) software was used to identify the sequence and the 
original protein source of the peptides (Matrix Science, USA; 
http://www.matrixscience.com).
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3.8 Results
3.9 Determination of cycle time
Using control peptides, several time frames were assayed and the best running 
time for detection of all relevant peptides eluted from the LC-MS column was shown 
to be less than 5 minutes. This can be seen in the LC-MS chromatogram in Figure 3.2.
The running time is time required to obtain a clear peptide peak profile without 
background interference. Although chemically synthesised, these peptides have 
similar properties and length to those expected in samples eluted from cultured cells, 
so should exhibit a similar running time. Pep2 and Pep3 were successfully detected, 
but Pepl detection was not achieved. This may be due to Pep2 becoming completely 
or patly stuck to the permanently swept parts of the column, leading to failure of 
detection.
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Figure 3.2. LC-MS chromatogram showing detection of control peptides Pep1, Pep2 
and PepS within 5min linear flow analysis. Peptides were prepared as described in section 
3.5. Briefly, 88gl of methanol was mixed with 3pl of each peptide (peptide stock was at 
1.5mg/ml each). The mixture was then incubated on ice for 15min and centrifuged. 
Supernatants containing the peptides were removed, and immediately analysed using LC- 
MS. The chromatogram shows a clear peak for peptides Pep2 and Pep3 within 5min of 
analysis. Pep1 was not detected within 5min of analysis (n=3). The Y axis shows the Total Ion 
Count (TIC) per peak given as a percentage and the X axis is the time in minutes of analysis 
of linear flow.
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3.10 The effect o f solvent
Ammonium acetate, citrate phosphate, methanol and Millipore water were 
tested because they were all used in this study for various parts of the analytical 
procedure. Methanol was used as a mobile phase, citrate phosphate buffer (pH 3) was 
used as an extraction buffer for peptides at the cell surface, and Millipore water with 
ammonium acetate were used to dissolve or reconstitute peptides. In addition, these 
chemicals have been commonly applied in LC-MS analyses in previous studies, 
giving confidence to their use in this study. Natural pH (pH 7.4) is usually 
recommended for better peptide solubilisation (www.sigmaaldrich.com/life- 
science/custom-peptides, www.chinapeptides.com) however there was no pH effect 
on peptide solubilisation in this study, because Pep2 and 3 were both dissolved in 
water and Pepl was dissolved in water with DMSO. The solvents discussed above 
were added to the aqueous peptide samples (section 3.5), which retained a clear 
solution.
Figure 3.3 shows an example of the detection of a mixture of Pepl, Pep2 and 
Pep3 control peptides using these different solvents. The best separation was obtained 
using either ammonium acetate, or methanol. Clear peaks at 1.82 and 1.99 retention 
times (RTs) were detected using ammonium acetate and methanol corresponding to 
peptides Pep2 and Pep3 respectively, within 5min of linear flow, while Pepl was not 
be detected with any of the conditions used.
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Figure 3.3, LC-MS chromatogram showing detection of a mixture of control peptides 
Pep1, Pep2 and Pep3 using 4 different solvents. Peptides were prepared similarly as 
previously described in section 3.5 but using different solvents [A. Ammonium acetate; B. 
Citrate phosphate; 0. Methanol and D. Millipore water]. The chromatogram shows a clear 
detection of peaks at 1.82 and 1.99 retention time (RT) corresponding to peptides Pep2 and 
PepS within 5 min of analysis (n=2). The Y axis shows the Total Ion Count (TIC) per peak as 
a percentage and the X axis shows the time in minutes of analysis of linear flow. Pep1 was 
not detected with any of the solvents used.
3.11 The effect o f sample concentration
The limit of detection (minimum concentration of peptide that the system can 
detect) was determined using different dilutions of Pep2 (described in section 3.5.1.3 
of the Materials and Methods) and LC-MS analysis was performed. The minimum 
concentration detected was 3000ng (Figure 3.4 A and B). The assay was repeated 
several times with different peptides, and the results were found to be consistent.
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Figure 3.4 LC-MS chromatogram showing detection of control peptide Pep2 at different 
concentrations (A: 750 -  GOOOng and B; 750, 6000 and 24000ng). Pep2 was prepared as 
described in section 3.5. Dilutions ranging from 750 to GOOOng (A) or 750 to 24000ng (B) 
were prepared using SOOpI of acetonitrile and 200pl of water. The mixture was incubated on 
ice for 15min and then centrifuged. Samples were lyophilised and reconstituted in 100pl of 
Millipore water and 80pl was used for LC-MS analysis. The chromatogram shows a clear 
peak 1.83 retention time (RT) corresponding to Pep2 (n=2). In (A) the peak was not 
detectable below 3000ng; in (B) the peak was detectable at 6000 and 24000ng.
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3.12 Effect o f different mobile phases
Two different mobile phases for LC-MS analysis were studied; acetonitrile 
and methanol. They were chosen because they are the most common mobile phases 
used with Cig BEH columns. Each mobile phase was prepared and used as described 
in section 3.7. Figure 3.5 shows the detection of Pep2 using these two mobile phases. 
A clearer result was achieved using acetonitrile. A clear peak at 1.82 RT was detected 
corresponding to Pep2 within 5min linear flow.
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Figure 3.5. LC-MS chromatogram showing detection of control peptide Pep2 with 
acetonitrile and methanol mobile phases. The peptide was prepared for analysis as 
described in section 3.5 and analysed by LC-MS using acetonitrile (ACN) (A) or Methanol (B). 
The chromatogram shows a clear peak at 1.83 RT corresponding to Pep2 with acetonitrile 
mobile phase (n=2). The Y axis states the Total Ion Count (TIC) per peak as a percentage 
and the X axis is the time of analysis in minutes of linear flow.
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3.13 The effect o f voltage and sample cone
The influence of capillary voltage and sample cone in the detection of peptides 
using LC-MS was studied. Evaporation of the sample drop plays a very important role 
in the detection of an analyte and can directly affect LC-MS analysis. Since voltage 
and sample cone alterations directly affect sample evaporation rates, these two 
parameters were investigated. Figure 3.6 shows that changes in these two parameters 
do not seem to affect detection of Pep2 as the peak at 1.83 RT is similar in the three 
conditions assayed. In order to verify this result, a spectrum analysis of the Pep2 peak 
(1.83) was performed. No differences were detected except for the appearance of a 
peak of 2269Da when using a 2KV Cap voltage and a 35V sample cone (Figure 3.7). 
This result may indicate that variation of these two parameters may lead to sample 
degradation during the analysis, which may not be apparent in the original LC-MS 
chromatogram.
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Figure 3.6. LC-MS chromatogram showing detection of control peptide Pep2 using 
different voltage and sample cone settings. Pep2 was prepared as described in section 
3.5. Dilutions of GOOOng were prepared using BOOpI of acetonitrile and 200pl of water (section 
3.5.1.3). The chromatogram shows an almost identical clear peak at 1.83 retention time (RT) 
in the three different conditions (3.1KV Cap with 35 Sample Cone (A), 2KV Cap with 35 
Sample Cone (B) and 3.1KV Cap with 20 Sample Cone(C) corresponding to Pep2 (n=2).
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Figure 3.7. Spectrum analysis of peak 1.83 and shown in Figure 3.7. A spectrum analysis 
of the peak corresponding to Pep2 (detected at 1.83 RT) in the three experimental conditions 
was performed to assess the integrity of the sample. Only a peak with 22690a was detected 
using 2KV Cap and 35V sample cone (B) as shown by the blue arrow (n=2).
3.14 The identification o f peptides derived from macrophages using LC/M S 
analysis
Using the conditions optimised for cycle time, solvent, mobile phase, capillary 
voltage and sample cone, a pilot study was performed using non-treated macrophages 
(J774.2 cells) and JY cells, which are known to express high levels of MHC- 
associated peptides on their plasma membrane (Koberne et al, 2001; Yuki et al, 
2006; Jochmus et al, 1997; Denkberg et al, 2002). The same cells incubated with 
either n-LDL or ox-LDL were used in parallel in order to recover peptides from their 
plasma membranes. Peptides were extracted from all the groups and analysed using 
LC-MS.
Eluted peptides were detected from both J774.2 and JY control cells using the 
optimised experimental conditions described in previous sections. The detected 
peptides appeared between 1.25 to 3 minutes of analysis (i.e. 2.27, 2.34, 1.67 and 1.9 
RT) (Figure 3.8).
55
A
JY_pos 1 TOFMSES+
2.12
309.13
TIC 
1 38e5
JY cell in ACN 4.73
305.8!
0.41
164.93
4.53
570.461.41
453.01
sifii '"r"0.61215.02 2.58176.08
3.41
415.21
B
2.25 2.50 2.75 3.00 3.25 3.50 3.75 4.000.25 1.00 1.25 1.50 4.75
1 :T0FM SES+
TIC
3.05e5
2.12
309.13
MQ cell in ACN peptides
1.67
930.07
2.27
1444.75
4.72
305.87
1.41
387.28 1101.55
0.42
164.9' 2.34
1557.81
2.58
160.04215.02
Time
0.25 0.50 0.75 1.00 1.25 1.50 1.75 2.00 2.25 2.50 2.75 3.00 3.25 3.50 3,75 4.00 4.25 4.50 4.75
Figure 3.8. LC-MS chromatogram showing detection of peptides derived from non­
treated JY and J774.2 cells. Cells were cultured and peptides eluted using citrate phosphate 
buffer (pH 3). Samples were lyophilised overnight and reconstituted in ammonium acetate (pH 
4.6) and then analysed using LC/MS (section 3.6). The arrow points to one of the potential 
peptides eluted from J774.2 macrophages (n=2).
Figure 3.9 shows a representative mass spectrum for one of these peptides 
with a single charge at 1444.73Da. The detection of these peptides is an indication of 
the effectiveness of the acid elution method in the extraction of MHC-associated 
peptides.
UltiMate 3000 Intelligent LC-MS equipment was used to obtain peptide 
sequences and Mascot™ software was used to determine the protein source of these 
peptides (Figures 3.10 and 3.11). Four matching proteins listed in Table 3.2, were 
eluted from non-treated JY cells. Using the same methodology, three proteins from 
non-treated J774.2 cells were identified that matched protein sequences in the Mascot 
database Table 3.2.
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Figure 3.9. Spectrum analysis of peak 2.27 from Figure 3.9. Spectrum analysis of the peak 
identified in Figure 3.9 was carried out in order to confirm the presence ofpeptides. The spectrum 
shows a peak at 1444.73Da with a single charged (indicated by a blue circle).
Table 3.2. Mascot results for proteins/peptides identified using LC-MS. Four different 
proteins (Y1-Y4) were identified from JY cells and three different proteins (J5-J7) were identified 
from J774.2 cells. All detected proteins were derived from untreated cells only.
Protein Cell samples Identified protein source ID
Y1 JY cells Actin Q2LDU9_9HYPO
Y2 JY cells Actin Q2HXS6_9NEOP
Y3 JY cells Actin Q7Z9F4_YARL1
Y4 JY cells HBA2 Q 7Z 6G 4H U M  AN
J5 .1774.2 cells alpha-1-antitrypsin precursor S21097
J6 J774.2 cells apolipoprotein A-II JC5734
J7 .1774.2 cells apolipoprotein A1 A46018
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Figure 3.10. Spectrum analysis of peptides eluted from JY cells analysed using the 
UltiMate 3000 LC-MS system. Cells were cultured as described in section 3.6. MHO class II 
bound peptides were extracted after 24h of culture using citrate phosphate buffer (pH 3) (section 
3.6). The spectrum shows peaks at different m/z ratios. Relevant peaks were used for sequence 
analysis.Red arrows indicate examples of detected peptides.
+TOF MS: Experiments 16.614to42.885 minfrom Sample 11 (sama2)of200ffl)109.vwff 
a=3.66460921814286740e004, #>.1.20231780485621630e+001
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Figure 3.11. Spectrum analysis of peptide eluted from J774.2 cells analysed using the 
UltiMate 3000 LC-MS system. Cells were cultured as described in section 3.6 and peptide 
elution was carried out as described in section 3.6.2. The spectrum shows peaks at different m/z 
ratios. Red arrows indicate examples of detected peptides.
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In contrast with the above results, LC-MS analysis of J774.2 cells treated with ox- 
LDL and n-LDL as part of the pilot study (Figure 3.12 and 3.13) did not identify any 
matching proteins in the database search, despite the differences observed in the general 
LC-MS profile. Of particular interest are the peaks at 1177.32 and 1550.70Da (Figure 
3.13; indicated by red arrows) that are absent in figure 3.12 and do not match any 
proteins in the Mascot database.
59
3^.1009
c  1000
'4.1693
502,2307 563.5341 705.2165
471.2247
599.2795
682.288<
437.2519
400. |5.::580 727.33595^1.1895
350 400 450 500 550 600 650 700 750 800 850 900 950 1000 1050 1100 1150 1200 1290 1300 1350 1400
m/z, amu
Figure 3.12. Spectrum analysis of peptides eluted from J774.2 cells treated with n-LDL 
analysed using the UltiMate 3000 LC-MS system. Cells were cultured and treated with n-LDL 
as described in section 3.6. MHO class II bound peptides were extracted after 24h of culture 
using citrate phosphate buffer (pH 3). The same peptide elution procedure was carried out for five 
days and samples pooled for LC-MS analysis. After peptide fractionation samples were 
lyophilised, reconstituted in ammonium acetate (pH 4.6) and analysed by LC-MS. The spectrum 
shows peaks at different m/z ratios.
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Figure 3.13. Spectrum analysis of peptide eluted from J774.2 cells treated with ox-LDL 
analysed using the UltiMate 3000 LC-MS system. Cells were cultured and treated with ox-LDL, 
and peptide elution was carried out as described in section 3.6. Notice the difference in peak 
profile compared with that shown in Figure 3.13, especially the appearance of peaks at 1177.32 
and 1550.73Da (red arrows). These peaks were analysed but didn’t matching protein sequences 
in the Mascot database.
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3.15 Discussion
Recent technological developments in the field of proteomies have facilitated a 
better understanding of the molecular components associated with the development of 
certain diseases. Emphasis is now being placed on peptide detection and identification so 
that peptides can be measured and evaluated as indicators of normal biological processes, 
pathogenic processes (i.e. atherosclerosis), or pharmacologic responses to specific drugs.
The objectives of this section of work were firstly, to standardise the conditions to 
detect peptides, and secondly, to identify new MHC-associated peptides derived from 
macrophages stimulated with low density lipoproteins. The purpose of this optimization 
stage was to determine the best conditions to suit the characteristics of the sample under 
investigation. This required adjustment of the parameters that can affect LC/MS analysis, 
such as sample concentration. Cap V and solvent composition. To identify these peptides, 
we took advantage of the new technological developments and knowledge in the field of 
proteomies. The methodology selected has been well validated and previously utilised by 
others for similar purposes in the field of cancer research (Storkus et al, 1993, Torabi- 
Pour et ah, 2001). This methodology involves the elution of peptides from MHC 
complexes using acid buffer extractions without affecting cell viability. Is the method 
with less time consuming, maximises the usage of samples (cells) and reduces the need 
for expensive reagents when compared with other similar approaches (i.e. affinity 
chromatography) (Provder, 1999; Feng et al, 2007).
The method described by Storkus (1993) is the only promising technique that is 
able to selectively isolate cell surface MHC-bound peptides. However, the main 
disadvantage of this technique is the high possibility of high molarity salt ions remaining 
in the peptide sample, which then requires further purification (Bonner et al, 2002). The 
main interest of Storkus and his group was the isolation and identification of MHC class 
I-associated peptides involved in cancer, and several studies have been published as a 
result of this work (Storkus et al, 1993; Mouritsen et al, 1994; Castelli et al, 1995). In 
1995, the six peptides identified by Storkus et al., in 1993 were tested therapeutically and 
three of these peptides produced promising results that led to the development of peptide- 
based immunotherapies for patients with melanoma (Castelli et al, 1995). In addition, 
Okano and Storkus identified novel CD8^  cytotoxicity lymphocyte cell (CTL) epitopes
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that have been implieated in peptide-based vaccines for glioma treatment (Okano et al, 
2002).
Despite the success in the identification of peptides using acid elution methods, 
scientists have been forced to optimise several parameters before LC/MS can be used, in 
order to guarantee optimal results (Niessen, 2006; Schmitt-Kopplin and Frommberger, 
2003). The parameters depend on the type of cells used and the MS equipment available 
for the analysis. In this study, the LC-ESI-MS system was used providing a rapid and 
sensitive analysis. This system is more effective than MALDI for the identification of 
high peptide numbers (Sehmitt-Kopplin and Frommberger, 2003) although this efficiency 
may depend on the specific type of application and protein source being analysed 
(http://www.forumsci.eo.il/HPLC/lcms_page.html).
The studies described in this chapter show that it is possible to detect peptides 
using 5 minute linear flow using either ammonium acetate or methanol as the solvent 
(Figure 3.2 and 3.3). Similar findings have been reported by others who also found that 
the use of ammonium acetate provides clearer peaks with less background (lida and 
Murata, 1990). Peptide was quantified before using LC/MS by loading a known volume 
and concentration of Pep2 in LC/MS (section 3.5.1.3). This step was performed to 
identify the sample load that provides an acceptable detection to be used in further 
experiments. Results show that the standards used were linear within the range of 750- 
24000ng (Figure 3.4). The lowest quantifiable concentration was 3000ng, which is a 
surprising result considering that this system can usually detect peptides with higher 
sensitivity. The low sensitivity for the detection of this peptide (Pep2) is unlikely to be 
due to the low solubility, because Pep2 dissolved in water as recommended by Sigma and 
formed homogeneous mixture. Additionally, Pep2 was sueeessfully detected in Figure
3.2 and 3.3, and appears exactly as suggested in the manufacturers guidelines (Sigma). 
Thus, the low sensitivity of the LC/MS to detect Pep2 (3pg/ml) may have occurred due to 
the inherent nature of the peptide, or because Pep2 may have been trapped in the 
permanently swept parts in the column. However, this result may not be a true reflection 
of the actual sensitivity of the system because it was not the ease for all peptide types, but 
may instead be related to the time scale used for the analysis. Perhaps by pinpointing the 
area where the peptides were detected (1.5 to 2min; Figure 3.4) it may be possible to
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detect lower concentrations. Another possibility, but a less likely explanation for the 
absence of peptide at lower concentrations (within the used 5min linear range used) could 
be peptide degradation.
Variation of sample cone and capillary voltage also had an effect on the detection 
of peptides. The normal range of cap voltage is 3-5kV (Lim and Lord 2002), but in our 
experiment the use of a high voltage of cap (3.1V) appears not be suitable for the analysis 
of these peptides as it could be responsible for peptide degradation in some of the 
samples (Figure 3.6 and 3.7). This is a common finding in LC-MS, not only during 
protein/peptide analysis but also when samples of a different nature are used. It has been 
reported that the Cap V changes during the analysis period and is usually different at the 
beginning and the end of the analysis (Marginean et al, 2009). However, experiments 
can be performed with constant eleetrospray voltage throughout the analysis period, as 
was performed in this study. From the basic standpoint for LC-MS analysis, the mobile 
phase is one of the central aspects that may affect peptide detection. Methanol and 
aeetonitrile were tested in this study because they are the eluents most commonly used 
(lida and Murata, 1990). Aeetonitrile showed an excellent result in control samples 
(Figure 3.5) and also in the analysis of samples extracted from JY and J774.2 cells 
(Figures 3.8 and 3.9). Interestingly, the use of different types of samples (Pep2, JY cells 
or J774.2 cells) produced the same clear results when aeetonitrile was used as a mobile 
phase, indicating the usefulness of this reagent in the analysis of our samples.
The most interesting result reported in this chapter was the detection of proteins 
eluted from control (non-treated) J774.2 and JY cells but not from n-LDL or ox-LDL 
treated cells (Figures 3.12 and 3.13) after two repeats. A comparison of the results found 
in this study and previous studies was not possible, because this is the first time these two 
cell types (J774.2 and JY) have been used to isolate and identify peptides associated with 
MHC molecules using the acid elution method and a LC/MS/MS system. Peptide 
extraction from MHC complexes has been classically carried out using affinity 
chromatography (Lemmel and Stevanovic, 2003; Copeland et al, 1996). However, other 
methods including acid elution and HF-NaOH have been used by others for the same 
purpose. HF-pyridine (hydrogen fluoride-pyridine) has been demonstrated to be a useful 
fluorinating agentand has been used under alkaline (NaOH) conditions to extract and
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identify eell wall proteins and peptides for drug discovery in previous studies (Yin et al, 
2005; Weig et al, 2004; Groot et al, 2004; Takaya, 1996). Storkus and Mouritsen's 
groups used acid elution to successfully extract MHC class I peptides and reported a 
revolutionary, useful alternative to affinity chromatography (Storkus et al, 1993; 
Mouritsen et al, 1994; Torabi-Pour et al, 2001). Storkus identified T eell epitopes 
presented by MHC class I molecules on melanoma cells using similar conditions as the 
ones used in this study. Seven matching proteins derived from control samples (Table 
3.2) were identified in this chapter, indicating that the reported conditions for the use of 
citrate phosphate buffer are reproducible and can effectively be used to extract peptides 
from MHC complexes. Torabi-Pour and eo-workers also managed to identify MHC class 
I associated peptides using a similar approach. They detected 20 peptides derived from 
cultured bladder tumour cells of approximate molecular weights between 700 and 
3000Da (Torabi-Pour et al, 2001). The peptides detected in the control samples in this 
study also fulfil a similar criteria providing additional support for the validity of this 
method.
However, despite the success of this method, no proteins matching the database 
were detected in cells treated with n-LDL or ox-LDL (Figure 3.12 and 3.13).The J774 
cells employed in the present study are known to be good models of antigen presenting 
cells and have been used in the past to study antigen presentation patterns (Kobeme et al, 
2001; Yuki et al, 2006). Thus, the choice of eell type is unlikely to be the cause of this 
result. A possible explanation might be the fact that these cells were treated differently, 
and that the nature of the peptides presented by the MHC complexes may also have 
varied. These new peptides may have different properties (i.e. size and/or binding 
affinities for the MHC molecules), which may affect the elution from the complexes 
under the pH conditions of the assay. The author who published the original method 
(Prof. Walter J. Storkus, University of Pittsburgh School of Medicine and Cancer 
Institute, Pittsburgh, Pennsylvania, USA) has since confirmed this hypothesis and has 
also suggested that pH 3 may not be as efficient as a less acidic pH range (i.e. 4 -5 pH) 
for the extraction of MHC class II associated peptides (personal communication by 
Dr.Emesto Oviedo-Orta). We have taken this opinion into consideration because the 
identification of MHC class I associated peptides in the cancer field has received much
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attention and because Storkus and his group are extremely experienced in this area 
(Storkus et al, 1993; Castelli et al, 1995; Okano et al, 2002). In addition, the acid 
elution method for peptide extraction, including the citrate phosphate buffer (by Storkus) 
has been sueeessfully used by Storkus and by other researchers (Storkus et al, 1993; 
Bonner et al, 2002).
Moreover, pH 3.0 could cause irreversible changes in the MHC class II 
molecules, causing dénaturation of the pocket containing the peptides and therefore 
making their elution from the complexes more difficult (Lee et al, 1992). Results 
obtained using pH range between 4-5 seem to have a less negative effect on the MHC 
class II molecule and provide better conditions for the stability and yield of the peptides 
extracted (Mouritsen et al, 1994; Lee et al, 1992).
Another factor that may have influenced the results in this chapter is the type of 
cells used. Most published results have used neoplastic cells or eell lines which are 
known to have particular ways of processing and presenting MHC derived antigens (Cruz 
et al, 1999). This study appears to be the first in which macrophages have been used to 
identify MHC class II associated peptides. Therefore, it is essential to further evaluate 
and optimise the elution methods in order to increase the yield of peptides in these 
samples. It is also essential to use citrate phosphate buffer at different pHs (pH 3, 4 and 
5) in order to identify protein and peptide profiles for each pH condition used.
To summarise, the present data in this chapter support the importance of 
optimisation for each study. The nature of each sample under investigation usually affects 
the research outcome and the standardisation step controls and fixes the conditions of the 
analyser system (e.g. LC/MS). Despite the popularity of methanol as the mobile phase of 
choice, or ammonium acetate as the best solvent, this may not be the ease for all studies. 
Our finding showed that clear peaks with higher resolution were achieved using 
aeetonitrile as the mobile phase. Methanol, ammonium acetate, and methanol and water 
(as solvents) were able to detect the peptide under investigation (Pep2 and Pep3) but 
background noise was higher compared to when aeetonitrile was usedThe results of these 
optimisation experiments provide the fundamental information and basis used to set up 
the LC/MS system for the following work described in the next chapters.
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Chapter 4 
Detection and Identification of Peptides
Abstract
Macrophages play a key role in the development of atherosclerotic lesions. Macrophages 
recognize LDLs through scavenger and toll-like receptors triggering metabolic changes in 
these cells, including the de novo synthesis and degradation of proteins that are presented 
in the form of peptides by the MHC class I and II molecules. The aim of the work 
presented in this chapter was to identify novel MHC-associated peptide patterns induced 
in vitro by stimulation of macrophages with LDL using LC-MS analysis. J774.2 mouse 
macrophages were treated with human native and oxidized LDL. Peptides were extracted 
from macrophage MHC complexes for five days using eitrate-phosphate buffer (pH 3, 4 
and 5). Samples were fractionated and then analysed by LC/MS/MS. MASCOT analysis 
was used to identify the source of the peptides. lEDB and NetMHCII 1.0 bioinformatic 
platforms were used to predict peptide-binding affinity to MHC class I and II complexes. 
Among the different groups, 135 peptides from 100 proteins were identified with this 
group containing 27 overlapping proteins. Ox-LDL treatment induced the display of 74 
peptides by macrophages, while treatment with n-LDL indued the expression of only 39. 
Based on predictive MHC binding analysis algorithms, we found 22 MHC class I 
peptides, 24 MHC class II peptides and 19 peptides predicted to bind both MHC class I 
and II. Importantly, 66.1% of these peptides had high promiscuity values. Furthermore, 
studies were also perfomed using oil red O stain to assess the effect of different culture 
conditions, including pre-treatment with n-LDL, ox-LDL or peptides derived from apoB- 
100 protein (Pepl, 2 and 3), on the maerophage-derived foam cells. Foam cells were 
generated using ox-LDL and high concentrations of Fep3, Pep2 and n-LDL .This study 
showed that treatment with different forms of LDL induces a differential pattern of 
expression MHC-assoeiated peptides by macrophages in vitro. These findings may 
contribute therapeutic attempts to suppress macrophage function during inflammatory 
responses.
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4.1 Introduction
Liquid chromatography mass spectrometry (LC/MS) is primarily a separation 
technique that can be used in different fields (e.g. clinical and industrial areas) and is 
probably the most powerful and flexible technique available to the modem analyst. In this 
chapter, the extraction of peptides from MHC molecules and their identification was 
carried out using the acid elution technique and LC/MS. In addition, ox-LDL derived 
foam cells were assessed using oil red O stain as a stain for lipids.
An important aspect that should be highlighted in this chapter is that a monolithic 
Ci8 column was employed in this work instead of the BEH Cig column used in the 
previous chapter. This change was necessary due to the use of the Ultimate miero- 
eapillaiy HPLC system in York’s proteomic centre. According to a study by Sharma et 
al (2009), replacement of the BEH Cig column by a monolithic Cig column should not 
alter the analysis outcomes, making the optimization step in chapter three, appropriate to 
the monolithic Cig column (Sharma et al, 2009). Sharma and his group demonstrated 
that monolithic and BEH Cig columns both obtain similar results with high throughput 
analysis, which present analyte eharaeteristies equally well (Sharma et al, 2009).
4.1.1 Macrophage derived foam cells in vitro
Monocyte-derived macrophages are essential cells that up take modified LDL 
(ox-LDL) in atherosclerotic lesions via scavenger and toll-like receptors (as discussed in 
section 1.75). In vitro, the formation of cytoplasmic lipid droplets in macrophages 
normally occurs after cells are loaded with ox-LDL. The visualisation and quantification 
of LDL droplets in macrophages is an important feature used to describe some of the 
histopathologieal changes that occur in atherosclerosis (Li and Glass, 2002; Napolitano et 
al, 2001). Traditionally, fluorescent dyes like Nile Red, Sudan dyes including the 
commonly used oil Red O (ORO) stain (a lysochrome fat-soluble diazo dye used to stain 
for neutral triglycerides and lipids) have been extensively used for fluorescent labeling of 
lipid droplets (Koopman et al, 2001; Greenspan et al, 1985). The use of ORO and Nile 
Red has been highlighted in studies investigating the role of chylomicrons (which deliver 
triglycerides to body cells to be used as fuel) in the role of foam eell formation using
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different in vitro models (Batt et al, 2004; Napolitano et al, 2001; Yu and Mamo, 
2000).
4.1.2 The evolution of epitope identification
Epitopes are the molecular structures (peptides) that interact with specific 
receptors of the immune system such as antibodies, MHC and T eell molecules (Figure 
4.1). Identification of immunodominant T eell epitopes derived from a given protein that 
best fits in the MHC molecule goove and are responsible for initiating the adaptive 
immune response, would advance peptide-based therapies and vaccine development. 
However, these peptides have not yet been identified in atherosclerosis (Robertson and 
Hansson, 2006; Hansson and Libby, 2006). Most atherosclerosis studies have focused on 
the discovery of a biomarker that may be used as a sign of the disease (Dupont et al, 
2005; Barderas et al, 2007), while the identification of MHC-associated peptides has 
been largely ignored. The genetic similarity between humans and mice make mice widely 
used models for biomarker discovery in different human diseases including cancer and 
cardiovascular diseases (Mayr et al, 2005; Wu et al, 2007). In the present study, mouse 
models were used to assess the feasibility of peptide identification in a system that is 
similar humans. On the other hand, this approach has been used in cancer, especially to 
identify MHC class I-assoeiated peptides (Storkus et al, 1993; Mouritsen et al, 1994; 
Torabi-Pour et al, 2001). The main aim of this chapter was to isolate MHC class I or II- 
associated peptides from the surface of ox-LDL pre-treated macrophages and identify 
these peptides, with the intention of discovering novel epitopes that may play an 
important role in the development of therapies for atherosclerosis.
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Figure 4.1. T cell recognition of a peptide-MHC complex. Peptides are transported to the 
surface of the ARC and presented to T-cells through MHC molecules. Peptides bind to MHC 
molecules in the peptide pocket called the groove.
4.2 Current tools used for T-cell epitope prediction and analysis
In order to discover more successful biomarkers and vaccines, a great deal of 
effort has been put into developing immunological prediction tools. Predicting the 
peptides that bind to MHC class I or II molecules is a beneficial way to decrease the 
number of experiments required for identifying helper T cell epitopes (Sette and Fikes, 
2003). MHC prediction methods are divided into two types: (1) the qualitative prediction 
process that determines the binding status (binder or non-binder) of peptides depending 
on the predictive score and (2) the quantitative prediction process that predicts the 
inhibitory concentration at 50% (IC50). The newest quantitative prediction 
approaches are support vector machine regression based method for modeling peptide- 
MHC binding (SVRMHC), Average Relative Binding (ARB), Epitope Prediction and 
Analysis Tools (lEDB) and the Stabilized Matrix Method (SMM-align) (Peters and Sette, 
2005). The ARB approach normally uses the full length of the peptide while SVRMHC 
uses an additional step involving the alignment of sequences depending on anchor 
position-specific residues (Nielsen et al, 2007).
4.2.1 lEDB
lEDB is one of the most popular T cell prediction tools (Peters et al 2005). lEDB 
contains specific information for each predicted peptide with I C 5 0  binding affinities for 
the 13 HLA (human MHC) and 3 mouse MHC class II alleles. This data has been used 
for quantitative prediction of MHC class 11 peptide binding (Nielsen el al, 2003; Nielsen
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et al, 2007). Three different predietion methods are involved in the lEDB analysis. Two 
of them are based on scoring matrices (ARB and SMM) (Zhang et al, 2008; Peters and 
Sette, 2005) and the third is based on an artifieial neural network (ANN) (Nielsen et al, 
2008). ARB matrix methods predict IC50 values that provide a eombination of searehes 
eomprising different peptide sizes and alleles in one single global predietion. Sourees 
have reported that predietion of MHC class I binding accuracy was more sueeessful (up 
to 95%) eompared to the MHC elass II binding seores (Salomon and Flower, 2006). In 
order to inerease MHC class II binding score effieiency, pattern recognition methods 
sueh as Artifieial Neural Networks (ANNs) and Support Veetor Machines (SVM) have 
been used (Salomon and Flower, 2006, Nielsen et al, 2003).
4.3 MASCOT and MOWSE statistical software
4.3.1 MASCOT
LC/MS/MS systems are merged with software paekages that link and eompare 
MS/MS throughput with databases, as diseussed before. Many online tools and software 
are now available (e.g. MASCOT), providing exeellent opportunities for protein and 
peptide identification. These tools are divided into two groups. First: the ExPASy (Expert 
Protein Analysis System) is a powerful tool related to the Swiss Institute of 
Bioinformaties (SIB), containing several useful online programs ineluding Peptldent, 
FindPept and PeptideMass. Seeond: tools focusing on translating nucleotide sequenees to 
peptide sequenees or aiming to prediet glyeosylation sites include Mapper, SEQUEST 
and MASCOT (Xu and Ma, 2006).
4.3.2 Probability Based MOWSE Score
MASCOT integrates a probability based implementation of the MOWSE 
(MOleeular Weight Search) algorithm. MOWSE is important statistical software because 
it aceurately models the behaviour of proteolytie enzymes (Perkins et al, 1999; 
Mirgorodskaya et al, 2005). However, false or random matehes arising from software 
analysis have to be taken into eonsideration. Mass speetrometry results are not always 
perfect and sometimes ions are generated that eannot be identified in every experiment. 
To overeome this problem, MASCOT ealculates a “threshold” seore representing a 5%
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confidence threshold (Xu and Ma; 2006). The threshold score for statistical significance 
is illustrated as a histogram in Figure 4,2.
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Figure 4.2. Representative histogram showing a probability based MOWSE score
(www.matrixsGience.com).
The number of protein matches for each score is presented by the red bars and the 
non-significant area is highlighted in green. A higher seore represents a more confident 
match with scores >48 being statistically significant (Perkins et al, 1999) 
(www.matrixseience.com). The probabilistic framework adds many benefits to MASCOT 
(Shadforth et al, 2005) (www.matrixscience.eom), and MOWSE enables researchers to 
compare scores from different databases and to judge the significance of identified 
proteins. To avoid any fault or error in the MASCOT report, the probability (P) is 
converted to a seore [(10*Log (P)] before reporting. P is the probability that the observed 
match is a random event (p<0.05) and is also shown in Figure 4.2. The protein database 
however is not random and the MOWSE seore only indieates the significanee of the 
match but not guarantee that it is eorrect (www.matrixscience.com).
4.4 Aim and objectives
4.4.1 Aim
To extract and to identity MHC class I or II associated peptides from the surface 
of macrophages pre-treated with ox-LD and n-LDL
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4.4.2 Objectives
• To investigate macrophage-derived foam cells by ORO staining
• To extract MHC class I or II peptides using the acid elution method with three 
different pHs
• To identify MHC-associated peptides using LC/MS/MS and MASCOT software
• To identify MHC class I and class II peptides using lEDB and NetMH websites
• To identify the biological role of the identified proteins using iHOP and gene 
ontology websites
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4.5 Materials and Methods
4.5.1 Peptide extraction
4.5.1.1 Cell Culture
Cells were cultured using two different methods. First, for subculture purposes, 
the J774.2 cells (~3xl0^cells/ml) were grown in T75 cm  ^tissue culture flasks with 20ml 
DMEM (Dulbecco’s Modified Eagle’s Media) containing 10% FCS and 5ml PSG 
(penicillin lOOu/ml, streptomycin lOOpg/ml, glutamine 2mM)). Cells were incubated at 
37°C in a 5% CO2 atmosphere (Hera cell 240, Heraeus). Secondly, for peptide extraction, 
cells (-50x1 O^cells/fiask) were cultured in three T175cm^ flasks with 50ml serum-free 
media (HyQ® ADCF-MAb™ without L-glutamine) containing 5ml PSG. After a 24h 
incubation period, 50pg/ml of either n-LDL or ox-LDL was added. MHC class II bound 
peptides were extracted after a further 24h of incubation as described below.
4.5.1.2 Analysis o f cell viability
J774.2 cells were cultured (-IxlO^cells/ml) in twelve well culture plates with 2ml/well of 
DMEM media containing 10% FCS and 5ml PSG. After a 24h incubation period, some 
cells were treated with 80pg/ml ox-LDL whilst others were kept as controls (untreated). 
Cells were washed with 1ml PBS and then treated in the same media with 80pg/ml ox- 
LDL every 24h for the following three days (Figure 4.3). Cells were incubated at 37°C in 
a 5% CO2 atmosphere. Three wells from each condition were picked randomly every 24h 
for cell counting. For counting, cells were mixed 1:1 with trypan blue in PBS and then 
counted using a Haemocytometer (Horsham).
24h 24h Collect cells
Cell Incubation Treatment incubation ^  & count
culture (80jjg/mLox- 24b
LDL) Incubation «^ount
Wash & treat cells
Inc
24h
jbation
- . ,, After each 24h
Collect cells < Wash & treat cells
& count
Figure 4.3. The experimental protocol used to a sse ss  cell viability.
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4.5.1.3 Peptide extraction andfractionation
Methods for peptide extraction and fractionation were n discussed in chapter 2 
(section 2.6). Figure 4.4 provides a summary of the peptide extraction and fractionation 
protocol.
nLDL / oxLDL
J774 cells
l i a a
0 _MS
Peptide extraction 
Citrate P hosphate Buffer 
pH 3, 4 &5
Purification 
•A eetonitrile  (CAN) 
•018  8 e p  Pak  
•C enter! eon-10
M ass Spec
Re-culture
/ n  vfitro o r  In  v i v o  
activity Assays
Peptide selection Sequencing
Figure 4.4. Summary of the protocol used for peptide extraction from macrophage 
MHC-class II complexes.
4.5.1.4 Oil red O staining
ORO stain is a member of the Sudan dye family that is used specifically to 
identify sudanophilic substances, such as lipids. ORO stain has a higher solubility in lipid 
cores than it does in the normal hydroalcoholic dye solvents and stains lipids dark red and 
nuclei a clear blue colour. A stock solution of ORO was prepared by dissolving 0.5g of 
ORO (C26H24N4O, Sigma, UK) in 200ml isopropanol (Sigma, UK). The solution was 
then heated (65°C) with slow stirring for 1 hour before being cooled, filtered twice 
through Whatman filter paper and stored at room temperature.Working solutions were 
prepared freshly before each experiment by diluting 4 parts of stock with 6 parts water 
and mixing for 1 Omin before filtering through Whatman filter paper.
Cells were cultured as described in chapter 2 section 2.5. To stain cells, 
supernatants were removed and chamber slides containing the cells were washed twice 
with PBS (Sigma, UK). A working solution (2ml/well) of ORO was added to the cells 
and incubated for 15-30min at room temperature. Cells were then washed twice for Imin
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with PBS (Koopman et al, 2001; Batt et al, 200). Cells were mounted in an aqueous
mounting medium (permanent Mounting Medium, VECTA MOUNT^^), and images
were captured using a Leica DMLB microscope (Wetzlae, Germany).
4.6 LC/MS analysis
4.6.1 LC/MS/MS conditions
An Ultimate micro-capillary HPLC system (Dionex) was used for reverse phase 
separation using an Onyx monolithic Cig silica column (100 pm x 15 cm, Phenomenex). 
Monolithic columns possess a different structure from traditional columns (e.g. Silica) in 
that they contain porous channels rather than beads. The main advantages of monolith 
columns are their superior performance for fast separation with low pressure at high flow 
rates, and their good mass transfer efficiency. Moreover, they are capable of high flow 
rates, low backpressure and increased reliability, reproducibility and lifespan 
(Phenomenex Inc., Torrance, CA, USA). HPLC was interfaced with a QSTAR® API 
Pulsar iHybrid LC/MS/MS System (Applied Biosystems, UK) with a Micro Ion Spray 
source (fitted with 20pm ID capillary). Positive mode [M+H]  ^ESI MS and MS/MS 
spectra were obtained over the range 350 -  1800 m/z using information dependent 
acquisition (IDA). Instrument control, data acquisition and analysis were performed with 
Analyst QS VI.1 software. The separation was achieved by gradient elution of two 
solvents of mobile phase:
A): 2% aeetonitrile (ACN) + 0.1% FA in H2O
B): 100% aeetonitrile (ACN) + 0.1% FA in H2O
An aliquot of each acidified sample (5 pi) was loaded on to the column with a flow rate of
1.2 pl/min and column temperature of 60°C.
The chromatographic profile used in the run was as follows:
Initial conditions of 100% solvent A 
Linear gradient 0 -  20% solvent B over 40min 
Linear gradient 20 -  50% over 20min 
Wash at 95% solvent B for 5mins 
Reconditioning in 100% solvent A
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4.6.2 Data analysis
Peptide MS and MS/MS data for database searching were submitted to MASCOT 
(V2.2, Matrix Science). The query data was generated from IDA files using either 
MASCOT script (V1.6b23) or MASCOT Daemon (V2.2). The databases searched were 
IPI human and IPI mouse. MASCOT results were archived to individual web-based 
folders.
4.6.3 MHC epitope and prediction tools
MHC epitope prediction and analysis tools were used to identify MHC class I and 
II alleles. These databases were:
• NetMHCII 1.0 Server (http://www.cbs.dtu.dk/services/NetMHC-2.0)
• lEDB analysis recourse (http://www.iedb.org/)
In order to identify protein properties including type, function and organism, two 
different software packages were used:
• The gene ontology (GO) (http://www.geneontology.org)
• iHOP (http://www.ihop-net.org/UniPub/iHOP)
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4.7 Results
4.7.1 Induction of foam cell formation in vitro by LDL and apoB-100 derived 
peptides
ORO stain was used in this study to investigate the uptake of n-LDL and ox-LDL 
by J774.2 cells and mouse peritoneal macrophages. Untreated J774.2 macrophages 
(negative control) are distinguished from treated cells because they have a clear 
cytoplasm, whereas treated cells stained red. Figures 4.5 - 4.6 show foam cells that were 
generated from ox-LDL treated J774.2 cells.
Figure 4.5. Induction of macrophage foam cells by ox-LDL (100pg/ml). J774.2 cells were 
treated with 100pg/ml of ox-LDL and then incubated for 72h. Cells were stained with ORO stain 
(section 4.5.1.1). Images were captured using a Leica DMLB microscope (magnification: 100X). 
Panel A shows untreated cells as a negative control. Panel B is a positive stain for treated cells. 
C and D show an individual treated cell (n=3).
The study shows how treatment of macrophages in vitro with 100 (Figure 4.5) and 
lOOpg/ml ox-LDL (Figure 4.6) was able to generate foam cells, however, lower 
concentrations of ox-LDL (<80pg/ml) were unable to induce foam cell formation (data 
not shown).
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Figure 4.6. Induction of macrophage foam cells by ox-LDL at 80pg/ml. J774.2 cells were 
treated with 80|jg/m! of ox-LDL and then incubated for 72h. Cells were stained with ORO stain 
(section4.5.1.1). Images were captured using a Leica DMLB microscope (magnification: 100X). 
Panel A shows untreated cells as a negative control. Panel B and 0 are a positively stained for 
treated cells (n=3).
In J774.2 cells treated with n-LDL, accumulation of lipid droplets was only seen 
at high concentrations (lOOpg/ml) (Figure 4.7), whereas lower concentrations (20, 40 and 
80pg/ml) failed to induce foam cell formation as assessed by ORO staining.
Figure 4.7. Induction of macrophage foam cells by n-LDL at 100pg/ml. J774.2 cells were 
treated with 100pg/ml of n-LDL and then incubated for 72h in standard culture conditions. Cells 
were stained with ORO stain (section 4.5.1.1). Images were captured using Leica DMLB 
microscope (magnification: 100X). Panel A is a negative stain of untreated cells. Panels B and C 
are positively stained for treated cells at lOOpg/ml n-LDL. Panel D shows negative staining of 
treated cells at (80pg/ml) n-LDL (n=3).
Pepl and Pep2 did not induce foam cell formation in J774.2 cells at any of the 
concentrations used, indicating an inability of these peptides to participate in this process 
even at high concentrations. Pep3 was the only peptide capable of inducing lipid droplet 
accumulation in J774.2 cells at lOOpg/ml, as shown inFigure 4.8.
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Figure 4.8. Induction of macrophage foam cells by Pep3. J774.2 cells were treated with 
100pg/ml of Pep3 and then incubated for 72h in standard culture condition. Cells were stained 
with ORO stain (section 4.5.1.1). Images were captured using a Leica DMLB microscope 
(magnification: 100X). Panel A is a negative stain of untreated cells. Panel B and C is a positive 
stain of cells treated with lOOpg/ml of Pep3 (n=3).
Mouse peritoneal macrophages were also studied using similar experiments, 
concentrations of n-LDL, ox-LDL and peptides. Incubation of cells with n-LDL at 20, 40 
and 80pg/ml did not induce foam cells. However, induction of foam cells was observed 
after treatment with ox-LDL, Pep2 and Pep3. Low concentrations of ox-LDL (<80pg/ml) 
did not induce foam cells, and around 90% of cells died when >80pg/ml of ox-LDL and 
n-LDL were used.
*
Figure 4.9. Induction of foam cells in peritoneal macrophages by ox-LDL at 80pg/ml.
Peritoneal macrophages were treated with BOpg/ml of ox-LDL and then incubated for 72h in 
standard culture conditions. Cells were stained with ORO stain (section 4.5.1.1). Images were 
captured using a Leica DMLB microscope (magnification: 100X). Panel A is a negative stain of 
untreated cells, panel B and C are positive stains for treated cells. Panel D shows cells treated 
with ox-LDL and pre-ORO staining, to indicate the change of cell morphology and show how cells 
were activated by treatment (n=3).
Lipid accumulation was observed in peritoneal macrophages treated with 80pg/ml 
of ox-LDL (Figure 4.9). Pep2 and Pep3 treated cells showed positive red staining only at 
high concentrations (lOOpg/ml) (Figure 4.10).
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Figure 4.10. Induction of foam cells In peritoneal macrophages at 100pg/ml of Pep2 and 
Pep3. Peritoneal macrophages were treated with 100pg/ml of Pep2 and Pep3 separately and 
then incubated for 72h under standard culture conditions. Cells were stained with ORO stain 
(section 4.5.1.1). Images were captured using a Leica DMLB microscope (magnification: 100X). 
Panels A and B show red lipid droplets within cells generated by 100pg/ml of Pep2 treatment, 
panel C and D show red lipid droplets resulting from 100pg/ml of Pep3 treatment (n=3).
In conclusion, the effect of ox-LDL and n-LDL treatment on the fonuation of 
foam cells derived from J774.2 and peritoneal macrophages was comparable at 
concentrations of 20 and 40pg/ml between the two cell types. Both treatments at these 
concentrations failed to result in any cytoplasmic accumulation of lipid droplets. 
Peritoneal macrophages were more sensitive to toxcicity at high concentrations 
(lOOpg/ml) of ox-LDL and n-LDL than J774.2 cells. In addition, the results using Pepl 
and Pep3 were similar using both cells types. Pepl was unable to induce lipid 
accumulation in both cell types, and Pep3 was only able to induce foam cells in both cell 
types when used at lOOpg/ml. On the other hand, Pep2 was able to induce foam cell 
formation in peritoneal macrophages only when used at lOOpg/ml.
4.7.2 The effect of ox-LDL on cell viability
The purpose of this experiment was to investigate the effects of chronic exposure 
of macrophages to ox-LDL in vitro. J774.2 cells were exposed to 80pg/ml ox-LDL for 
three days as described in section 4.5. Exposure of cells to constant concentrations of ox- 
LDL allowed steady and significant uptake of lipoprotein by the cells, to induce toxic 
effects to be observed. Three individual experiments were performed and means and 
standard deviations were calculated. Cell numbers increased from approximately -1.5 
xlO^to 8 xlO^cells/ml in both conditions (untreated and ox-LDL) during days 1-2 (Figure 
4.11). Untreated cells appeared to replicate quicker than treated cells after two days and
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reached ~9 xlO cells/ml at day 3 and 4. Between day 4 and day 7, cell numbers declined 
but from day seven until last day of culture (day 11), cell growth remained relatively 
constant (~6 xlO  ^ eells/ml). Conversely, the number of cells treated with ox-LDL 
dropped after day 2, suggesting that the two doses of ox-LDL administered were the 
cause of this cell death. By day 7, numbers of treated cells had dropped from 8 xlO  ^to 
~5.6xl0^eells/ml and only ~3xl0^cells/ml remained after the last treatment at day eleven 
(Figure 4.11). This indicates the ability of untreated J774.2 cells to survive for longer 
with high viability in normal culture conditions compared cells treated with ox-LDL. 
Though J774.2 cells can survive and proliferate for a period of time in the presence of ox- 
LDL, cell death occurs at a higher rate after just two doses and cells appear to die more 
rapidly during the last stage of culture (day seven) due to increased toxicity. Based on 
this observation, cells were cultured in the presence of ox-LDL for up to six days for the 
purpose of these experiments.
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Figure 4.11. A ssessm ent of J774.2 cell viability. Cells were cultured in twelve-well culture 
plates with 2ml/well of DMEM media supplemented with 10% PCS and 5ml PSG as described in 
section 4.5.1.3. (n= 3). The green curve represents untreated cells and the red curve represents 
cells pre-treated with ox-LDL.
4.7.3 Protein and peptide identification using LC/MS/MS and MASCOT software
All chromatograms presented hereing are representative of three technical repeats: 
Two repeats were completed by MASCOT software analysis and the third repeat was 
conducted by ProteinPilof^’'^  software (v3.0). Both types of software obtained the same 
protein and peptide identification with similar scores for both. In our study, all identified
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proteins fell in to the prediction category with a probability value of presumably P>0.05 
and a protein score ranging from 48 to >76 indicating a significant prediction.
Search strategy and parameters were the same for all samples indentified by 
LC/MS/MS and MASCOT and are outlined belo:
Database 
Mass values 
Protein Mass 
Peptide Mass Tolerance 
Peptide Charge State 
Max Missed Cleavages 
Database 
Instrument type
IPI mouse (55272 sequences; 24903527 residues) 
Monoisotopic 
Unrestricted 
± 0.2 Da 
1+
1
SwissProt 51.6 (257964 sequences; 93947433 residues) 
ESI-QUAD-TOF
The chromatogram peaks presented herein show the sum of all MS signals within 
the analytical range. These peaks were annotated to indicate the most abundant ion, 
known as the base peak. For example, the 824.4 peak shown in Figure 4.12A was 
assigned to the major ion in the chromatogram. Each spectrum is an average spectrum of 
the whole chromatogram. However, the peaks depicted in these cases do not correspond 
to those used for the database search and peptide identification. The database search was 
conducted using MS/MS data to provide sequence information and not just to match 
peptides with an indentified mass The search data was comprised of a series of peak lists 
(generated from the mass spectrometer raw data file) that contained the fragmented ions 
observed for each precursor ion (molecular ion) that was selected for MS/MS. 
Essentially, not all peaks in the spectrum were subjected to MS/MS; only those that met 
the following criteria: m/z, 350 - 1800; z, +2 - +5; minimum 20 counts; ion mass 
tolerance, 200ppm. This range was chosen to select the most likely fragments to identify 
a peptide of interest that could be derived from MHC complexes.
4.7.3.1 The effect o f ox-LDL and different pHs o f citrate phosphate buffer
A chromatogram and its related spectrum analysis derived from cells treated with 
ox-LDL and acid elution buffer (pH 3) are presented in Figures 4.12A and B. Two 
different sample injections were analysed but were found to produce the same 
chromatogram. The probability based MOWSE score is presented in Figure 4.12C. A P- 
value [(10*Log (?)] indicates the probability observed from random matched events.
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Protein and peptide scores (Table 4.1) were derived from ion scores as a method for 
ranking the probability of protein hits. For this process, chromatogram and spectrum 
analysis for citrate phosphate buffer and serum free media were both used as negative 
controls (results presented in appendix 4). Twenty one source proteins derived from ox- 
LDL treated cells were identified and from these, 32 peptides were derived (Table 4.1). 
Five overlaping proteins were identified and are shown in Table 4.1 (highlited with 
yellow).
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Figure 4.12: The analysis of peptides produced by J774.2 cells treated with ox-LDL and 
peptide profile generated with citrate phosphate buffer at pH 3. Cells were cultured and 
peptides eluted using citrate phosphate buffer (pH 3). Samples were lyophilised overnight and 
reconstituted in ammonium acetate (pH 4.6). Concentrated peptides were analysed using the 
Ultimate micro-capillary HPLC system (Dionex) (section 4.6). Panel A shows the Chromatogram 
analysis (Y axis shows total ion counts (TIC), and X axis presents analysis period 
(mins)). Chromatograms represent 3 technical repeats. Panel B shows the spectrum analysis for 
selected peptides from panel A. The mass spectrum shows peaks at different mass/charge (m/z) 
ratios that were used for sequence analysis (Y axis shows intensity counts and X axis presents 
m/z). P anel 0 sh o w s the probability b a se d  MOWSE sc o r e  for proteins. Hits <48 were excluded and can 
be seen highlighted in green. The number of matched hits in the database is shown on axis Y, 
while the axis X represents a MASCOT score for predicted proteins; scores >67 are significant.
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Table 4.1. Proteins and peptides predicted from MS/MS and MASCOT software [ox-LDL, pH
3]. Peptides are listed according to their code (i.e. Pepi). Overlapping proteins and peptides (i.e.
those also identified in experiments using different conditions) are highlighted with yellow.
Protein name Accession 
NCBI BLAST
Protein
MASCOT
score
Sequence 
coverage %
Peptide
ID
Mr (calc) Peptide
MASCO
Tscore
LOC633468 predicted XP 002288043 196 30 Pep 1 
Pep 2 
Pep 3 
Pep 4
1395 9
1433.7
1576.7 
1923.9
32
50
28
65
Histlh3c;Histlh3b;Hist
lh3f
P84228 173 29 Pep 5 
Pep 6 
Pep 7 
Pep 8
1108.5 
1395 9 
1433.7 
1886 8
39
32
50
29
Histlh2bl;Histlh2bf;Hi
stlh2bn
CAI24103 137 22 Pep 9 
Pep 10
1008.6
2982.6
49
88
Pfol NP 035202 93 13 Pep 11 1960.0 94
Pgkl CAM 17784 91 3 Pep 12 1509. 8 92
100039528 similar to 
hCG2038359
77 2 Pep 13 1138.6 26
Rail AAI45885 70 2 Pep 14 
Pep 15 
Pep 16
1522/7 
1550 8 
1655.8
23
36
21
Actbl2 Beta-actin MGI:2444552 70 6 Pep 17 
Pep 18
1165.6
1410.7
36
37
Rapgef2 Rap MGI:2444552 69 0 Pep 19 1417.7 27
SlOOall MGI: 1338798 65 12 Pep 20 1202.5 6
Mtap2 MGP97175 64 2 Pep 21 1524.8 27
Ep400 MGI:1276124 61 0 Pep 22 792.41 27
Paxipl NP 061366 60 2 Pep 23 1902.9 42
Dnahc8 NP 038839 58 0* Pep 24 1808 9 30
Clqll AAH22724 56 3 Pep 25 1011.6 56
Hhipll MGI: 1919265 55 1 Pep 26 1389T) 29
Ncoa2 MGI: 1276533 55 0* Pep 27 
R # 2 8
1395.7
1407.7
25
34
DdxlV MGI: 1914290 51 7 Pep 29 1412.6 27
Dhx8 NP 659080 50 2 Pep 30 2335.3 30
5430427019Rik 
Uncharacterized
AAI15577 50 6 Pep 31 1292 6 21
Lass5 NP 082291 48 4 Pep 32 1114.6 24
* 0% se q u e n c e  co v erag e ; The minimum sequence coverage MASCOT can record is 1%. All proteins with high 
molecular weight showed 0% of sequence coverage. This because the number of identified amino acids in the 
peptide is very low compared to the overall number of amino acids in the whole protein (WVVW.dionex.com) 
Mathematically,in Table 4.1: the Rapge protein MW =166324 & MW for the identified peptide = 1417.7 [1417.7 / 
166324= 0.0085], The actual percentage of sequence coverage is 0.85%, but MASCOT system s record it as 0%.
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The chromatography and spectrum results generated using citrate phosphate buffer pH 4 
are presented in Figures 4.13A and B and the associated probability graphs are shown in 
Figure 4.13C. Table 4.3 shows all proteins and peptides that were identified using citrate 
phosphate. Protein and peptide scores and NCBI accession numbers are listed.
Nineteen proteins were identified from cells treated with ox-LDL and extracted 
using citrate phosphate buffer at pH 4. It was possible to predict 23 peptides derived from 
these 19 proteins with high probability (Figure 4.7C) and high protein scores (Table 4.2). 
Some of the proteins identified were also generated by cells treated with other conditions 
and are thus considered as ‘overlapping’. After exclusion of these overlapping proteins, 
13 were found to be unique to the pH 4 extraction buffer condition.
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Figure 4.13: The analysis of peptides produced by J774.2 cells treated with ox-LDL and 
peptide profile generated with citrate phosphate buffer at pH 4. Cells were cultured and 
peptides eluted using citrate phosphate buffer (pH 4). Samples were lyophilised overnight and 
reconstituted in ammonium acetate (pH 4.6). Concentrated peptides were analysed using the 
Ultimate micro-capillary HPLC system (Dionex) (section 4.6). Panel A shows the Chromatogram 
analysis that represents 3 technical repeats. Panel B shows the spectrum analysis for selected 
peptides from panel A. The mass spectrum shows peaks at different mass/charge (m/z) ratios, 
which were used for sequence analysis. P anel C sh o w s  the  probability b a sed  M O W SE sc o r e  for 
proteins. Hits <48 were excluded and can be seen highlighted in green and scores >67 are 
significant.
87
Table 4.2. Proteins and peptides predicted from MS/MS and MASCOT software [ox-LDL, pH
4]. Peptides are listed according to their code (i.e. Pep33). Overlapping proteins and peptides
(i.e. those also identified in experiments using different conditions) are highlighted in yellow.
Protein name Accession 
NCBI BLAST
Protein
MASCOTS
core
Sequence 
coverage %
Peptide
ID
Mr(calc) Peptide t 
MASCOT 
score
Tsc22d2 AAI17999 99 7 Pep 33 1292.6 22
Rnfl57 CAM 16809 91 22 Pep 34 2129.1 28
Pgkl CAM 17784 84 3 Pep 35 1509.8 85
Tnrc6c NP 932139 79 3 Pep 36 
Pep 37
2233 1 
2852.3
28
32
Cacna2d2 NP 064659 77 3 Pep 38 2809.0 22
Dcdc5 XP 001481374 76 2 Pep 39 1004.5 42
Gm22 XP 111398 67 0 Pep 40 824.46 32
Histlh2ba iCAd35973 66 7 Pep 41 1008.6 66
Naca NP 001106670 66 2 Pep 42 3805.0 25
Sftpd INP 033186 64 5 Pep 43 
Pep 44
1403.61
1531.7
27
40
Ep300 AA144977 58 1 Pep 45 
Pep 46
742.37
1441.7
24
21
Ror2 Tyrosine-protein BAA75481 54 1 Pep 47 1773.8 398
2810002009Rik RIKEN 
cDNA 2810002009
NP 780388 53 1 Pep 48 1267.6 27
M112 AAH58659 52 1 Pep 49 
Pep 50
1389.6
1518.7
27
30
Wdr46 NP 065628 51 3 Pep 51 992.49 32
Tcf20 NP 065628 48 1 Pep 52 1305.5 23
Jhdmld NP 001028602 48 3 Pep 53 3189.6 31
Zhx3 106 kDa protein AAH58111 48 1 Pep 54 796.48 23
AU04267I MGE2141089 48 0 Pep 55 1264.7 22
Figure 4.14 A, B and C illustrates the results of peptides extracted from cells pre­
treated with ox-LDL using citrate phosphate buffer at pH 5. All proteins and peptides 
predicted from this chromatogram and spectrum analysis are presented in Table 4.3. 
There were fifteen predicted proteins and only one of these proteins overlapped with 
other conditions. Eighteen peptides were identified from fourteen non-overlapped 
proteins. Most of these proteins and peptides had high ion scores.
To summarise the results derived from ox-LDL treatment condition:
• The number of identified proteins was 55 (Table 4.10)
• Fifty seven (57) peptides were identified from forty three proteins after 
exclusion of overlapping proteins.
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Figure 4.14; The analysis of peptides produced by J774.2 cells treated with ox-LDL and 
peptide profile generated with citrate phosphate buffer at pH 5. Cells were cultured and 
peptides eluted using citrate phosphate buffer (pH 5). Samples were lyophilised overnight and 
reconstituted In ammonium acetate (pH 4 .6 ) .  Concentrated peptides were analysed using the 
Ultimate micro-capillary HPLC system (Dionex) (section 4 .6 ) .  Panel A  shows the Chromatogram 
analysis that represents 3 technical repeats. Panel B shows the spectrum analysis for selected 
peptides from panel A. The mass spectrum shows peaks at different mass/charge (m/z) ratios, 
which were used for sequence analysis. P anel C sh o w s  the probability b a se d  M O W SE sc o r e  for 
proteins. Hits < 4 8  were excluded and can be seen highlighted In green and scores > 6 7  are 
significant.
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Table 4.3. Proteins and peptides predicted from  MS/MS and MASCOT software [ox-LDL, pH
5]. Peptides are listed according to their code (i.e. Pep56). Overlapping proteins and peptides
(i.e. thos also identified in the experiment using different conditions) are highlighted in yellow.
Protein name Accession 
NCBI BLAST
Protein 
Mascot score
Sequence 
coverage %
Peptide
ID
Mr(calc) Peptide 
Mscot score
Zfpml NP_033595.1 88 4 Pep 56 
Pep 57
598.25
2726.4
30
33
Asxl2 AAI41I41 79 0 Pep 58 710.34 49
Bsn Isoform 2 MGI: 1277955 78 1 Pep 59 895.4 28
Gabre CAMI4990 72 2 Pep 60 
Pep 61
938.41
1354.6
32
22
Aridla NP 001074288 64 4 Pep 62 574.27 28
Dcdc5 XP 001481374 62 I Pep 63 739.39 31
Med25 NP 083641 61 I Pep 64 792.42 39
Ncoal EDL01367 58 Pep 65 I02I.5 22
DnahcS NP 579943 57 0 Pep 66 739.40 26
Slc39al4 AAH21530 57 4 Pep 67 710.31 20
Ncorl CAI35322 53 I Pep 68 
Pep 69
1176.6
1395.6
21
22
Plchl NP_899014 51 2 Pep 70 
Pep 71
1078.4
3086.4
33
23
Ferll4 CAX15727 51 1 Pep 72 1192.6 25
Polm NP_059097 50 5 Pep 73 811.38 30
Hoxa3 NP 034582 47 4 Pep 74 1565.7 26
4.7.3.2 The effect o f n-LDL and different pHs o f citrate phosphate buffer
In contrast to ox-LDL treatment, fewer proteins and peptides were identified 
when treated with n-LDL. The chromatogram, spectrum analysis and probability based 
scores are shown in Figures 4.15A, B and C respectively, for peptides extracted with 
citrate phosphate buffer pH 3. These graphs and scores predict eighteen different 
proteins and twentytwo peptides at this pH. Six overlapping proteins (highlighted in 
yellow), the MASCOT scores, sequence coverage, NCBI BLAST accession numbers and 
molecular weights are shown in Table 4.4.
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Figure 4.15: The analysis of peptides produced by J774.2 cells treated with n-LDL and 
peptide profile generated with citrate phosphate buffer at pH 3. Cells were cultured and 
peptides eluted using citrate phosphate buffer (pH 3). Samples were lyophilised overnight and 
reconstituted in ammonium acetate (pH 4.6). Concentrated peptides were analysed using the 
Ultimate micro-capillary HPLC system (Dionex) (section 4.6). Panel A shows the Chromatogram 
analysis that represents 3 technical repeats. Panel B shows the spectrum analysis for selected 
peptides from panel A. The mass spectrum shows peaks at different mass/charge (m/z) ratios, 
which were used for sequence analysis. P anel C sh o w s  th e  probability b a se d  M O W SE sc o r e  for 
proteins. Hits <48 were excluded and can be seen highlighted in green and scores >67 are 
significant.
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Table 4.4. Proteins and peptides predicted from MS tandem and MASCOT software [n-LDL,
pH 3]. Peptides are listed according to their code (i.e. Pep75). Overlapping proteins and peptides
(those also identified in experiments using different conditions) are highlighted in yellow.
Protein name Accession 
NCBI BLAST
Protein
Mascot
score
Sequence 
coverage %
Peptide
ID
Mr(calc) Peptide
Mscot
score
Aridlb N P_001078824 95 3 Pep 75 
Pep76
2541.1
2945.2
23
37
Histlh2bl;Histlh2bf CAI24103.1 69 22 Pep 77 2982 6 69
EG545306 MGI:3644176 69 4 Pep 78 1715.9 21
Ttn Isoform 1 of Titin CAM23448 68 0 Pep 79 1535.8 25
EG623365 MGI:3647311 67 22 Pep 80 
Pep 81
1433.7
1923.9
22
48
Atrn Attractin 
precursor
NP 033860 65 3 Pep 82 
Pep 83
1329.6
2815.2
22
32
Pgkl CAM 17784 64 3 Pep 84 1509.8 65
Rbm9 NP 001104299 60 7 Pep 85 1775.9 34
Zfp516 NP 898854 56 3 Pep 86 1714.8 23
BC052688 MGL3583898 55 4 Pep 87 755.38 38
BC052040 MG1:3026886 54 7 Pep 88 1380.6 322
LamaS NP 001074640 53 0 Pep 89 951.47 21
Rail NP 033047 51 0 Pep 90 1325.6 27
Smarcc2 NP 001107569 51 2 Pep 91 1918.9 25
Setbpl NP 444329 50 1 Pep 92 
Pep93
938.51
1132.6
21
32
Rapgef2 NP 001093094 50 1 Pep 94 1304.6 35
Stau2 NP 079579 50 5 Pep 95 1743.8 35
Pfnl NP 035202 51 13 Pep 96 1960.0 51
The results obtained from studies looking at the effeet of n-LDL using citrate 
phosphate buffer at pH 4 for peptide extraction are shown in Figures 4.16A, B and C and 
Table 4.5. Nine proteins were identified from cells treated with 50pg/ml of n-LDL for 
five days (section 4.5.1) and six peptides were predicted from six proteins after exclusion 
of overlapping proteins. Only three proteins were associated with other conditions. 
Several of these overlapping proteins were predicted from the ox-LDL conditions and 
some are produced from untreated cells.
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Figure 4.16: The analysis of peptides produced by J774.2 cells treated with n-LDL and 
peptide profile generated with citrate phosphate buffer at pH 4. Cells were cultured and 
peptides eluted using citrate phosphate buffer (pH 4). Samples were lyophilised overnight and 
reconstituted in ammonium acetate (pH 4.6). Concentrated peptides were analysed using the 
Ultimate micro-capillary HPLC system (Dionex) (section 4.6). Panel A shows the Chromatogram 
analysis that represents 3 technical repeats. Panel B shows the spectrum analysis for selected 
peptides from panel A. The mass spectrum shows peaks at different mass/charge (m/z) ratios, 
which were used for sequence analysis. Panel C sh o w s th e  probability b a se d  M O W SE sc o r e  for 
proteins. Hits <48 were excluded and can be seen highlighted in green and scores >67 are 
significant.
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Table 4.5. Proteins and peptides predicted from MS/MS and MASCOT software [n-LDL, pH
4]. Peptides are listed according to their code (i.e. Pep97). Overlapping proteins and peptides
(i.e. those also identified in experiment using different conditions) are highlighted in yellow.
Protein name Accession 
NCBIBLAST
Protein 
Mascot score
Sequence 
coverage %
Peptide
ID
Mr(calc) Peptide 
Mscot score
Ttn Isoform 1 of CAM23448 87 0 Pep 97 598.29 27
Titin Pep 98 2466 5 21
Vpsl3a NP 766616 65 1 Pep 99 814.38 24
M112 AAH58659 54 0 Pep 100 1901.9 37
Vsigl NP 084457 50 3 Pep 101 1022L5 27
M112 NP 694794 50 2 Pep 102 1389.6 33
Tbx2 NP 033350 50 2 Pep 103 629.30 31
KctdV NP 766097 48 13 Pep 104 3193.3 21
Blnk NP 032554 48 4 Pep 105 798.4 30
Nhedcl NP 083222 74 8 Pep 106 1548.8 27
Treatment with n-LDL with the use of citrate phosphate buffer pH 5 (Figures 
4.17A, B and C) induced the lowest number of proteins and peptides derived from 
treatment with n-LDL. Only six proteins were predicted, and six peptides were identified 
after exclusion of overlapping proteins (Table 4.6).
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Figure 4.17: The analysis of peptides produced by J774.2 cells treated with n-LDL and 
peptide profile generated with citrate phosphate buffer a t pH 5. Cells were cultured and 
peptides eluted using citrate phosphate buffer (pH 5). Samples were lyophilised overnight and 
reconstituted in ammonium acetate (pH 4.6). Concentrated peptides were analysed using the 
Ultimate micro-capillary HPLC system (Dionex) (section 4.6). Panel A shows the Chromatogram 
analysis that represents 3 technical repeats. Panel B shows the spectrum analysis for selected 
peptides from panel A. The mass spectrum shows peaks at different mass/charge (m/z) ratios, 
which were used for sequence analysis. Panel 0 sh o w s the  probability b a se d  M O W SE sc o r e  for 
proteins. Hits <48 were excluded and can be seen highlighted in green and scores >67 are 
significant.
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Table 4.6. Proteins and peptides predicted from MS/MS and MASCOT software [n-LDL, pH
5]. Peptides are listed according to their code (i.e. Pep107). Overlapping proteins and peptides
(i.e. those also identified in experiments using different conditions) are highlighted in yellow.
Protein name Accession 
NCBIBLAST
Protein 
Mascot score
Sequence 
coverage %
Peptide
ID
Mr(calc) Peptide
Mscot
score
Foxi2 NP 068699 73 5 Pep 107 598.27 25
ENSMUSGOOOOOO
515
uncharacterized
protein
52 10 Pep 108 1773.8 30
Arhgefl? NP 001074585 51 5 Pep 109 1389.7 37
Sftpd NP 033186 50 5 Pep 110 1403.6 31
Ccdc32 CAM45959 49 12 Pep 111 1773.8 24
Ttcl5 AAH30887 48 8 Pep 112 
Pep 113
824.40
1630.7
20
32
In conclusion the experiments in which cells were treated with n-LDL have shown that:
• The overall number of predicted number of proteins was 33
• The overall number of identified peptides were 39 (Table 4.10)
4.7.3.3 The effect o f different pHs o f citrate phosphate buffer on untreated cells
In order to provide a complete profile of the effect of different buffer pH, 
untreated cells were studied as a control. Untreated cells were cultured for five days and 
cells harvested every 24h (section 4.5.1). MHC-associated peptides were extracted from 
cell surfaces using three different pHs of citrate phosphate buffer (pH 3, 4 and 5) as 
described previously (section 4.5.1).
Results show that untreated cells induced the lowest numbers of proteins and 
peptides at all pHs of acid elution buffer compared to treated cells. The results using pH 3 
are shown in Figures 4.18 A, B and C. Only four proteins were identified and from these, 
only five peptides were identified from the three proteins remaining after exclusion of 
those that were overlapping (Table 4.7).
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Figure 4.18: The analysis of peptides produced by untreated J774.2 cells and peptide 
profile generated with citrate phosphate buffer at pH 3. Cells were cultured and peptides 
eluted using citrate phosphate buffer (pH 3). Samples were lyophilised overnight and 
reconstituted in ammonium acetate (pH 4.6). Concentrated peptides were analysed using the 
Ultimate micro-capillary HPLC system (Dionex) (section 4.6). Panel A shows the Chromatogram 
analysis that represents 3 technical repeats. Panel B shows the spectrum analysis for selected 
peptides from panel A. The mass spectrum shows peaks at different mass/charge (m/z) ratios, 
which were used for sequence analysis. P anel C sh o w s  th e  probability b a se d  M O W SE sc o r e  for 
proteins. Hits <48 were excluded and can be seen highlighted in green and scores >67 are 
significant.
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Table 4.7. Proteins and peptides predicted from MS/MS tandem and MASCOT software 
[Cont, pH 3], Peptides are listed according to their code (i.e. Pep114). Overlapping proteins and 
peptides (i.e. those also identified in experiments using different conditions) are highlighted in 
yellow.
Protein name Accession 
NCBIBLAST
Protein
Mascot
score
Sequence 
coverage %
Peptide ID Mr(calc) Peptide
Mscot
score
Naca NP_001106670 62 3 Pep 114 
Pep 115 
Pep 116
2469^ 
3292 8 
3805^
27
23
24
Akapll XP 920371 59 1 Pep 117 
Pep 118
1304.6 
2002 9
37
29
Ambn NP 033794 54 7 Pep 119 
Pep 120
1267.6
1739.7
24
34
Mamdc4 CAM25170 49 2 Pep 121 1509.8 28
Results obtained from the elution of peptides with citrate phosphate buffer pH 4 
from untreated cells were of particular interest. After exclusion of overlapping proteins, 
two peptides were identified that originated from one protein (Table 4.8). Two of the 
detected proteins (Titin and Pgkl, shown highlighted in yellow) produced by control cells 
were also induced in treated cells. All graphs and statistical results for this experiment are 
shown in Figures 4.19 A, B and C.
Table 4.8. Proteins and peptides predicted from MS/MS and MASCOT software [Cont, pH
4]. Peptides are listed according to their code (i.e. Pep122). Overlapping proteins and peptides 
(i.e. those also identified in experiment using different conditions) are highlighted in yellow.
Protein name Accession 
NCBI BLAST
Protein 
Mascot score
Sequence 
coverage %
Peptide
ID
Mr(calc) Peptide
Mscot
score
Ttn Isoform 2 of CAM23448 61 0 Pep 122 1596.6 25
Titin Pep 123 1775.8 23
Pep 124 3107.4 21
Pgkl CAM 17784 50 3 Pep 125 1509.8 51
E2f7 NP 848724 48 2 Pep 126 798.35 28
Pep 127 1676.8 25
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Figure 4.19: The analysis of peptides produced by untreated J774.2 cells and peptide 
profile generated with citrate phosphate buffer at pH 4. Cells were cultured and peptides 
eluted using citrate phosphate buffer (pH 4). Samples were lyophilised overnight and 
reconstituted in ammonium acetate (pH 4.6). Concentrated peptides were analysed using the 
Ultimate micro-capillary HPLC system (Dionex) (section 4.6). Panel A shows the Chromatogram 
analysis that represents 3 technical repeats. Panel B shows the spectrum analysis for selected 
peptides from panel A. The mass spectrum shows peaks at different mass/charge (m/z) ratios, 
which were used for sequence analysis. Panel 0 sh o w s the  probability b a sed  M O W SE sc o r e  for 
proteins. Hits <48 were excluded and can be seen highlighted in green and scores >67 are 
significant.
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Finally, the last condition to be investigated was untreated cells using acid elution 
buffer at pH 5 to extract peptides. Six proteins were produced in this condition, from 
which three peptides were extracted after exclusion of overlapping proteins. Proteins and 
peptides identified by this condition are shown in Table 4.9. Figures 4.20 A and B show 
the chromatographic and spectrum analysis for this experiment and the histogram of 
probability is shown in Figure 4.20C,
Table 4.9. Proteins and peptides predicted from MS/MS and MASCOT software [Cont, pH
5]. Peptides are listed according to their code (i.e. Pep128). Overlapping proteins and peptides 
(i.e. those also identified in experiments using different conditions) are highlighted in yellow.
Protein name Accession 
NCBI BLAST
Protein 
Mascot score
Sequence 
coverage %
Peptide
ID
Mr(calc) Peptide
Mscot
score
Ttn titin isoform CAM23448 79 0 Pep 128 598.29 24
N2-A Pep 129 982.50 21
Pep 130 3045.75 21
Nfya AAH57099 67 14 Pep 131 1804^ 29
Pskl CAM] 7784 54 3 Pep 132 1509.8 55
Arhgefl AAH12488 51 1 Pep 133 1405.6 26
UspSl XP 357781 49 1 Pep 134 1176.5 32
Blnk NP 032554 49 4 Pep 134 1176.5 32
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Figure 4.20: The analysis of peptides produced by untreated J774.2 cells and peptide 
profile generated with citrate phosphate buffer at pH 5. Cells were cultured and peptides 
eluted using citrate phosphate buffer (pH 5). Samples were lyophilised overnight and 
reconstituted in ammonium acetate (pH 4.6). Concentrated peptides were analysed using the 
Ultimate micro-capillary HPLC system (Dionex) (section 4.6). Panel A shows the Chromatogram 
analysis that represents 3 technical repeats. Panel B shows the spectrum analysis for selected 
peptides from panel A. The mass spectrum shows peaks at different mass/charge (m/z) ratios, 
which were used for sequence analysis. P anel C sh o w s the  probability b a se d  M O W SE sc o r e  for 
proteins. Hits <48 were excluded and can be seen highlighted in green and scores >67 are 
significant.
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To summarise the results of untreated cells
• The overall number of detected proteins was 13
• The overall number of identified peptides was 22
All of the proteins and peptides from all conditions identified in this study are shown 
below in Table 4.10.
Table 4.10. Summary of results of protein and peptide identification.
Experimental condition Identified Identified Proteins (after Peptides (after
proteins peptides exclude overlap exclude overlap
proteins) peptides)
Ox-LDL, pH 3 2 1 32 16 24
pH 4 19 23 13 15
pH 5 15 19 14 18
Total = 55 74 43 57
n-LDL, pH 3 18 2 2 1 2 16
pH 4 9 1 0 6 6
pH 5 6 7 5 6
Total = 32 39 23 28
Untreated (Cont), pH 3 4 8 3 5
pH 4 3 6 1 2
pH 5 6 8 3 3
Total = 13 2 2 7 1 0
Total identifîcation 1 0 0  proteins 135 peptides 73 proteins 95 peptides
4.8 Overlapping proteins and peptides
Table 4.11 shows the predicted proteins and peptides that overlapped across the different 
experimental conditions used. For example, Blnk protein was expressed in cells treated 
with n-LDL when extracted at pH 4 and in untreated cells extracted at pH 5. However, 
the peptides identified from this protein were different (Mass= 798.5 and 1176.5 
respectively) (Table 4.11). Pfnl protein was detected following treatment with ox-LDL 
and n-LDL when extracted at pH 3 and both treatment conditions produced the same 
peptide (Mass=1960.0). These findings indicate that not all overlapping proteins 
produced the same peptide under specific stimulatory conditions. Another example was 
the Ttn protein, which resulted in the expression of only one peptide when treated with n- 
LDL and extracted at pH 3, whereas more peptides were produced from Ttn protein by 
untreated cells at pH 5. The assessment of proteins and peptide profiles, and the
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contribution of these proteins in atherosclerosis and macrophage activation are presented 
and discussed in the following section.
Table 4.11. Overlapping proteins and peptides identified using different experimental 
conditions. Peptide mass in Bold numbers indicate similar peptides induced by different 
conditions.
Overlapped
proteins
Conditions Overlapped peptides [Mr(calc)l
Pgkl [Ox-LDL, pH 3 &4] 
[n-LDL, pH 3] 
[Control, pH 4 & 5]
[Ox-LDL, pH3] = 1509.8 
[Ox-LDL, pH41 = 1509.8 
[n-LDL, pH4] = 1509.8 
[Control, pH4 & 51 = 1509.8
Blnk [n-LDL, pH 4] 
[Control, pH 5]
[n-LDL, pH 4] = 798.5 
[Control pH 5 1 = 1176.5
Naca [Ox-LDL, pH 4] 
[Control, pH 31
[Ox-LDL, pH 41 = 3805.0
[Control, pH 31 = 2469.2, 32928.8 & 3805.0
Ttn [n-LDL, pH 3 & 4] 
[Control, pH 4 & 5]
[n-LDL, pH 3] = 1535.8 
[n-LDL, pH 4] = 598.29 & 2466.5 
[Control, pH 41 = 1596.6, 1775.8 & 3107.4 
[Control, pH 51 = 598.29, 982.5 & 3045.7
DcdcS [Ox-LDL, pH 4 & 5] [Ox-LDL, pH 41 = 1004.5 
[Ox-LDL, pH 51 = 739.39
Histone [Ox-LDL, pH 3 & 4] 
[n-LDL, pH 3]
[Ox-LDL, pH 31 = 1008.6 & 2982.6 
[Ox-LDL, pH 4] = 1008.6 
[n-LDL, pH 31 = 2982.6
Pfnl Profilln-1 [Ox-LDL, pH 3] 
[n-LDL, pH 31
[Ox-LDL pH 31 = 1960.0 
[n-LDL, pH 31 = 1960.0
RapgefZ Rap [Ox-LDL, pH 31 
[n-LDL, pH 31
[Ox-LDL, pH 31 - 1417.7 
[n-LDL, pH 3] =1304.6
Sftpd [Ox-LDL, pH 4] 
[n-LDL, pH 51
[Ox-LDL, pH 4] = 1403.6 & 1531.7 
[n-LDL, pH 51 = 1403.6
MII2 [Ox-LDL, pH 41 
[n-LDL, pH 41
[Ox-LDL, pH 41 = 1389.5 & 1518.9 
[n-LDL, pH 41 = 1901.9
Rail [Ox-LDL, pH 3] 
[n-LDL, pH 31
[Ox-LDL, pH 3] = 1522.7, 1550.8 & 1655.8
[n-LDL, pH 31 = 1325.6
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4.9 Proteins and peptide profiles
An important aspect of this study was the detection of proteins and peptide 
profiles under all of the different conditions selected. Tables 4.12A, B and C show the 
proteins resulting from proteomics identification analysis in all conditions of treatment 
after the subtraction of all overlapping proteins.
Table 4.12A. Protein profile from three culture conditions (n-LDL, ox-LDL and untreated 
cells) using citrate phosphate buffer a t pH 3. Ox-LDL expressed highest number of proteins 
than the other two conditions. These profiles present only specific proteins detected in each 
condition after subtraction of overlapped proteins.
Ox-LDL n-LDL Untreated cells
LOC633468 hypothetical protein 
isoform 1 Aridlb Akapl 1
Actbl2 Beta-actin EG545306 Ambn protein
100039528 EG623365 hypothetical protein isoform 1 Mamdc4
SlOOall Protein SlOO-All Atm Attractin precursor
Mtap2 Rbm9 Isoform 5
Ep400 Isoform 5 of ElA-binding 
protein p400 Zfp516
Paxipl PAX-interacting protein 1 BC052688 cDNA sequence
Dnahc8  Isoform 1 BC052040 hypothetical protein
Hhipll Isoform 2 Lama5 laminin, alpha 5
Ncoa2 Smarcc2
Ddxl7 Setbpl
Dhx8 Stau2 Isoform 1
5430427019Rik Uncharacterized 
protein
Lass5
Clqll
Histlh3c
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Table 4.12B. Protein profile from three culture conditions (n-LDL, ox-LDL and untreated 
cells) using citrate phosphate buffer a t pH 4. Untreated cells expressed the lowest number of 
proteins of all culture conditions at pH 4. These profiles present only specific proteins for each 
condition after subtraction of overlapped proteins.
Ox-LDL n-LDL Untreated cells
Tsc22d2 protein Vpsl3a Isoform 2 E2f7
Rnfl57 Vsigl Isoform 1
Tnrc6 c Tbx2
Cacna2d2 Kctd7
Gm22 similar to KIAA1858 protein Nhedcl
Ep300 protein M112
Ror2
2810002009Rik RIKEN cDNA
Wdr46 WD
Tcf20 transcription factor 20 isoform a
Jhdmld JmjC
Zhx3
AU042671
Table 4.12C. Protein profile from three culture conditions (n-LDL, ox-LDL and untreated 
cells) using citrate phosphate buffer at pH 5. Cells treated with n-LDL produced more number 
of proteins than untreated cells. These profiles present only specific proteins for each condition 
after subtraction of overlapped proteins
Ox-LDL n-LDL Untreated cells
ZfjDml Foxj2 Forkhead box protein J2 Nfya nuclear transcription factor-Y alpha isoform a
Asxl2 ENSMUSG00000051555 Putative uncharacterized protein
Arhgefl
Bsn Isoform 2 of Protein bassoon Arhgefl 7 Usp31
Gabre gamma-aminobutyric acid (GABA- 
A)receptor Ccdc32
Aridla AT rich interactive domain lA Ttcl5
Med25 Isoform 2
Ncoal ;LOC 100044566 Isoform 1 of 
Nuclear receptor coactivator 1
Dnahc5
Slc39al4 54 kDa protein
Ncorl nuclear receptor co-repressor 1
Plchl Isoform 2
Per 14
Polm DNA polymerase mu
Hoxa3
In conclusion, the results clearly indicate that the highest numbers of identified 
proteins (and their peptides) were derived from cells treated with ox-LDL at all buffer 
pHs. Untreated cells produced the lowest number of proteins, and n-LDL-treated cells
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demonstrated intermediate expression levels. These findings suggest that the proteins 
expressed by the treated cells are specifically related to the treatment used.
4.10 Functional role of the proteins identified
A search for the function of the identified proteins was carried out using iHOP 
(http://www.ihop-net.org/UniPub/iHOP) and gene ontology (GO) websites (http://www. 
geneontology.org) (results presented in appendix 1). A total of 135 peptides derived 
from 100 different proteins were identified and are listed in the previous section (Tables 
4.1-4.9). Of these proteins 17% were found to be associated with the cell membrane, 20 
% were derived from the cytoplasm and 6% from the extracellular matrix (Figure 4.21 A).
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Figure 4.21 A. Distribution of identified protein locations. Out of the 100 proteins identified, 
20 % were cytoplasmic proteins and 4% were derived from the endoplasmic reticulum. The 
remainder of proteins were derived from the nucleus (31%) as well as a variety of other 
organelles as shown in the graph. Assignments were made on the basis of information provided 
by the iHOP and gene ontology websites.
Of the proteins identified, 3.92% were related to the pathophysiology of 
atherosclerosis, including macrophage activation factors lipids and lipoproteins (Figure 
4.2IB). In addition, -3% were B cell activation proteins, 1% were related to other 
immune responses and 11.76% to ATP and ADP related proteins. In addition, 1% of the 
predicted proteins were related to the family of matrix metalloproteinases, which are 
important elements that contribute to plaque rupture during the late stages of 
atherosclerosis. Unfortunately the function of 16% of the predicted proteins still remains
06
unknown and will require elucidation in the future when protein databases are more 
complete.
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Figure 4.21 B. Association of predicted proteins with atherosclerosis and m acrophage- 
related factors. Each of the factors highlighted in the graph (i.e. MMPs, lipid and lipoproteins, B 
cell activation, ATP and ADP) play a significant role in the development of atherosclerosis and 
macrophage activation function. The larger numbers of proteins (62%) may pertain to those with 
various functions in cell signalling, cell proliferation and cell cycle.
4.11 Association of predicted proteins with atherosclerosis and macrophage 
functions
Further focus was placed on searching the relationship between proteins detected 
in this study with clinical diseases or important biological processes. Interestingly, some 
of the predicted proteins have been previously reported and associated with diseases 
including asthma, leukaemia, hypertension and cancer (Ohoka et al, 1995; Smart et al, 
2002; Wang et al, 2008). Table 4.13 shows a group of identified proteins which have 
been previously found to be associated, and involved, in disease development and that 
may reflect their importance in cardiovascular disease.
A similar association was found between some of the proteins identified and their 
relationship with proteins related to macrophage activation. Table 4.14 lists 16 of the 
identified proteins identified in literature as markers, or factors, associated with 
macrophages. Interestingly most of the proteins listed in Table 4.14 (detected in our 
study) were derived from cells treated with ox-LDL, with the exception of some that 
were derived from n-LDL, ox-LDL and untreated condition (SWl/SNF and Sftpd).
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Collectively, these findings confirm the reports showing that ox-LDL treatment of 
macrophages is able to activate them and trigger inflammatory and immune responses, as 
well as participating in atherosclerotic plaque development.
Table 4.13. The involvement of predicted proteins in different diseases.
Predicted
proteins Detection of proteins in diseases-associated models Reference
ProfiIin-1:
[ox-LDL,pH3] 
[ n-LDL, pH3]
1. Vascular Hypertrophy and Hypertension Caused by Transgenic
Over expression of Profîlin 1
2. Attenuated Expression of Profilin-l Confers Protection From
Atherosclerosis in the LDL Receptor-Null Mouse
(Bayoumi et al, 2007) 
(Romeo et al, 2007)
Rail:
[ox-LDL,pH3]
1. The identification of Retinoic acid (Rail) in leukaemia
2. Retinoic acid induces and inereases the differentiation of 
membrane cholesterol content of embryonal carcinoma cells
3. Effect of retinoic acid on cell proliferation and differentiation as 
well as on lipid synthesis, lipoprotein secretion, and apolipoprotein
biogenesis
(Ohoka e/a/., 1995) 
(Searls and Edidin, 1981)
(Grenier et al, 2007)
RnfI57:
[ox-LDL, pH41
Rnfl57 has been identified by Framiingham Heart Study within 
atherosclerosis genes
(Donnell et al, 2007)
Sftpd:
[ox-LDL, PH4] 
[ n-LDL, pH51
Sftpd is involved for the regulation of pulmonary macrophage 
activation and air space remodelling (Kingma et al, 2006)
SIc39:
[ox-LDL, pH5] SIc39al4 is known to be expressed by J774.2 cell line (Endaya, 2007)
Atrn:
[n-LDL, pH31
Atrn involved in the activation of brain macrophage/ microglia 
and inflammatory response (Sakakibara et al, 2008)
Blnk:
[n-LDL, pH4 & 
Con pH51
Blnk is required for B & T cell receptors function (Ishiai et al, 2000; Fu et 1998)
SlOO:
[ox-LDL,pH3]
1. Colorectal cancer progression correlates with upregulation of 
SlOOAll expression in tumor tissues 
2. A review of the SlOO proteins in cancer
(Wang et al, 2008) 
(Salama et al, 2008)
TSC22:
[ox-LDL,pH4]
Specific TSC22 domain transcripts are hypertonically induced and 
alternatively spliced to protect mouse kidney cells during osmotic
stress
(Fiol et al, 2006)
Naca:
[ox-LDL, pH4 
and Con, pH3]
1. Naca is a potential cellular target of hepatitis B virus PreSl 
Protein
2. The role of Naca in the prevention of short recently synthesized 
ribosome -associated polypeptides
(Li et al, 2005)
(Wiedmann e/a/., 1994; 
Rospert et al, 2002)
Hoxa3:
[ox-LDL,pH5]
1. Impaet of the Loss of HoxaS Funetion on Lung Alveogenesis
2. HoxA3 induces cell migration in epithelial cells promoting 
angiogenesis and wound repair
(Mandeville et al, 2006) 
(Mace et al, 2005)
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Foxj2:
[n-LDL,pH5]
Critical Roles of Forkhead Box A2 (Foxj2) During Lung 
Development (Khoore/a/., 2004)
Setbpl:
[n-LDL,pH3]
The implication of Setbp protein in allergy, asthma and leukaemia 
diseases (Smart et al, 2002)
Table 4.14. Detection of proteins in non- diseased-associated models (macrophage cells).
Predicted
proteins
Detection of peptides on non- diseased- 
associated model Reference
H2B:
[ox-LDL,pH3]
The identification of histone H2B as a major acceptor 
for mono- and poly (ADP-ribose) in dimethyl sulfate- 
treated hepatoma AH 7974 cells
(Adamietz and Rudolph, 
1984)
Rapgef2:
[ox-LDL, pH3]
1. RapgefZ is a critical factor in T cell receptors
signalling to RAPl
2. MAGI-1 is required for Rapl Activation upon 
cell-cell contact and for enhancement of vascular
endothelial cadherin-mediated cell adhesion
(Letschka et al, 2008) 
(Sakurai et al, 2005)
SlOO/All:
[ox-LDL,pH3]
1. Th2 cytokines act on SlOO/All to down regulate 
keratinocyte differentiation.
(Howell et al, 2008)
Mtap2:
[ox-LDL, pH31
Epinephrine increases phosphorylation of MAP-2c in 
rat pheochromocytoma cells (PC 12 Cells)
(Tie et al, 2008)
DnahcS:
[ox-LDL,pH31
Multiple mouse chromosomal loci for dynein-based 
motility
(Vaughan e/a/., 1996)
EP400:
[ox-LDL,pH31 P400 is required for EIA to promote apoptosis
(Samuelson et al, 2005)
Nacoa2:
[ox-LDL,pH3]
1. pl60/SRC/NCoA co-activators form complexes 
via specific interaction of their PAS-B domain with 
the CID/ADl domain
(Lodrini et al, 2008)
LASS5:
[ox-LDL,pH3]
LASS5 is a bona fide dihydroeeramide synthase that 
selectively utilizes palmitoyl-CoA as Acyl donor
(Lahiri and Futerman, 2005)
Naca:
[ox-LDL,pH41
Naca is a positive regulator of human eiythroid-cell 
differentiation (Lopez et al, 2005)
Smarcc2 [n-
LDL,pH3 Regulating SWI/SNF subunit levels via protein- protein interactions and proteasomal degradation (Chen and Archer, 2005)
Sftpd:
[n-LDL,pH5] [ox- 
LDL,pH41
Sftpd is required for the regulation of pulmonary 
maerophage activation, airspace remodeling, and 
surfactant lipid homeostasis.
(Kingma et al, 2006)
MU:
[ox-LDL,pH41
Proteolysis of MU family proteins is essential for 
taspase 1 -orchestrated cell cycle progression. (Takeda et al, 2006)
Basn:
[ox-LDL,pH5]
Bassoon, a novel Zinc-finger CAG/Glutamine-repeat 
protein selectively localized at the aetive zone of 
presynaptic nerve terminals
(Diecke/a/., 1998)
Gapa:
[ox-LDL,pH5]
Securinine, a Gapa  ^receptor antagonist, enhances 
maerophage clearance of phase II C. burnetii: 
comparison with TLR agonists
(Lubick et al, 2007)
Nacoal:
[ox-LDL,pH5]
Elevated phosphorus modulates vitamin D reeeptor- 
mediated gene expression in human vascular smooth 
muscle cells
(Wong et al, 2007)
Zipl4:
[ox-LDL,pH51
Regulation of macrophage Zipl4 by inflammation 
and iron (Endaya, 2007)
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4.12 The extraction of MHC class I and class II molecules
In order to identify which predicted peptides could bind MHC class I or II alleles, 
searches were performed using lEDB and NetMHCl.O prediction algorithms. The 
significance of predictions made by the lEDB prediction method has been studied by 
Peters and his group in 2006. They reported that each prediction tool in lEDB gives a 
different statistical significance value (ARB=0.55, SMM=0.62 and ANN=0.69), and that 
ANN is the best tool to provide predictions with the highest confidence (Peters et al, 
2006). On the other hand, NetMHC prediction methods have been statistically evaluated 
and compared with other prediction tools including KISS, ADT, Consensus, 
NetMHCpan-I.O and NetMHC-3.0. Zhang and his colleagues demonstrated that the 
prediction performance of these tools are also different and can be ranked as follows: 
consQmus>NetMHCpan-l.0 = NetMHC-3.0>ADT KISS C>' indicates a significant 
difference (P<0.05)) (Zhang et al, 2009).
From a total of 135 peptides derived from 100 proteins (Tables 4.1 to 4.9), 22 
peptides were predicted to bind MHC class I alleles and 24 peptides were predicted to 
bind MHC class II alleles (Table 4.15). Interestingly, 19 peptides were predicted to bind 
both molecules and the remaining peptides were predicted to bind neither of the two 
MHC molecules by both of the programs (lEDB and NetMHC 1.0) (Figure 4.22).
52.23%
■ MHC class l-assodated 
peptides
\  i  MHC class ll-associated 
17.90% j peptides
Î Peptide associated with 
both molecules
I Non-MHC association
Figure 4.22: Percentage of Identified peptides predicted to bind MHC alleles. Binding 
specificity was predicted using lEDB and NetMHOTO software.
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Table 4.15. MHC class I and II allele peptide binding identification. lEDB and NetMHCl.O 
was used for the prediction analysis. The table shows the total number of peptides predicted to 
bind to each MHC molecule. Peptide codes (i.e. Pep1) correspond to those shown in Tables 4.1 
to 4.9.
Conditions
MHC 
class I 
peptides
MHC 
class II 
peptides
Both MHC 
class I & II 
peptides
Peptide code
[Ox-LDL, pH 3] 8 2 (MHC class I) Pep:
[Ox-LDL, pH 4] 5 2 1,2,3,4,22,23,25,32,39,40,50,
[Ox-LDL, pH 5] 1 5 13 52,53,55
(MHC class II) Pep:
8,31,33,34,69,70,71,73,14
[n-LDL, pH 3] 3 6 (MHC class I) Pep:
[n-LDL, pH 4] 2 0 82,83,91,99,102,111.
[n-LDL, pH 5] 1 2 6
(MHC class II) Pep: 81, 84,
85,86,96,109,100, 112.
[Cont, pH 3] 1 4 (MHC class I) Pep: 118,121
[Cont, pH 4] 1 2 Non
[Cont, pH 5] 0 1 (MHC class II) Pep:
114,115,116,120,124,125.
130
(Both MHC class I & II) Pep:
Total = 2 2 24 19 10,11,12,35
36,37,38,39,42,43,44,54,
74,75,76,77,104,108,113.
In order to evaluate the sensitivity of the detection method of MHC-associated 
peptides, the affinity score and the binding level of each peptide was studied. According 
to lEDB and NetMHCl.O prediction algorithms, a high affinity score is that between 0 
and 50 nM, and the binding level is given as either strong or weak for each peptide. All 
peptides with low affinities and weak binding levels were excluded from the results. 
Selected peptides with affinities between 0 and 46nM, with most ranging from 0-12 nM 
are displayed in Table 4.15. . Importantly, most predicted alleles associated with MHC 
class I peptides belong to Kk, Kb and Dd alleles and a few were associated to Ld and Db 
alleles. Most of the predicted MHC class II alleles derived from lAB, lAD, IAS alleles 
and a few were related to DRB1*0I01. This result indicates that 66.1% of the predicted 
peptides are promiscuous, which means that they bind to a variety of alleles at the same 
time with the same high levels of affinity and binding (Table 4.16).
I l l
Table 4.16. *Promiscuous peptides. 66.1% of MHC class I and II peptides were promiscuous 
with high binding affinities.
Condition Promiscuous peptides (code) Total for each condition
[Ox-LDL (pH 3)1 Pep 3,4,10,11,12,14,15, 16,18,19,21,23, 24, 14
[Ox-LDL (pH 4)] 29. 1 1
[Ox-LDL (pH 5)1 Pep 34,35,36,38, 43,44,46,47, 50, 52, 53. 
Pep 57,69, 74.
3
[n-LDL (pH 3)1 Pep 77,79, 83,86, 88,91. 6
[n-LDL (pH 4)] Pep 98,100, 104, 106. 4
[n-LDL (pH 5)1 Pep 111, 112, 113. 3
[Cont-LDL (pH 3)] Pep 118 & 120. 2
ICont-LDL (pH 4)] No 0
[Cont-LDL (pH 5)1 No 0
Total promiscuous peptide 43 peptides from total 65 MHC class I & II 
peptide
^Promiscuous peptides are peptides that bind more than one MHC allelic variant (Brusic e t al., 2002).
To summarize, 135 peptides were identified which were derived from 100 
predicted proteins. Regarding the relationship of these peptides to MHC molecules, 22 
were MHC class I associated peptides and 24 were MHC class II associated peptides. In 
addition, ninteen peptides were associated with both MHC class I class II molecules, 
while seventy peptides were not associated with either of the two molecules. More 
importantly, 66.1% of the identified peptides were promiscuous according to the lEDB 
and NetMHCl.O prediction algorithm program.
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4.13 Discussion
Antigen-induced immune responses are responsible for the development 
of both pro- and anti-inflammatory processes. An essential part of this study was to 
extract and identify peptide antigens displayed by MHC complexes on macrophages that 
could potentially induce T-cell-mediated immune responses and/or induce metabolic 
changes in these cells in the context of athero-related- processes. The present study tested 
the hypothesis that low density lipoproteins (n-LDL and ox-LDL) may induce a 
differential expression profile of peptides presented by macrophages on MHC class I or II 
complexes, which may explain their immunomodulatory effect through the activation of 
T cell immune responses.
Experiments were carried out using a monocyte cell line. This cell line is a 
subclone derived from a reticulum cell sarcoma cell line (Ralph et al, 1975). J774.2 
cells had previously been found to be a suitable macrophage model system in 
atherosclerosis-related studies because of their ability to present antigens to T cells and 
their ability to express Fc receptors for all immunoglobulin G (IgG) subclasses. J774.2 
cells are able to carry out Fc-mediated phagocytosis, and they produce both lysozyme and 
plasminogen activator factors (Schwarzbaum and Bettydiamond, 1983). Furthermore, 
J774 cells have been reported as good model for antigen presentation using MHC 
molecules and have been used as a model to study MHC class I and II pathways 
(Kobeme et al, 2001; Yuki et al, 2006; Murphy et al, 2002; Webster, 2002; Seaman et 
al, 1999; Sijts and Pamer, 1997). In our study, J774.2 cells showed the ability to express 
both MHC class I and II molecules according to the data generated using lEDB & 
NetMHCl.O programs. Several functional assays could be applied to confirm the actual 
binding of identified peptides to MHC molecules. A number of functional assays have 
been described in literature to identify MHC class I and II candidate binding peptides 
including the iTOPIA assay for MHC class I binding, screening for MHC class II (HLA- 
DR) binding to a peptide library in a chip-format and immunoaffinity techniques such as 
affinity chromatography, which can be used for both classes. Unfortunately, no functional 
assay was carried out to demonstrate and specify MHC classes in the present study 
because of time and finance constrains.
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In the present study foam cells were derived from peritoneal macrophages and 
J774.2 cells that had been treated with n-LDL and ox-LDL. This was performed in the 
absence of any other effectors such as IFN-y or LPS, which have been used by others to 
assess similar effect on other macrophage-like cell types (Kosaka et al, 2001, Mori et al,
2001). The effect of different concentrations of ox-LDL and n-LDL were assessed in this 
study. The concentrations used were selected based on previous published studies and 
preliminary data from our laboratory (Yang et al, 1996; Hamilton et al, 1999). It has 
been found that a high concentration of ox-LDL (>100pg/ml) normally leads to cell death 
(Han and Pak, 1999), and therefore, low concentrations of ox-LDL (40, 50 or 80pg/ml) 
are typically used for in vitro studies to avoid any toxicity (Yang et al, 1996; Hamilton et 
a/., 1999).
Experiments were performed to assess lipid droplet accumulation in macrophages 
as a result of n-LDL and ox-LDL treatment. The effect of apo-BlOO derived peptides 
(Pep 1, 2 and 3) on lipid accumulation was also assessed using J774.2 cells and peritoneal 
macrophages. An accumulation of clear red lipid droplets was seen in the cytoplasm of 
J774.2 cells treated with a high concentration of ox-LDL (80 or lOOpg/ml) (Figure 4.6). 
A similar effect was observed with peritoneal macrophages using 80pg/ml of ox-LDL 
(Figure 4.9). Peritoneal macrophages did not survive when a high concentration of ox- 
LDL (lOOpg/ml) was used, which is likely to be due to the high toxicity of ox-LDL 
(Yang et al, 1996; Hamilton et al, 1999). This supports the idea that the type of 
treatment, the concentration of LDL, the incubation period and the cell type all play a 
role in the formation of foam cells and the manifestation of cell toxicity, as has been 
reported before (Han and Pak, 1999; Smith, 1990; Kruth et al, 2002). Moreover, 
peritoneal macrophages and J774.2 cells treated with a low concentration of ox-LDL 
(40pg/ml) showed no lipid accumulation in the cytoplasm indicating that this 
concentration is insufficient to induce foam cell formation, or that longer incubation 
periods may be required.
Importantly, treatment of macrophages with n-LDL at a high concentration 
(lOOpg/ml) produced clear lipid accumulation in J774.2 cells (Figure 4.7), but did not 
generate foam cells in peritoneal macrophages. However, it has been reported that a low 
level of lipid accumulation in peritoneal macrophages can be induced at the highest dose
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of nLDL used herein (Smith, 1990; Kruth et al, 2002). One reason for this discrepancy 
could be the existence of different types of foam cells, arising due to the precursor cell 
type and treatment condition (Brown et al, 2000). For example. Brown and his 
colleagues found that 7-ketocholesterol (7K) was presented in human lesions while it was 
not present in human monocyte derived macrophages treated with (ac-LDL).
Three different peptides were used to test their ability to induce foam cell 
formation. Two of these peptides, Pepl and Pep2 are derived from the apolipoprotein B- 
100 polypeptide sequence and were identified by Chicz and his group (Chicz et al, 1993; 
Verreck et al, 1996). The third peptide, Pep3, is a scrambled peptide derived from the 
sequences of Pepl and Pep2 (Table 3.1, chapter 3). Interestingly, Pep3 (lOOpg/ml) 
caused clear red lipid droplet accumulation in both macrophage cell types (Figure 4.8 and 
4.10), and Pep2 produced peritoneal macrophage derived foam cells (Figure 4.10). The 
ability of these peptides to cause foam cell formation may be based on the fact that they 
are derived from the apo-BlOO protein and may thus facilitate or trigger metabolic routes 
involved in accumulation process. These observations represent a major breakthrough 
and will require further investigation in future.
The findings of this study clearly show that 80pg/ml of ox-LDL, and above, 
produce effective proliferative responses in J774.2 cells with no increase in cytotoxicity 
until day 7 of treatment Figure 4.11. The cytotoxicity effect increases when ox-LDL 
concentrations rise from lOOpg/ml to 240pg/ml and thus may explain why cell numbers 
declined more at the end of the study, which correspons with previous observations (Han 
and Pak, 1999; Bjorkerud and Bjorkerud, 1996). It has been reported that low 
concentrations of ox-LDL (<90jiig/ml) induce a proliferatative response in macrophages, 
whereas concentrations >98pg/ml are usually toxic and limitthe survival of J774.2 
macrophages by up to 50% (Bjorkerud and Bjorkerud, 1996; Yang et al, 1996; Hamilton 
et al, 1999). We found that extended exposure of J774.2 macrophages (within the times 
used in this study) to high concentration of ox-LDL produced a significant resistance to 
ox-LDL-mediated cytotoxicity (Bjorkerud and Bjorkerud, 1996).
Our results demonstrate for the first time that citrate phosphate buffers used at 
various pH can be effectively used for peptide extraction and can also potentially replace 
affinity chromatography methods to study protein and peptide profiles. Affinity
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chromatography is usally used to specifically identify proteins and peptides depending on 
the availability of antibodies specific for the targets, but this approach remains expensive 
and quite laborious. Because of these drawbacks it was decided to use an alternative 
method to extract MHC class I and II associated peptides in this study. As discussed 
previously in chapter three, the acid elution method used in this study has been 
previously tested and successfully used, although only for the extraction of MHC class I 
associated peptides in cancer research (Storkus et al, 1993, Torabi-Pour et al, 2001).
As presented in Table 4.15 and Figure 4.16 the proportions of MHC class I 
(16.41%) and class II (17.9%) extracted peptides was similar despite using buffers of 
different pH. However, these numbers (16.41% & 17.9%) only reflect the proportions of 
MHC-associated peptides detected and not the absolute number. Therefore, the method 
required further validation to confirm the efficiencies of both buffer conditions. This 
study identified 12 peptides associated with MHC class I and 12 peptides associated with 
MHC class 11 molecules when citrate phosphate buffer pH 3 was used. In contrast, high 
numbers of MHC class 1 associated peptides (8 peptides) compared to MHC class 11 
associated peptides (4 peptides) were observed when citrate phosphate buffer pH 4 was 
used. The opposite effect was observed at pH 5 when the number of MHC class 11 
peptides was found to be four-fold higher compared to MHC class 1 peptides (8 MHC 
class 11 peptides and 2 MHC class 1 peptides). In previous studies, buffers with pH 
values of 4-5 were used to extract MHC class 11 molecules and pH3 was used for MHC 
class 1, since these conditions provided a better environment for maintaining the stability 
and yield of the peptides extracted (Mouritsen et al, 1994; Lee et al, 1992; Storkus et 
al, 1993). Results from this study showed that buffer pH (pH 3, pH 4 and 5) impacted on 
the identification of MHC class 1 and 11 peptides. Each buffer had the ability to extract 
both MHC molecules but with different efficiencies. It is important to point out that the 
number of peptides extracted with each pH elution condition could have also been 
affected by individual peptide properties (such as size, binding affinity and MHC 
occupancy), or by factors that affected the cells, including temperature (Csuka et al, 
1987; Petritis etal, 2006).
In relation to the characteristics of the protein and peptide profiles identified, the 
results show clear differences for each culture condition (Table 4.12 A, B and C). As
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expected ox-LDL induced the expression of the highest number of proteins and peptides 
compared to non-treated and n-LDL treated cells. This suggests that ox-LDL may have 
triggered specific activation pathways on macrophages which may be activated under 
stress conditions such as the presence of high concentrations of this oxidized molecule. 
Nevertheless, treatment with n-LDL resulted in the expression of a higher number of 
proteins compared to untreated cells. It has been previously reported that high 
concentrations of n-LDL are able to induce foam cell formation (Kruth et al, 2002), and 
some have even reported the production of foam cells in vitro using <100 pg/ml n-LDL 
(Smith and Ashall, 1983; Smith, 1990; Kruth et al, 2002). In the present study, cells 
were treated with 50pg/ml of n-LDL which reached maximum levels of 250pg/ml of 
LDL in culture by day five (the final day of treatment). This may explain why n-LDL 
treatment induced the expression of more proteins than observed in untreated cells. The 
overlapping proteins induced in both ox-LDL and n-LDL conditions (Table 4.11) may be 
due to the stimulation of common activation pathways in macrophages (Kruth et al, 
2002). Unfortunately this theory cannot be tested, because the proteins identified in our 
study cannot be compared to previous studies, mainly because of fundamental differences 
in the experimental design.
Focusing on the source of predicted proteins identified (Figure 4.21 A), 17% were 
cell membrane proteins and 20% were related to cytoplasmic proteins. A greater number 
of extracellular proteins were identified (6%) than intercellular (4%). 4% of proteins 
were also found to be related to the endoplasmic reticulum (ER), which plays a 
significant role in antigen presentation mechanisms. These results are similar to other 
cardiovascular studies in which proteins derived fi-om the cytoplasm, cell membrane, ER 
extracellular matrix and intercelluar space have been identified (Koomen et al, 2006). In 
these studies, the authors used different human tissues, plasma and serum from patients 
with the purpose of identifying novel cardiovascular biomarkers (Koomen et al, 2006; 
Dupont et al, 2004). As previously discussed, the identification of proteins belonging to 
different cellular compartments is indicative of multiple pathway activation including ox- 
LDL uptake by macrophages, antigen processing and presentation, cell signaling and 
differentiation. An example of this is the expression of Ttn and Naca proteins: Ttn is a 
key component in the assembly and function of vertebrate striated muscles, and may link
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the lumen network to chromatin, nuclear actin, or both during interphase (Gerull et al,
2002). The detection of Ttn mutations within patients suffering from cardiac disease, 
especially those presenting dilated cardiomyopathy mutations (DCM) has been 
previously reported (Gerull et al, 2002; Gerul et al, 2006). On the other hand, Naca has 
been shown to prevent inappropriate targeting of non-secretory polypeptides to the 
endoplasmic reticulum (Wiedmann et al, 1994; Rospert et al, 2002).
Interestingly, our search identified a group of Zinc finger proteins, Zhx3, Zfp516, 
Zfpml and M112, the latter of which is still a hypothetical Zinc-finger-like protein. These 
proteins are multiple and play essential roles in normal cell metabolism, serve as DNA 
binding domains in transcription factors and resemble a finger with a base (normally 
cysteines (C) and histidines (H)) linking a zinc ion (Klug and Schwabe, 1995). 58 
CCCH-zinc finger protein families have been identified in the mouse and 55 in humans 
(Liang et al, 2008). Several of them (Mbnl3, Zfp3612, Zfp36 and others) have been 
reported as regulatory factors of LPS-induced bone-marrow derived macrophage 
activation, which may be implicated in inflammatory diseases (Liang et al, 2008; 
Minoda et al, 2006). The link between zinc finger proteins, especially ZCCHCll in the 
RAW 264.7 cell line, and the up regulation of Toll-like receptors (TLRs) (which act as 
receptors for the clearance of n-LDL and ox-LDL) has been demonstrated previously 
(Minoda et al, 2006). The zinc finger gene 202 (ZNF202), located within a 
hypoalphalipoproteinemia susceptibility locus (chromosome llq23) is a transcriptional 
repressor of different genes implicated in lipid metabolism (Porsch-ôzcürümez et al, 
2001).
All of these previous studies and findings may provide evidence for a role of zinc 
finger proteins as macrophage activation factors during immune responses linked to 
atherogenesis, or when lipid accumulation and inflammatory processes are induced by n- 
LDL and ox-LDL. We hypothesize that peptides derived from these proteins may be used 
as early markers of inflammation or macrophage stimulation and may thus aid the early 
diagnosis of the disease, or lead to the development of future drug treatments We are not 
the first to suggest this hypothesis; (Liang et al, 2008) nevertheless, our work contributes 
to the identification of such biomarkers and lends support to the theory.
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H0XA3 (homeo box A3) is a transcription factor that controls cell fate and is 
linked with several types of cancer including lung cancer, breast cancer and leukemia 
(Novak et al, 2006; clavo et al, 2000). The implication of this protein in cancer suggests 
that it may also play an important role in atherosclerosis, since oxidatativestress is 
involved in both diseases. In addition, endothelial dysfunction and uncontrolled cell 
growth are general mechanisms in both diseases, and similar pathogenetics contribute to 
both cancer and atherosclerosis (Morganti et al, 2002; Ramos and Partridge, 2005). Pfn- 
1 (profiling 1) is a conserved actin-monomer-binding protein found in all eukaryotes. 
Previous investigations found that the Pfn-1 protein is up-regulated in atherosclerotic 
plaques, ECs and bone marrow derived macrophages pre-treated with ox-LDL (Libby, 
2002; Romeo et al, 2007; Bayoumi et al, 2007). These studies demonstrated that 
different levels of Pfn-1 protein contributed to the incidence of atherosclerosis (Romeo et 
al, 2007; Giulio et al, 2007). Pfn-1 protein, which was identified in this study and the 
peptides derived from this protein may be used as therapeutic epitopes to treat 
atherosclerosis. In our study this protein was detected using two different treatment 
conditions: ox-LDL (pH 3) and n-LDL (pH 3) but was not expressed by untreated cells. 
This finding once more highlighs the potential of this protein as a marker for LDL- 
induced inflammation.
Sftpd (pulmonary surfactant protein) is a surface-active lipoprotein complex 
formed by type 11 alveolar macrophages (Kingma et al, 2006). This protein is required to 
control the stimulation of air space remodelling and pulmonary macrophage activation 
(Kingma et al, 2006; Lacaze-Masmonteil, 2007). The specific up-regulation of this 
protein by ox-LDL, observed in this study could also be used as a potential marker in 
atherosclerosis. This protein has also been shown to have therapeutic potential, as it has 
been previously shown to improve pathological conditions such as lung disease by 
reducing surface tension (Lacaze-Masmonteil, 2007; Ikegami et al, 2007). Sftpd proteins 
have also been successfully used as drugs against lung inflammation in the USA 
(Taeusch et al, 2002).
SlOO/All is a calcium binding protein which was discovered during the study of 
different types of cancer and inflammatory processes (e.g. breast, lung, bladder, thyroid 
and kidney) (Salama et al, 2008; He et al, 2009). In addition, this protein participates in
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innate immune responses by regulating skin barrier integrity (Howell et al, 2008). 
Importantly, SlOOAll protein has been shown to be involved in energy metabolism, 
oxidative stress, cell growth and differentiation. Moreover, SlOOAll protein has been 
found over expressed in VLDL and ox-LDL treated macrophages indicate to implicate in 
foam cell formation (Lu et al, 2009).
Usp31 (ubiquitin specific peptidase 31) is a Ubiquitin-mediated signalling protein 
that inhibits NF-kB activation by shutting down signalling pathways related to TNF and 
TLR-lL-1 receptors (Wullaert et al, 2006). In our experiments, this protein was 
identified in extracts derived from untreated cells at pH 5 (Table 4.11). The involvement 
and association of this protein with atherosclerosis remains unstudied and as yet we have 
no explanation to why this protein was expressed in untreated cells. Vsigl (V-set and 
immunoglobulin domain-containing protein 1), also called cell surface A33 antigen 
(Swiss-Prot (Q9D2J4)), was discovered as a cell-surface antigen associated with 
stimulated macrophages (murine peritoneal macrophages) (Kaplan et al, 1978). In this 
study, Vsigl was specifically induced by treatment of J774.2 cells with n-LDL (pH 4) 
(Table 4.5). This specific finding deserves further investigation as the expression of this 
protein could be used as biomarker for early atherosclerosis development.
Detection of actin, or polypeptides derived from actin (e.g. Actbl2 and Pfn-1) or 
other proteins with roles in the cytoskeleton was a common finding in our study. The 
association of actin with activated macrophages, especially in J774.2 cell lines has been 
previously reported (Zerbinatti and Robert, 2003). It has been shown that ox-LDL 
treatment causes an imbalance of actin polymerization leading to massive changes in the 
cell cytoskeleton (Miller et al, 2003), and highly disruptive alterations in cell locomotor 
mechanisms (Zerbinatti and Robert, 2003). TcfZO is a transcriptional activator factor that 
binds to the regulatory region of the matrix metalloproteinase, MMP3. MMP3 plays a 
key role in inflammation leading to atherosclerosis and in plaque rupture mechanisms, 
especially in the late stages of atherosclerosis (Silence et al, 2001). In our study Tcf20 
was identified (Figure 4.18B) in the ox-LDL (pH 4) condition only, indicating the 
relationship between ox-LDL and the expression of MMPs.
Other proteins involved in catalytic activity and ATP binding, including Mg"^  and 
Ca^ "^  binding proteins such as Actio 12 and Lama5 were also identified. The requirement
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of high energy to complete the antigen presentation mechanism may explain the detection 
of ATP/ADP regulatory proteins (11.76%) in this study (Figure 4.2IB). We also 
identified proteins related to Ca^  ^metabolism (e.g. Ttn and SI00a). Calcium is a common 
regulator in cell processes including cell proliferation, development and motility 
(Berridge, 2005; Fache et al, 2005). Ox-LDL can block macrophage apoptosis by 
mobilising calcium and activating eEF2 kinase, which leads to the phosphorylation 
(inhibition) of eEF2 and results in decreased pro-apoptotic protein synthesis (this 
mechanism is commonly seen in cancer) (Chen et al, 2009). Several studies have 
demonstrated that Ca^  ^ may be an important factor in the early development and 
progression of atherosclerotic lesions (Fleckenstein-Griin and Fleckenstein, 1991; Shi et 
al, 1996). In addition, modification of Ca^  ^gradients by ox-LDL has been shown to be 
associated with the formation of macrophage-derived foam cells (Deng et al, 2005; Deng 
et al, 2009).
Most importantly, peptides derived from all of the proteins mentioned above 
could play a significant role in the early clinical diagnosis of atherosclerosis. These 
peptides and others could also aid the discovery of new drugs to treat the disease and in 
the development of new vaccines to prevent atherosclerosis. The fact that these peptides 
constitute highly immunodominant T cell epitopes makes them more attractive for the 
development of immunomodulatory components, since they are better able to invoke 
rapid, robust and specific responses compared to immunorecessive epitopes.
The methodology used to extract surface associated peptides yielded some 
important results. However, a concern remains due to the fact that apo-lipoprotein B (the 
main protein component of LDL particles) or peptides derived from it were not detected. 
This may be due to the experimental design utilized in our study in which isolated 
macrophages were used. The non-identification of this protein and related peptides 
present a fundamental different between our results and those obtained by others. One 
reason for this descepancy may be due to the use of whole tissue, or plasma samples, to 
identify these proteins/polypeptides (Barderas et al, 2007; Dupont et al, 2005; Almofti 
et al, 2006) in other studies. Another reason may be that other studies have used different 
cell lines such as THPl and RAW264, which may have fundamental differences 
associated with the metabolic pathways linked to LDL action. The absence of apo-B or
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any other LDL-associated proteins in our study may also be due to resistance of LDL 
particlesto intracellular degradation. In 1992, Roma and his group demonstrated that 
chemically and biologically oxidized LDL (Ox-LDL and BioOx-LDL) have similar 
metabolic fates in J774.2 cells, characterised by weak degradation (Roma et al, 1992). 
Lougheed reported the accumulation of ox-LDL in macrophages which in effect makes 
them more resistant to cathepsin D degradation and to degradation by other proteolytic 
enzymes present within lysosomes (Lougheed et al, 1991).
Obviously, the efficiency of the different buffers in the extraction of MHC class 1 
and 11 peptides was different at different pH, but still the results will help use fine tune 
the methodology for its use in similar, or different experimental, settings.
Peptide length, affinity and hydrophobicty influence their conformational shape 
and binding properties to MHC class 1 or 11 complexes (Purcell and Gorman, 2004; 
Wiliams, 2005). Most of the predicted peptides (66.1%) were promiscuous peptides with 
high affinity and avidity for both MHC class 1 and 11 alleles (Table 4.16). Promiscuous 
peptides are usually used in the design of vaccines and immunotherapeutic acgents 
because they have a higher genetic representation within the general population (Brusic et 
al, 2002; Kobayashi et al, 2000).
In conclusion, where as this chapter focused on the identification of proteins and 
peptides induced by LDL exposure, the next chapter evaluates the effect of the peptides 
on key functional roles of macrophages.
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Chapter 5: In vitro Assessment of the 
Biological Effect of Predicted Peptides on 
Macrophages
Abstract
Atherosclerosis results from the build up of fatty deposits, including cholesterol, in the 
wall of arteries. Monocytes play a key role in atherosclerotic plaque formation and 
rupture. In response to inflammation, monocytes move from the bloodstream to the artery 
wall where they differentiate into macrophages. This differentiation is followed by the 
expression of different pattem-recognition receptors including scavenger receptors and 
TLRs. The accumulation of modified low density lipoprotein (ox-LDL) is controlled by 
scavenger receptors. This accumulation leads to foam cell formation and the up­
regulation of different pro-inflammatory molecules such as TLR-2, TLR-4 and matrix 
metalloproteinases (MMPs). This chapter describes the work undertaken to evaluate the 
effect of the novel peptides (Pep4 and Pep5), that were identified in chapter four, on the 
functions of macrophages (J774.2 cells and peritoneal macrophages) pre-treated or not 
with ox-LDL in vitro using flow cytometry analysis. Untreated cells were used as a 
control. In addition, the effect of ox-LDL and n-LDL at different concentrations and 
incubation periods on the expression of MMP-2 and MMP-9 was assessed using 
zymography. The secretion of MMP-2 and MMP-9 was ox-LDL concentration-dependent 
and n-LDL showed an inhibitory effect on MMP-2 expression that was dependent on 
incubation period. Interestingly, Pep4, Pep5 and Pep3 inhibited the expression of TLR-2, 
TLR-4, MHC class 11 and CD 14 by macrophages pre-treated with ox-LDL. In addition, 
Pepl and Pep2 showed an anti-inflammatory effect on ox-LDL function by stimulating 
the expression of PD-Ll.These findings may contribute to the understanding of the role 
of different concentrations of ox-LDL and n-LDL on the formation of foam cells and on 
MMP secretion. Importantly, the use of the novel predicted peptides (Pep4 and Pep5) and 
apoB-100 derived peptides (Pepl, 2 and 3) generated tolerant macrophages that might be 
useful as therapeutic agents in the prevention of the development of atherosclerotic 
plaques.
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5.1 Introduction
5.1.1 Pattern recognition receptors (PRRs)
Microbial substances that are able to trigger immune responses are known as 
pathogen associated molecular patterns (PAMPs). These molecules are recognised by 
special receptors called pattern recognition receptors (PRRs) (Chou et al, 2008; Hansson 
et al, 2002). When microbes invade the human body, the initial recognition step depends 
on PRRs. PPRs can be subdivided into different families based on their functions and the 
specificity of their ligand (Abbas and Lichtman, 2004). PRRs bind to carbohydrates such 
as mannose residues on macrophages, bacteria and viruses. The different groups of PRRs 
include toll-like receptors (TLRs), cytoplasmic receptors (NOD-like receptors (NLRs)) 
and RJG-like receptors (RLRs) (Chou et al, 2008; Abbas et al, 2007). For the purpose of 
this research, the section below provides more details on TLRs, as these have particular 
relevance in mediating the immune respsonses involved in atherosclerosis.
5.1.1.1 Toll-like receptors (TLRs)
TLRs are pattern recognition receptors that detect signatures from bacteria, 
viruses, protozoa and fungi. They are part of what has been called ‘the front line of 
defence’ against microbial pathogens in the innate immune response (Takeda et al,
2003). Over thirteen TLR (TLR1-TLR13) members have been reported in humans and 
mice (Abbas et al, 2007). The TLR family is categorized by the presence of leucine-rich 
repeats, which mediate ligand binding. The Toll/interleukin-1 receptor-like domain (TIR) 
controls the interaction with intracellular signalling proteins (Takeda et al, 2003; 
Altenbach and Robatzek, 2007). TLRs function as homo- and heterodimers with different 
ligand-binding specificity, depending on TIR co-receptors for effective ligand sensitivity 
(Takeuchi and Akira, 2008; Ting and Williams, 2005). Thus, the specificity of TLR 
signalling is due to adaptor proteins including the Toll-interleukin 1 receptor (TIR) 
domains.
Five different TIRs have been discovered: MyD88, TAM, SARM, TRIF and Mai. 
TIR adaptor proteins are able to stimulate intracellular molecules containing protein 
kinases (IKKi, IRAK4, TBKl and IRAKI) that may be involved in the initiation, or 
suppression, of the inflammatory response (Michelsen et al, 2004; Takeda et al, 2003).
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A major downstream effect of TLR signaling is the activation of the transcription factor 
NF-KB. In normal cells, functional NF-KB dimers will be present in the inactive state in 
the cytoplasm because of its binding to inhibitory proteins called IKBs. TLR members, 
TLR-1 to TLR-9, appear to be orthologous between mice and humans (Nilsson and 
Hansson, 2008; Michelsen et al, 2004; Abbas and Litchman, 2004). Table 5.1 shows the 
TLR members together with their ligands and cell sources.
TLRs are able to affect atherosclerosis development in several ways, including 
endogenously via products of tissue injury (e.g. minimally modified LDL (MM-LDL) 
and HSP60) and also exogenously via pathogen molecules (Jiang et al, 2005; Liu et al, 
2008). The most important receptors are TLR-2 and TLR-4. However, several studies 
have also reported the involvement of other TLRs such as TLR-7, TLR-3 and TLR-9 in 
plaque formation (Liu et al, 2008; Curtiss and Tobias, 2009). The involvement of TLRs 
in stress mechanisms in general, whether initiated by infectious, or non- infectious 
means, suggests they may be implicated in several other diseases as well as 
atherosclerosis. More importantly, TLRs may affect atherogenesis by their involvement 
in cholesterol metabolism by macrophages; a suggestion that has been reported 
previously for TLR-4 (Castrillo et al, 2003; Curtiss and Tobias, 2009).
Table 5.1. Toll like receptor family members (Abbas e ta l ,  2007, Wood, 2006, Plowden et  
al, 2004; Hansson, 2008).
TLR members Cell types Ligands
TLR-1 Macrophages, DCs, B cell Lipopeptides baeteria
TLR-2 Maerophages and mast cells Glyeolipid
TLR-3 B eells and DCs Double-strand RNA ( viruses)
TLR-4 Maerophages, mast cells and DCs Lipolyseharide (LPS)
TLR-5 Maerophage and DCs Bacterial
TLR-6 Macrophages and B eells Lipoproteins
TLR-7 Macrophages and B eells single-stranded RNA (viral)
TLR-8 Macrophages and DCs single-stranded RNA (viral)
TLR-9 Maerophages and B eell Viral and bacterial
TLR-10 Maerophages and B cell No information
TLR-11 Macrophages Profil in
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5.2 The role o f macrophages and toll like receptors in atherosclerosis
The main step in atherosclerotic plaque formation is the uptake of modified LDL 
via monocyte/macrophage scavenger receptors and the formation of foam cells (Glass 
and Witztum, 2001; Taylor et al, 2005). Scavenger receptors recognize different 
oxidation-specific epitopes present on ox-LDL (chapter one, section 1.6.4) in a way 
similar to TLRs, which also bind oxidation-specific epitopes (Medzhitov, 2001; Miller et 
al, 2005).
A variety of animal models have been developed to study the role of TLRs in 
cardiovascular disease. Research on the role of TLR-2 has been carried out using mice 
deficient for this receptor crossed with hypercholesterolemic LDLr ' mice, apoE" ' or 
apoE'^  ^ mice. These studies showed that TLR-2 promotes the progression of 
atherosclerosis (Akira and Takeda, 2004; Mullick et al, 2005; Madan and Amar, 2008). 
TLR-1, 2 and 4 are the most studied TLR proteins in the context of atherosclerosis 
because they have been shown to be the most abundant in atherosclerotic lesions (Liu et 
al, 2008; Madan and Amar, 2008; Curtiss and Tobias, 2009). Macrophages, DCs, ECs, 
and vascular SMCs within lesions appear to up regulate the expression of TLR-2 and 
TLR-4 under stimulatory conditions (Curtiss and Tobias, 2009).
Importantly, ox-LDL can also mediate TLR-4-dependent pro-inflammatory 
responses by macrophages (Dzumhur et al, 2009). For example, TLR-4 has been found 
to be critical in arterial remodeling (Curtiss and Tobias, 2009). When apoE"^ " mice are 
exposed to lipopolysaccharides, plaque formation increases and outward arterial 
remodeling occurs (Hollestelle et al, 2004). In general, TLRs are the best characterized 
signal-generating receptors among the PRRs and are known to initiate key inflammatory 
responses and mediate adaptive pro-Thl immunity.
5.3 Matrix metalloproteinases (MMPs)
MMPs are a family of zinc metallo-endopeptidases secreted by cells that are 
responsible for much of the turnover of matrix components. The metalloproteinase family 
is characterized by tight binding of zinc ions to their active site and all share a conserved 
zinc binding motif. There are more than twenty members of the family sharing structural 
homology (Stocker et al, 1995; Lijnen, 2002; Marchenko et al, 2002). All MMPs are
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able to degrade one or more component of the extracellular matrix but MMPs are 
classified into five main groups based on substrate specify Table 5.2 (Lijnen, 2002).
Each member of the MMP family has a five-domain structure with 70% similarity 
between members of the same group and 50% similarity between members of different 
groups (Ye et al, 1998). The MMPs differ in the structure of their active site groove, 
allowing for different substrate and inhibitor specificities (Marchenko et al, 2002). The 
activity of MMPs is controlled at several levels, including transcription, activation of 
zymogens and by interaction with specific inhibitors (TIMPs: tissue inhibitors of MMPs). 
MMPs, especially MMP-2, are expressed in normal tissues, although MMP-2 expression 
is limited to stromal cells (Matrisian, 1994). MMP-9 is actively expressed by 
haematopoietic cells (Hibbs et al, 1987) and both MMP-2 and MMP-9 activity is 
controlled by reactive oxygen species presented by macrophage derived foam cells 
(Pasterkamp and Falk, 2000).
Table 5.2. The matrix metalloproteinase family.
Family groups MMP members
Collagenases
MMP-1 
MMP-8 
MMP-13 
MMP-18
Gelatlnases MMP-2
MMP-9
Stromelysins MMP-3 MMP-10 
MMP-11
Member type
MMP-14 
MMP-15 
MMP-16 
MMP-17
Others MMP-7
MMP-12
5.4 Tissue Inhibitor MMPs (TIMPS)
TIMPs (tissue inhibitor of MMPs) act against MMPs to reduce their activity 
within disease situations by inhibiting the activity of the fully competent MMP and 
potentially blocking MMP precursor activation (DeClerck et al, 1991a; Howard et al, 
1991b). The TIMP family currently includes four different members (TIMPs-1 to 4). 
TIMP-1 and TIMP-2 are the most studied members, both of which are produced in 
soluble forms. TIMP-1 is induced by growth factors (e.g. transforming growth factor p
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(TGF- p)), while TIMP-2 is normally constitutively expressed. TIMP-3 is associated with 
the extracellular matrix and its expression appears to be inducible (Mattila et al, 1998; 
Abbas et al, 2007). TIMPs appear to be distributed widely in tissues and fluids (Murphy 
et a.,, 1991a) and are expressed by many different wild-type and transformed, cell types 
from skin (Hembry and Ehrlich, 1986), lung (Welgus et a., 1985a), mucosal membranes 
(Drouin et al, 1988), dental pulp (Kishi and Hayakawa, 1984) and ovaries (Curry et al, 
1990). Any disruption to the balance between MMPs and TIMPs can result in serious 
diseases such as tumor growth and atherosclerosis. More importantly, therapeutic 
inhibition of MMPs is a promising approach for treatment in different diseases.
5.5 The role o f matrix metalloproteinase in atherosclerosis
The remodeling of aterial extracellular matrix (ECM) homeostasis, caused by 
changes in the synthesis or degradation rates has been associated with vascular diseases. 
There is growing evidence to suggest that MMPs are involved in all stages of the 
atherosclerosis process, from the initial lesion to plaque rupture (Pasterkamp and Falk, 
2000, Molloy et al, 2004; Libby, 2008). Plaque formation occurs as a result of migration 
and proliferation of different types of cells found in the ECM. The activated macrophages 
in the atheroma can produce proteolytic enzymes capable of degrading the collagen that 
provides strength to the plaque’s protective fibrous cap, causing thinning and weakening 
and increased susceptibility to rupture. Stable plaques are characterised by a thick fibrous 
cap overlying a plaque that does not contain a cholesterol-rich necrotic core. By contrast, 
unstable plaques have a thin fibrous cap, contain a higher ratio of macrophages to SMCs 
and have a lipid-filled necrotic core (Yoon et al, 2002; Schwartz et al, 2007).
Immunocytochemistry and zymography studies have demonstrated an increased 
expression of different MMPs in human atherosclerotic plaques (Taurino et al, 2008). 
Moreover, atherosclerotic plaque instability has been associated, in particular, with 
increased MMP-2 and MMP-9 expression. In addition, histochemical and genetic 
association studies have implicated MMP-1, MMP-2, MMP-3 and MMP-9 as important 
players in vascular pathology (Price et al, 2001; Taurino et al, 2008). During the last 
phases of atherosclerosis, thrombotic problems often result from disruption of the 
atherosclerotic plaque due to rupture of the thin fibrous cap (Thim et al, 2008; Lusis,
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2000). Most coronaiy thrombi (75%) are caused by plaque rupture leading to myocardial 
infarction or death (Thim et al, 2008). MMP-2-dependent vascular ECM degradation 
supports the migration of SMCs in the early stage of plaque formation. In addition, the 
external growth of the arterial area generates an enlargement that involves matrix 
remodeling and leads to accumulation of collagen and loss of elastin (Thim et al, 2008; 
Libby, 2008).
Increased levels of MMP-9 in unstable carotid plaques have also been reported, 
and are increased in patients suffering from carotid artery symptoms (Taurino et al, 
2008). Gough and his colleagues artificially introduced the autoactivating form of MMP- 
9 into the macrophages of atherosclerotic lesions developed in apo-E''^ ' mice, resulting in 
the promotion of elastin degradation and plaque disruption (Gough et al, 2006). MMPs, 
like MMP-9 can be activated by ligation of CD40 on atheroma-associated cells, which 
improves the induction of adhesion molecules and pro-inflammatory cytokines causing 
plaque destabilization and the formation of intravascular thrombi (Libby, 2008). Platelets 
can also activate CD40 ligands providing a possible amplification loop in thrombosis 
(Henn et al, 1998). Platelet-derived CD40 ligands may activate local tissue factor 
production and increase the possibility of plaque disruption by exposing that region to the 
blood compartment.
In conclusion, the imbalance between MMP levels and their inhibitors may alter 
the balance from matrix accumulation to matrix degradation, causing plaque rupture and 
thrombosis formation. There are different ways to prevent the effect of MMPs as 
degradation factors in atherosclerosis, including the use of antioxidant vitamins and 
statins (Libby et al, 2002; Libby, 2006). MMPs therefore, provide an important target to 
prevent plaque destabilization.
5.6 Markers o f macrophage phenotype and activation
The phenotype of a macrophage is easy to identify and distinguish by examining 
the morphology, the expression of cell-surface markers and most importantly, their 
function. Unfortunately, there is a considerable overlap between markers of macrophages 
and DCs and it is therefore important to distinguish the characteristic features of 
macrophages from DCs.
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Morphology cannot be used to distinguish the two eell types because 
macrophages and DCs can look similar under the microscope. However, the morphology 
of both cell types does vary and is influeneed by the physical characteristics of each 
tissue (Girschick et al, 2001). The most extensively used and reliable way to distinguish 
macrophages from DCs is by looking at the expression of different surfaee markers. The 
expression of combinations of surface molecules changes over time in both cell types and 
they exhibit different markers aceording to the stimuli type reeeived. The most common 
macrophage phenotypic markers are CD14 or CDl lb (Striz et al, 1993; Shashkin et al, 
2005), while DCs are characterized by intermediate expression of CDl Ic and high 
expression of CD45 (Caminschi et al, 2006). The usual pathway for macrophage 
aetivation is their differentiation from monocytes by IFN-y stimulation, which triggers a 
strong pro-inflammatory response (Martinez et al, 2009).
Macrophages can be divided into two types, ealled Ml and M2 macrophages, 
depending on the aetivation technique used. Classical stimulation occurs by adding 
lipopolysaccharide (LPS) in the presenee of IFN-y to macrophages (Ml). This 
stimulation technique induces high levels of pro-inflammatory cytokines including IL-12, 
IL-23, IL-6, IL-1, and TNF-a and also causes the up-regulation of surface molecules such 
as MHC class II and B-7 (CD86). In order to induce the formation of M2 macrophages, 
IL-4, IL-I3, IL-1 or vitamin D3 is added to the cells to induee expression of IL-IO (Th2- 
type humoral-immune response to antigen), scavenger receptors and mannose receptors 
(Figure 5.1) (Stein et al, 1992; Mantovani et al, 2005). Both Ml and M2 macrophages 
are present in atherosclerosis plaques (Galkina and Ley, 2009).
IL-12
IL-6
Proinflam m atory
M l IL-1
IFN-y
IL-23
Pro & anti >IL-10
Scavenger
recep tors
M2 inflam m atory
M annose recep tors
IL-1
IL-4~
"Or"
IL-13
LPS 
and 
IFN -y
Vitamin D3
Enaottwium , ,
D is e a s e d  A rtery
Figure 5.1. Macrophage differentiation. Both M1 and M2 macrophage types are present within 
the atherosclerotic plaque.
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Furthermore, macrophages can he stimulated by the interaction between 
CD40/CD40L, which are known as co-stimulatory factors. Activated CD4^ T cells 
express a surface protein that belongs to the TNF family, called CD40 ligand (CD40L or 
CD 154), that binds to CD40 on B lymphocytes, macrophages, DCs and ECs. The 
interaction between CD40 and its ligand on helper T cells stimulates B cells to produce 
antibodies, to activate dendritic cells during the beginning of cell-mediated immunity, 
and to activate macrophages to destroy phagocytosed microbes (Schonbeck and Libby, 
2001; Hansson et al, 2002). Macrophage CD40 expression is induced by ox-LDL within 
atheromas. Thus, CD40/CD40L is one route by which macrophage activation by plaque 
T-lymphocytes occurs (Schonbeck and Libby, 2001; Wick et al, 2004; Boyle, 2005). 
Importantly, disruption of the CD40/CD40L interaction leads to reduced lipid 
accumulation and enhanced collagen content (Pearson, 1996; Lutgens et al, 2000). 
Finally, macrophage-derived growth factors that have significant effects on the pathology 
of atherosclerosis include fibroblast growth factors (FGFs), platelet-derived growth factor 
(PDGF, a potent mediator of SMC growth, migration and differentiation) and also 
macrophage colony-stimulating factor (M-CSF, a differentiation factor) (Galkina and 
Ley, 2009).
5.7 Aims and objectives
5.7.1 Aims
To assess the effect of Pepl to Pep5 on the function of macrophages (J774.2 cell lines 
and mouse peritoneal macrophages) and on macrophage pre-treated with ox-LDL.
5.7.2 Objectives
• To assess the effect of different incubation periods and concentrations of n-LDL 
and ox-LDL on MMP secretion by macrophages using zymography
• To evaluate the effect of novel peptides (predicted inchapter 4) and apoB-100 
derived peptides on macrophage and ox-LDL function, using flow cytometry 
analysis.
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5.8 Materials and Methods
5.8.1 Isolation of mouse peritoneal macrophages and cell culture
These procedures were carried out as described in section 2.4 of the methods chapter
5.9 Zymography
Zymography is a simple, sensitive and quantifiable approach for the analysis of 
proteolytic activity in cells and tissues (Heussen and Dowdle 1980; Alderton et al,
2004). It can be defined as an electrophoretic technique based on sodium dodecyl sulfate 
polyacrylaminde gel electrophoresis (SDS-PAGE), a method that separates a substrate 
within the polyacrylamide gel. Zymography is usually used to study ECM-degrading 
enzymes, especially members of the MMP family (discussed in section 5.3). In 
zymography, the gel is stained with coomassie blue and sites of proteolysis show up as 
white bands on a dark blue background.
The majority of MMPs are secreted as inactive zymogens that become activated 
upon removal of their amino terminal propeptide. The stimulation of MMPs is controlled 
through Cys-Zn^  ^interactionsknown as a ‘cysteine switch mechanism’ (Springman et al, 
1990). In the cysteine switch mechanism, a cysteine residue is presented as a fourth zinc- 
binding ligand to control the enzyme activity. In addition, the catalytic domain has the 
zinc-binding motif that controls a zinc atom at the active point (Stocker et a l 1995; Grant 
et al, 1992). The MMP prodomain is presented as an egglike shape with a preserved 
cysteine switch motif that controls proMMP. MMPs can be activated chemically by 
exposure to SDS, leading to disruption of the Cys-Zn^  ^bond (Grant et al, 1992). The 
dissociation of the cysteine from the zinc atom and its subsequent replacement by water 
opens up the enzyme, exposing the active site and causing removal of the propeptide 
domain (Grant et al, 1992).
5.9.1 Sample preparation
J774.2 cells and peritoneal macrophages were cultured and treated as described in 
section 2.5. Supernatants were collected and stored at -20°C and then used to assess the 
synthesis and secretion of MMP-2 and MMP-9 by zymography. Supernatants were 
concentrated using Microcon Centrifugal Filter Devices (Microcon YM-30, regenerated 
cellulose, 30,000 MWCO, Amicon, Cat. No.42410) and centrifuged at 13.8xg for 30min
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(Biofpge pico, Heraeus). Concentrated samples were collected by inverting the filter over 
a clean tube and centrifuging at 13.8xg for Imin (Biofuge Pico, Haraeus), and were 
analysed as follows.
5.9.2 SDS-PAGE zymography analysis
Concentrated samples (lOpl) were mixed with an equal volume of zymogram 
sample buffer (62.5mM Tris-HCl, pH 6.8, 25%, glycerol 4% SDS, 0.01% Bromophenol 
Blue) (BioRad). Samples were loaded onto a 10% gelatin Zymogram Ready Gel (10 well, 
30pl, and 8.6cm x 6.8cm) (BioRad) and separated using a Mini protean 11 electrophoresis 
system (BioRad). Tris/glycine/SDS running buffer (25mMTris, 192mM Glycine and
0.1% ÇW/Y) SDS, PH 8.3 (BioRad)) was used to run the gels at 200V for 40min using an 
Apelex PS 90097X programmable electrophoresis power supply (BioRad). Gels were 
then incubated twice in renaturation buffer (Triton X-100, 25% (v/v) in distilled water) 
(BioRad) for 30min at room temperature, followed by incubation at 37°C with zymogram 
development buffer overnight (Tris-HCl 63.Og, NaCl: 117g CaCl]: 7.4g and distilled 
water to IL) (BioRad). Gels were then stained using Coomassie brilliant blue [Coomassie 
Blue (4g), Methanol (200 ml), water (200 ml) and Glacial Acetic Acid (40ml)] (BioRad, 
Cat. No. 161-0463) for 30min at room temperature. Finally, gels were destained by 
incubation in Destain buffer (10% Methanol, 5% acetic acid) (Fisher Scientific UK Ltd, 
Leichester) overnight at room temperature. Bands were visualised and images of 
destined gels were captured using a GeneGenius Biolmaging System (Syngene, 
Germany) and semi-quantification analysis was carried out using Gene Tools software. 
MMP-9 and MMP-2 bands were expected at 82 and 62kD respectively (compared to 
western blot protein standared (MajicMark XP, Invitrogen)).
5.10 Flow cytometry
Flow cytometry is a quantitative method that is able to examine the physical and 
chemical characteristics of single cell a the sample under investigation. In addition, it is 
able to separate and isolate cells (sorting) depending on their properties. The instrument 
uses a laser-based technique to analyze each cell. A beam of light is directed onto a 
hydro-dynamically-focused stream of fluid containing the cells. Beams of different 
wavelength can be used to test each cell resulting in light scattering combined with
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fluorescent emission. Normally, cells are labelled with a monoclonal antibody conjugated 
to a specific fiuorochrome that can be detected by a specific beam of light.
5.10.1 Detection of surface markers on macrophages by flow cytometry
Macrophages express a variety of surface markers depending on their phenotype and 
activation state. In the present study it was important to assess if the macrophages under 
investigation (J774.2 cells and peritoneal macrophages) were stimulated or inhibited 
under different treatment conditions (ox-LDL, n-LDL and Pep 1-5). Pep land Pep2 both 
derived from the apoB-100 polypeptide sequence and has previously been identified by 
Chicz and his group (Chicz et al, 1993; Verreck et al, 1996). Pep3 is a scrambled 
peptide derived from the sequences of Pepl and Pep2. Pep4 and Pep5 are novel peptides 
predicted in chapter four. Pep4 and Pep5 were chosen for two reasons: both are MHC 
class 11 peptide relays identified with lEDB and Netl.O programs. In addition, they are 
both derived from proteins implicated in atherosclerosis and/or in macrophage 
stimulation state, as reported previously (Bayoumi et al, 2007; Romeo et al, 2007; 
Kingma et al, 2006). All peptides (Pep 1-5) were chemically synthesized with no 
modifications by Sigma, UK (95% purity, lyophilised powder).
This was achieved by looking at the different cell-surface markers. Five different 
surface markers were evaluated (TLR-2, TLR-4, PD-l/PD-Ll, MH class 11 and CD 14) 
(Table 5.3).
Table 5.3. Macrophage surface markers applied in this study.
Macrophages 
surface markers
Specificity Isotype
CD14 A marker for monocyte/macrophage phenotype, 
and a mediator of bacterial LPS
IgG2a
MHC class II Is a peptide-binding proteins that modulate 
antigen presentation
IgG2b
TLR-2 (CD282) Is a receptor for gram-positive bacteria and 
fungi on activated macrophages
IgGI
TLR-4 (CD284) Is a receptor for gram-negative bacteria and 
LPS on activated macrophages
IgGl
PD-1 (CD279) Is a programmed death-1 (PD-1) receptor and 
expressed by T, B cells and activated 
macrophages
IgG2b
PD-Ll (CD274) Is a ligand for PD-1 on macrophages and 
continually expressed on their surface
IgG2a
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Table 5,3 shows the functional markers selected on the basis that they are able to 
indicate to cell activation state (promoting a pro-inflammatory immune response), such as 
TLR-2 and TLR-4, whereas other markers represent a cell suppression state (e.g. PD- 
l/PD-Ll). These markers can therefore demonstrate the potential polarization of the 
immune response that a stimulus may trigger. Direct immunofluorescent detection was 
applied using a monoclonal antibody. Mouse monoclonal antibodies raised against 
CDllb, TLR-2 and 4, Programmed Death-1 (PD-1), PD-Ll, MHC class 11 and CD14 in 
rat were directly conjugated to RPE, FITC, Alexa 488 and 647 and then used for flow 
cytometry analysis.
5.10.2 Cell culture
J774.2 and peritoneal macrophages were cultured in twelve-well plates at 
~lxl0^cell/ml in 2ml of DMEM and RPMl media respectively and treated as previously 
described (chapter2, section 2.5). Cells were stained with the relevant fluoresently- 
labelled monoclonal antibodies as described in the next section. A group of J774.2 cells 
was incubated for 72h in parallel with both ox-LDL (80pgml) and each peptide 
(80pg/ml) in order to assess their effect on ox-LDL activity.
5.10.3 Direct immune fluorescence labelling o f surface markers
After 72h of culture, cells were scraped and collected in falcon tubes and then 
centrifuged at 400xg for 5min at 4°C (Beckman GPR, UK). The supernatant was 
discarded and cell pellets were resuspended in 1ml of FACS buffer [(1% BSA in PBS) 
(Fluka, Germany) and 0.05% sodium azide pH 7.4]. Cells were counted using a 
haemocytometer (Horsham) and the concentration adjusted to IxlO^cell/ml in FACS 
buffer. Mouse Seroblock FcR (Ipg/ml) [BUF041A, Serotec] was added and cells 
incubated for 5-lOmin on ice. Cells (lOOpl containing 1x10  ^ cells) were placed into 
FACS tubes (Becton Dickinson) and stained as follows:
1. Rat anti-Mouse CDl Ib-RPE + Rat anti-Mouse TLR-2-Alexa 647 + Rat anti-Mouse
TLR-4-Alexa 488
2. Rat anti-Mouse CDllb-RPE + Rat anti-Mouse PDl-Alexa 488 + Rat anti-Mouse
PD-Ll-Alexa 647
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3. Rat anti-Mouse CDllb-RPE + Rat anti-Mouse MHC 11-Alexa 488 + Rat anti- 
Mouse CD14-APC
Details of the antibodies used in this experiment are shown in Table 5.4. Four different 
isotype control samples were prepared as follows:
1. Un-stained cells
2. Rat lgG2b-RPE + Mouse IgGl-Alexa 647 + Mouse IgGl-Alexa 488
3. Rat lgG2b-RPE + Rat lgG2b-Alexa 488 + Rat lgG2a-Alexa 647
4. Rat lgG2b-RPE + Rat lgG2b-Alexa 488 + Rat lgG2a-APC
Table 5.4. Flow cytometry antibody types, sources and working concentrations.
Antibody Supplier
Working
concentration
(pg/ml)
Mouse Seroblock FcR Serotec 2 0
Rat anti-mouse CDllb-RPE Serotec 2
Mouse anti-Mouse/Hum TLR-2-Alexa 647 (CD282) BioLegend 2.5
Mouse a-Mouse TLR-4-Alexa 488 (CD284) cBiosciences 2.5
Rat anti-mouse PDl-Alexa 488 (CD279) Serotec 1
Rat anti-mouse PD-Ll-Alexa 647 (CD274) Serotec I
Rat anti mouse MHC-II I-Ak,d,b,q,r-Alexa 488 Serotec 1
Rat anti-mouse CD14-APC cBioscience 1
Mouse IgGl-Alexa 647 BioLegend 2.5
Mouse IgGl-Alexa 488 cBioscience 2.5
Rat IgG2b-Alexa 488 Serotec 1
Rat IgG2a-Alexa 647 Serotec 1
Rat IgG2a-APC cBioscience 0.5
Rat anti-mouse CD4-FITC Serotec 2
Rat anti-mouse CD25-RPE Serotec 2
Hamster anti-mouse CD69-RPE Serotec 1
Rat IgG2a-FITC cBioscience 2
Rat IgGI-RPE cBioscience 2
Hamster IgG-RPE cBioscience 2
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All samples were vortexed and incubated at 4°C for 30mins on ice in the dark. 
Washing buffer (2ml) [0.5% BSA, 0.05 Sodium azide in PBS, PH 7.4] was added and 
samples were centrifuged at 400xg for 5 mins at 4°C. Cells were resuspended in 3 00pi of 
1% formaldehyde (Sigma-Aldrich, USA) in PBS and stored at 4°C in the dark until 
required for analysis. Flow cytometry was performed using a FACS Canto (BD 
Biosciense, UK).
5.10.4 Assessment o f mouse peritoneal macrophage preparation purity
To test the purity of the peritoneal macrophages isolated, three different Serotec 
antibodies were used, CD4, CD25 and CD69, as follows:
1. Rat anti-Mouse CD4-FITC + Rat anti-Mouse CD25-RPE
2. Rat anti-Mouse CD4-FITC + Hamster anti-Mouse CD69-RPE 
In addition, two different isotypes were also used:
1. Rat IgG2a-FITC + Rat IgGI-RPE
2. Rat IgG2a-FITC + Hamster IgG-RPE
5.10.5 Analysis of surface markers on macrophages by flow cytometry
Samples were analyzed for allophycocyanin APC (excitation at 633nm and 
emission at 661nm), PE (excitation at 488nm and emission at 695nm), Alexa 647 
(excitation at 488nm and emission at 667nm), Alexa 488 (excitation at 488nm and 
emission at 519nm) and FITC (excitation at 488nm and emission at 525nm) using FACS 
Canto (Becton Dickinson). Data were generated using 1x10  ^cells for each sample and 
analyzed using BD FACSDiva software (version 5.03, 2007). Different negative 
(compensation) controls were used to set up the quadrant for each and are outlined below.
5.10.5.1 Compensation controls to set up quadrant
Unstained cells
Rat anti-Mouse TLR4-Alexa 488 
Rat anti-Mouse MHC II-Alexa 488 
Rat anti-Mouse TLR2-Alexa 647
Rat anti-Mouse CD14-APC 
Rat anti-Mouse PDI-Alexa 488 
Rat anti-Mouse CDl Ib-RPE 
Rat anti-Mouse PD-Ll-Alexa 647
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In addition, all flow cytometry analyses were completed with the same instrument
settings as follows:
Detector Voltage Mode Threshold
FSC 25 Lin Parameter Value
SSC 295 Lin FSC 20.000
FITC 385 Log
PE 365 Log
5.11 Data analysis
Upon treatment and labeling as described above, cells were analysed using the following 
strategy. First, a forward scatter (FSC) vs side scatter (SSC) analysis was performed and 
cells were gated according to typical morphological characteristics (Figure 5.2). The 
importance of the gating step is to pre-set all analysis parameters to the cell population of 
interest for further analyses (Figure 5.2 and 5.3). Gating provides an opportunity to go 
through the list-mode data file and to carry out specific analyses on the cells of interest 
based on their size and density, which corresponds to forward and side scatter 
characteristics (FSC-H vs SSC-A).
Single +ve 
P aram eter 1
Double +ve 
P aram eter 1+2
Double -ve
Single +ve 
P aram eter 2
--------------------------- >
C D llb* CDllb*/TLR-4*
D ouble -ve TLR-4*
APC-AP aram eter 2
Figure 5.2. Flow cytometry quadrants set up. Allophycocyanin (APC-A) on "X" axis and 
Phycoerythrin (PE-A) on "Y" axis.
Gating step helps to select cells with different physical criteria from a cell mixture 
or non-homogeneous population, and to exclude aggregated cells and debris from the
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sample. The analysis of specific cell populations using fluorescent markers is another tool 
used for cell identification. Regions are established based on the staining given by the 
isotype control and the unstained cells (negative control), which help to set up the 
quadrants for the analysis (Figure 5.3). Analysis of the different macrophage populations 
was based on the percentages obtained from regions Q2 and Q2-1, as shown in Figure 
5.2. Isotype controls were used to exclude non-specific binding therefore enabling false 
positive to be identified and excluded, leaving a region that should only contain positive 
signals derived from the samples. Figure 5.3 shows a dot plot graph for FSC-H vs SSC-A 
and a density plot with outliers for isotype controls. The numbers in the upper right hand 
corner of the dot plots represents the percentage of cells expressing both the phenotypic 
marker CDl lb and the various activation markers discussed (Figure 5.2 and 5.3).
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Figure 5.3. The setting of quadrants and the determination of axis values for each  
parameter analysed. 50,000 events were used to set up the side scatter (SSC-A) v s  forward 
scatter (FSC-H). Unstained cells and four different isotypes (negative controls) for TLR-2, TLR-4, 
MHC II and CD14 were used (described in section 5.11.1). The quadrants Q1 and Q4 represent 
single positive cells and Q2 represents double positive cells. Panel A shows the analysis of 
peritoneal macrophages using (SSC.A) v s  (FSC-H), and panel B represents Allophycocyanin 
(APC) on "X" axis and Phycoerythrin (PE) on "Y" axis. The fluorecent emission using an isotype 
control is shown in panel C, and panel D is an example of data collected from a sample treated 
with ox-LDL.
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5.12 Results
The following results have been divided into two parts depending on the methods 
used to assess the effect on macrophages. First: The study of macrophage activation 
through the analysis of the secretion of matrix metalloproteinases using zymography. 
Second: the evaluation of macrophage activation via the expression of cell surface 
markers using flow cytometry
5.13 The effect of LDL on the synthesis of matrix metalloproteinases in vitro
The expression MMP-2 and MMP-9 in peritoneal macrophages and J774.2 cells 
in three different culture conditions was examined using zymography (section 5.9). Each 
experiment was performed in triplicate and the significant changes in MMP-2 and MMP- 
9 secretion were assessed using densitometric analysis as described in section 5.9.2. The 
secretion pattern of MMPs from peritoneal macrophage and J774.2 cells was similar 
between the two cell types after ox-LDL treatment with the only differences between 
MMP-2 and MMP-9 expression being observed when cells were treated with n-LDL.
Semi quantitative assessment of gel bands corresponding to MMP-2 and 
MMP-9 (62 and 82kD respectively) was carried out by densitometric analysis (Figure 
5.4). Macrophages incubated for 48h and dosed with lOOpg/ml of ox-LDL had 
significantly (P < 0.05) up-regulated expression of MMP-9 and MMP-2 compared to 
control cells (Figure 5.4B & C). No other significant changes in expression levels of 
MMP-2 and MMP-9 were observed at any dose by either treatment compared to PBS 
control.
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Figure 5.4. MMP secretion of peritoneal macrophages after 48h in culture assessed by 
zymography. Peritoneal macrophages were independently treated with different concentrations 
of n-LDL and ox-LDL and incubated for 48h. The supernatants were then analysed by 
zymography (section 5.9). Panel A shows a representative SDS-PAGE gel for MMP-2 and MMP- 
9. Panel B (MMP-9) and C (MMP-2) represent the quantification by densitometric analysis. 
Statistical analysis was carried out using GraphPad Prism software (one way AN OVA), data are 
mean ±S.D. of three independent experiments (*P < 0.05).
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Similarly, J774.2 cells were exposed separately to ox-LDL and n-LDL at 40, 80 
and lOOpg/ml for 48h (Figure 5.5). The secretion of MMP-9 was significantly higher (P < 
0.05) for cells treated with 80and lOOpg/ml of ox-LDL compared to PBS control 
samples. MMP-2 secretion was also increased at high concentration (lOOpg/ml) with both 
treatments (ox-LDL and n-LDL).
Similar experiments were carried out for a 72h culture period in order to compare 
the effect of n-LDL and ox-LDL treatment on MMP secretion at different incubation 
periods. High concentrations of n-LDL (lOOpg/ml) significantly (p < 0.05) stimulated 
macrophages and J744.2 cells to express high levels of MMP-9 (Figure 5.6B & C 
respectively). Interestingly, inhibition of the secretion of MMP-2 from peritoneal 
macrophages was observed when using n-LDL at 40 and lOOpg/ml with significant 
down-regulation of MMP-2 at a dose of 80pg/ml (Figure 5.6D).
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Figure 5.5. MMP secretion from J774.2 cells after 48h in culture a sse sse d  by zymography.
J774.2 cells were treated with different concentrations of n-LDL and ox-LDL and incubated for 
48h. The supernatants were then analysed by zymography (section 5.9). Panel A shows a 
representative SDS-PAGE gel for MMP-2 and MMP-9. Panel B (MMP-9) and C (MMP-2) present 
the quantification by densitometric analysis. Statistical analysis was carried out using GraphPad 
Prism software (one way ANOVA), data are mean ±S.D. of three independent experiments (*P < 
0.05).
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Figure 5.6. MMP secretion from J774.2 cells and mouse peritoneal macrophages pre­
treated with n-LDL. Cells were cultured and treated with n-LDL at different concentrations and 
incubated for 72h. The supernatants were then analysed by zymography (section 5.9). Panel A 
shows a representative gelatin zymography gel. The quantification of MMP-9 secretion by 
peritoneal macrophages is shown in panel B and for J774.2 cells in panel 0. The quantification of 
MMP-2 secretion is shown in panel D and E for peritoneal macrophages and J774.2 cells 
respectively. Statistical analysis was carried out using GraphPad Prism software (one way 
ANOVA), data are mean ±S.D. of three independent experiments (*P < 0.05).
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Peritoneal macrophages and J774.2 cells exposed to 40, 80 and lOOpg/ml of ox- 
LDL for 72h and showed a significant up-regulation of MMP-9 and MMP-2 expression 
when treated with high concentration of ox-LDL (Figure 5.7, Table 5.5). In contrast, low 
concentrations of ox-LDL (40 and SOpg/ml) showed insignificant changes to expression 
of MMP-9 and MMP-2 compared to PBS control.
Longer periods of incubation (6 days) with both ox-LDL and n-LDL, used at the 
same concentrations, were also assessed (Figure 5.8). However, changes in MMP 
secretion could not be assessed in peritoneal macrophages because the high toxicity of 
ox-LDL killed the cells. Expression of MMP-9 and MMP-2 from J774.2 cells was 
significantly up-regulated when treated with lOOpg/ml ox-LDL for 6 days. On the other 
hand, n-LDL induced an insignificant down-regulation of MMP-2 expression when used 
at 40pg/ml after 6 days of incubation. Likewise, ox-LDL treatment showed a similar 
affect on both MMPs at 48h, 72h and 6 days incubation. These findings show that longer 
incubation periods with lOOpg/ml of ox-LDL, do not change the expression of those 
MMPs that underwent an expression change in a shorter time period. A summary of the 
zymography analysis is presented in Table 5.5.
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Figure 5.7. MMP secretion from J774.2 and mouse peritoneal macrophages pre-treated 
with ox-LDL. Cells were cultured and treated with ox-LDL at different concentrations and 
incubated for 72h. The supernatant was then analysed by zymography (section 5.9). Panel A 
shows a representative gelatin zymography gel of MMP-2 and MMP-9. The quantification of 
MMP-9 secretion by peritoneal macrophage is shown in panel B and for J774.2 cells in panel 0. 
The quantification of MMP-2 secretion is shown in panel D and E for peritoneal macrophages and 
J774.2 cells respectively. Statistical analysis was carried out using GraphPad Prism software 
(one way ANOVA), data are mean ±S.D. of three independent experiments (*P < 0.05).
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Figure 5.8. MMP secretion from J774.2 cells after six days o f incubation. Cells were treated 
with different concentrations of n-LDL and ox-LDL and incubated for 6 days. The supernatant was 
then analyed by zymography (section 5.9). Panel A shows a representative SDS-PAGE gel for 
MMP-2 and MMP-9. Zymographic band densities from all samples were quantified by 
densitometry. Panel B (MMP-9) and panel C (MMP-2) represent the quantification of MMPs. 
Statistical analysis was carried out using GraphPad Prism software (one way ANOVA), data are 
mean ±S.D. of three independent experiments (*P < 0.05).
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Table 5.5. Summary o f MMP-2 and MMP-9 expression in peritoneal macrophages and 
J774.2 cells. Each time core was normalized against a PBS control. This table provides a 
summary of the data presented in Figures 5.4 to 5.8. Values represent mean ± SD for each 
condition (n=3), stars with bold values show significant results.
Culture
condition
Culture
period
Concentration
(pg/ml)
J774.2.2 cells 
MMP-9
J774.2.2 cells 
MMP-2
Peritoneal
macrophages
MMP-9
Peritoneal
macrophages
MMP-2
48h 100 (102.8 ±3.08)* (100.6 ±1.80)* (138.1 ±3.15)* (58.92 ±1.44)*
80 (99.68 ±2.80)* (92.62±5.13) (98.88 ±2.65) (40.19 ±2.07)
40 (81.15 ±2.46) (76.02 ±4.82) (58.183 ±7.08) (38.18 ±1.53)
72h 100 (141.3 ±7.33)* (161.5±9.17)* (130.5 ±0.6)* (159.3 ±2.22)*
Ox-LDL 80 (132.5 ±4.08) (134.3± 12.6) (113.1 ±2.66) (76.35 ±7.04)
40 (119.6 ±7.02) (153.3 ±9.38) (125.9 ±2.86) (113.8 ±6.16)
6 days 100 (139.6±7.00)* (121.9 ±6.44)*
80 (59.06 ±5.94) (106.1 ±3.90)
40 (98.31 ±6.44) (77.53 ±6.86)
20 (23.22 ±2.36) (32.65 ±3.42)
48h 100 (62.36 ±2.39) (100.5 ±2.5)* (40.77 ±3.70) (37.89 ±1.31)
80 (49.10 ±3.21) (98.72±4.88) (42.85 ±6.25) (40.07 ±2.32)
40 (50.10 ±2.54) (75.82 ±4.98) (37.55 ±2.35) (23.96 ±1.75)
72h 100 (59.45 ±1.82)* (40.04 ±2.13) (39.33 ±2.27)* (31.77 ±1.77)
n-LDL 80 (42.07 ±2.36) (33.23 ±1.18) (29.27±1.90) (22.23 ±3.17)*
40 (39.30 ±2.38) (31.45 ±2.44) (35.49 ±4.11) (27.69 ±3.16)
6 days 100 (42.74±3.84) (37.28 ±3.17)
80 (38.92 ±6.174) (38.03 ± 7.30)
40 (38.92±3.06) (21.86 ±5.05)
20 (21.83 ±5.02) (46.88 ±4.47)
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5.14 Differential expression of cell surface markers induced by LDL and peptides 
in peritoneal macrphages
Peritoneal maerophages were eultured as deseribed in section 5.10.2. PBS treated 
cells were used as negative controls and LPS (5pg/ml) treated cells as positive controls. 
The effect of n-LDL, ox-LDL (both used at 80pg/ml) and five different peptides (Pepl -  
5) (all used at 80pg/ml) were evaluated by flow cytometry. The exposure of peritoneal 
macrophages to Pep3 led to a significant up-regulation in the expression of TLR-2 
(Figure 5.9). In contrast, Pep5 appeared to inhibit (insignificantly) the expression of 
TLR-2 compared to PBS controls. Other treatments, including n-LDL, LPS and Pepl, 2 
and 4, showed no significant changes in TLR-2 expression compared to PBS controls.
Exposure of peritoneal macrophages to ox-LDL increased the expression of TLR-4, 
but the variability around the mean meant that the result was not found to be significant 
(Figure 5.10). No other treatments altered the expression of TLR 4 and levels remained 
similar to the PBS negative control.
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Figure 5.9. Effect of treatment with different compounds on the expression of TLR-2.
Thioglycolate-induced peritoneal macrophages were collected from C57BL/6 mice. Cells were 
cultured as described in section 5.10.2 and analysed by flow cytometry after treatment with n-LDL 
and ox-LDL (80pg/ml), Pep1, 2, 3, 4 and 5 (80pg/ml) and LPS (5pg/ml). Panel A shows a 
representative dot plot analysis. Panel B shows the complete analysis of four independent 
experiments for each treatment. Control samples are cells treated with PBS. Statistical analysis 
was carried out using GraphPad Prism software (one way ANOVA), data are mean ±S.D. of three 
independent experiments (*P < 0.05).
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Figure 5.10. TLR-4 expression in mouse peritoneal macrophages. Thioglycolate-induced 
peritoneal macrophages were collected from C57BL/6 mice. Cells were cultured as described in 
section 5.10.2 and analysed by flow cytometry after treatment with n-LDL and ox-LDL (80pg/ml), 
Pepl, 2, 3, 4 and 5 (80pg/ml) and LPS (5pg/ml). Panel A shows a representative dot plot 
analysis. Panel B shows the complete analysis of four independent experiments for each 
treatment. Control samples are cells treated with PBS. Statistical analysis was carried out using 
GraphPad Prism software (one way ANOVA), data are mean ±S.D. of three independent 
experiments (n=3).
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The expression of the program death ligand 1 (PD-Ll) was also assessed 
(Figure 5.11). High expression of PD-Ll was observed in the negative control, n-LDL, 
ox-LDL and Pepl, Pep2 and Pep3 treated cells, suggesting that no inductive effect was 
observed. However, cells treated with Pep4 and Pep5 expressed lower levels of PD-Ll, 
possibly indicating a repressive effect on expression.
In addition, PD-1; the membrane counterpart of PD-Ll that is normally expressed 
on T-cell surfaces and other cell types was also assessed. In vitro exposure of peritoneal 
macrophages to ox-LDL caused insignificant up-regulation of PD-1 on these cells (Figure 
5.12). No PD-1 response was observed with any of the other treatments. Treatment of 
cells with LPS as a positive inducer did not result in the expected outcome; cells 
expressed similar levels of PD-1 compared to the negative control rather than 
significantly increasing the expression of this species.
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Figure 5.11. Effect of treatment with different compounds on the expression of PD-Ll.
Thioglycolate-induced peritoneal macrophages were collected from C57BL/6 mice. Cells were 
cultured as described in section 5.10.2 and analysed by flow cytometry after treatment with n-LDL 
and ox-LDL (80pg/ml), Pepl, 2, 3, 4 and 5 (80pg/ml) and LPS (5pg/ml). Panel A shows a 
representative dot plot analysis. Panel B shows the complete analysis of four independent 
experiments for each treatment. Control samples are cells treated with PBS. Statistical analysis 
was carried out using GraphPad Prism software (one way ANOVA), data are mean ±S.D. of three 
independent experiments.
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Figure 5.12. Effect of treatment with different compounds on the expression of PD-1.
Thioglycolate-induced peritoneal macrophages were collected from C57BL/6 mice. Cells were 
cultured as described in section 5.10.2 and analysed by flow cytometry after treatment with n-LDL 
and ox-LDL (80pg/ml), Pepl, 2, 3, 4 and 5 (80pg/ml) and LPS (5pg/ml). Panel A shows a 
representative dot plot analysis. Panel B shows the complete analysis of four independent 
experiments for each treatment. Control samples are cells treated with PBS. Statistical analysis 
was carried out using GraphPad Prism software (one way ANOVA), data are mean ±S.D. of three 
independent experiments.
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Macrophages are antigen presenting cells that express high levels of MHC class II 
molecules on their cell surfaces. Incubation of these cells with ox-LDL was shown to 
increase the expression of MHC class II molecules on their surfaces (Figure 5.13). This 
finding contrasted with the lack of expression of this marker in all other groups when 
compared to PBS treated control cells.
CD 14 is a characteristic phenotypic marker for macrophages, which explains why 
high levels of CD 14 expression were noted in most treatment conditions, including the 
negative control (Figure 5.14) but not in samples treated with Pep5 (Figure 5.14). 
Expression of CD 14 was lower after treatment of cells with Pep4 and 5, however the 
reduction in expression was of big enough magnitude to be significant compared to the 
PBS control group. A summary of the results using peritoneal macrophages is shown in 
Table 5.6.
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Figure 5.13. Effect of treatment with different compounds on the expression of MHC class
II. ThioglyGolate-incluced peritoneal macrophages were collected from C57BL/6 mice. Cells were 
cultured as described in section 5.10.2 and analysed by flow cytometry after treatment with n-LDL 
and OX-LDL (80pg/ml), Pepi, 2, 3, 4 and 5 (SOpg/ml) and LPS (5pg/ml). Panel A shows a 
representative dot plot analysis. Panel B shows the complete analysis of four independent 
experiments for each treatment. Control samples are cells treated with PBS. Statistical analysis 
was carried out using GraphPad Prism software (one way ANOVA), data are mean ±S.D. of three 
independent experiments.
56
(A)
Control n-LDL
Specimen 003
31.7%
tm r-m im r
10 10 to" 10"
CD14APC-A
Ox-LDL
Specimen 003 CD11b-MHC-ll
1 .5% 02 63.5%
1 3 1 % w
"S ] 2 2 .0 %
IP’  to’ ......y
CD14APC-A
Specimen 003 CD11b-MHC-ll
60.7%
iw iniiiB I
to to" to to" 
CD14APC-A
LPS
Specimen 003
riiif 11111^
46.8%
CD14APC-A
Pep i
45% 0266.0%
1 8 .6 % ^ [ j
21.9%
Q
Ü  Pep2 Pop3 Pep4 Pep5 ISOTYPE
Specimen 003 C D llb -M H C -i Specimen 003 CD11b-MHC-laï%Specimen 003 CD11P-HHC-I 3.1%
Specimen 003 CD11b-MHC-lSpecimen 003 CD11b-MHC-l 
7.4% 02 23.8%
1.7% 59.3% 36.4% TRW02 60.8%
til Sn
■92.6%
27.1 21.4% 22.9%
CD14APC-ACD14APC-A CD14APC-A
CD14
(B)
80-1
e  6 0 -
4 0 -
2 0 -
C u l t u r e  c o n d i t i o n s
Figure 5.14. Effect of treatment with different compounds on the expression of CD14.
Thioglycolate-induced peritoneal macrophages were collected from C57BL/6 mice. Cells were 
cultured as described in section 5.10.2 and analysed by flow cytometry after treatment with n-LDL 
and OX-LDL (80pg/ml), Pepi, 2, 3, 4 and 5 (80pg/ml) and LPS (5pg/ml). Panel A shows a 
representative dot plot analysis. Panel B shows the complete analysis of four independent 
experiments for each treatment. Control samples are cells treated with PBS. Statistical analysis 
was carried out using GraphPad Prism software (one way ANOVA), data are mean ±S.D. of three 
independent experiments.
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5.15 Differential expression of cell surface markers induced by LDL and peptides 
in J774.2 cells
The expression of TLR-2 was significantly up-regulated by treatment of cells with 
Pepi. No significant change in TLR-2 expression was observed using other treatments, 
when compared to the negative control (PBS) (Figure 5.15). Exposure of J774.2 cells to 
Pepi and Pep3 led to significant up-regulation of TLR-4, when compared to the negative 
control, indicating their positive effect on the activation of macrophages (Figure 5.16).
There was noticeably high expression of PD-Ll in negative control cells as well 
as in most of the other treatment groups, excluding cells treated with Pep5, which 
expressed slightly lower levels of PD-Ll (Figure 5.17). The effect of Pep5 on the 
expression of PD-Ll by J774.2 cells was similar to that observed in peritoneal 
macrophages, in that levels were slightly but not significantly reduced (Figure 5.11). PD- 
1 expression by J774.2 cells did not significantly change in response to LPS, n-LDL, or 
Pepi-Pep5 treatments (Figure 5.18). The highest PD-1 expression was observed in 
response to ox-LDL treatment, but it was not significant.
Pepi and Pep3 insignificantly up-regulated the expression of MHC class II 
molecules in J774.2 cells (Figure 5.19) but no effect was observed in cells treated with 
LPS, n-LDL, Pep2 or Pep5. CD 14 was highly expressed by J774.2 cells treated with LPS, 
n-LDL, ox-LDL and Pep 1-3 but the effect was not significantly different compared to the 
negative control (Figure 5.20). Conversely, we observed a down-regulation of the 
expression of CD 14 in cells treated with Pep5 and Pep4 but this was not significant. 
Table 5.7 shows a summary of all findings obtained with J774.2 cells.
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Figure 5.15. Effect of different treatments on the expression of TLR-2 by J774.2 cells. Cells 
were cultured for 24h and then treated with n-LDL and ox-LDL (80jjg/ml), Pep1, 2, 3, 4 and 5 
(80|jg/ml) and LPS (Spg/ml) (section 5.10). Cell pellets were labeled with different fluorescent 
antibodies and analysed by flow cytometry (section 5.10). Panel A shows a representative dot 
plot analysis. Panel B shows the complete analysis of four independent experiments for each 
treatment. Control samples are cells treated with PBS. Statistic analysis carried out using 
GraphPad Prism software (one way ANOVA), data are mean ±S.D. of three independent 
experiments (*P < 0.05).
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Figure 5.16. Effect of different treatments on the expression of TLR-4 by J774.2 cells. Cells 
were cultured for 24h and then treated with n-LDL and ox-LDL (SOpg/ml), Pep, 2, 3, 4 and 5 
(80pg/ml) and LPS (Spg/ml) (section 5.10). Cell pellets were labeled with different fluorescent 
antibodies and analysed by flow cytometry (section 5.10). Panel A shows a representative dot 
plot analysis. Panel B shows the complete analysis of four independent experiments for each 
treatment. Control samples are cells treated with PBS. Statistic analysis carried out using 
GraphPad Prism software (one way ANOVA), data are mean ±S.D. of three independent 
experiments (*P < 0.05).
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Figure 5.17. Effect of different treatm ents on the expression of PD-Ll by J774.2 cells. Cells 
were cultured for 24h and then treated with n-LDL and ox-LDL (SOpg/ml), Pep1, 2, 3, 4 and 5 
(SOpg/ml) and LPS (5|jg/ml) (section 5.10). Cell pellets were labeled with different fluorescent 
antibodies and analysed by flow cytometry (section 5.10). Panel A shows a representative dot 
plot analysis. Panel B shows the analysis of four independent experiments for each treatment. 
Control samples are cells treated with PBS. Statistic analysis carried out using GraphPad Prism 
software (one way ANOVA), data are mean ±S.D. of three independent experiments.
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Figure 5.18. Effect of different treatm ents on the expression of PD-1 by J774.2 cells. Cells 
were cultured for 24h and then treated with n-LDL and ox-LDL (BOpg/ml), Pepi, 2, 3, 4 and 5 
(BOpg/ml) and LPS (5pg/ml) (section 5.10). Cell pellets were labeled with different fluorescent 
antibodies and analysed by flow cytometry (section 5.10). Panel A shows a representative dot 
plot analysis. Panel B shows the analysis of four independent experiments for each treatment. 
Control samples are cells treated with PBS. Statistic analysis carried out using GraphPad Prism 
software (one way ANOVA), data are mean ±S.D. of three independent experiments.
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Figure 5.19. Effect of different treatm ents on the expression of MHC class II by J774.2 
cells. Cells were cultured for 24h and then treated with n-LDL and ox-LDL (SOpg/ml), Pep1, 2, 3, 
4 and 5 (80|jg/ml) and LPS (Spg/ml) (section 5.10). Cell pellets were labeled with different 
fluorescent antibodies and analysed by flow cytometry (section 5.10). Panel A shows a 
representative dot plot analysis. Panel B shows the complete analysis of four independent 
experiments for each treatment. Control samples are cells treated with PBS. Statistic analysis 
carried out using GraphPad Prism software (one way ANOVA), data are mean ±S.D. of three 
independent experiments.
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Figure 5.20. Effect of different treatm ents on the expression of CD14 by J774.2 cells. Cells 
were cultured for 24h and then treated with n-LDL and ox-LDL (80|jg/ml), Pep1, 2, 3, 4 and 5 
(80|jg/ml) and LPS (5|jg/ml) (section 5.10). Cell pellets were labeled with different fluorescent 
antibodies and analysed by flow cytometry (section 5.10). Panel A shows a representative dot 
plot analysis. Panel B shows the complete analysis of four independent experiments for each 
treatment. Control samples are cells treated with PBS. Statistic analysis carried out using 
GraphPad Prism software (one way ANOVA), data are mean ±S.D. of three independent 
experiments.
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Table 5.6. Summary of the main findings from the experim ents with peritoneal 
m acrophages experim ents (Figure 5.9 -  5.14). Each time core was normalized against PBS 
control. Values represent mean ±SD for each condition (n=4), stars with bold values show 
significant results.
Macrophage
surface
markers
PBS n-LDL Ox-LDL LPS Pepi Pep2 Pep3 Pep4 Pep5
TLR-2
18.40
±1.79
28.01
±1.05
25.13
±1.97
25.91
±1.69
29.42
±2.90
26.42
±1.53
40.80
±1.80*
17.13
±2.04
13.16
±1.36
TLR-4
0.40
±0.49
0.25
±0.19
17.90
±15.54
0.32
±0.40
0.80
±0.53
0.35
±0.38
1.7
±1.6
0.50
±0.40
0.35
±0.20
PD-Ll
47.38
±22.92
46.90
±23.32
54.0
±24.48
41.80
±31.36
52.0
±29.91
52.55
±27.86
36.80
±22.17
25.0
±4.93
21.08
±4.68
PD-1
1.80
±2.50
1.32
±2.19
13.40
±9.85
1.10
±1.29
1.52
±1.60
1.17
±1.64
2.37
±2.378
0.875
±0.870
0.30
±0.16
MHCII
0.47
±0.12
0.32
±0.12
7.85
±1.65
0.45
±0.19
0.60
±0.27
0.30
±0.08
1.45
±0.17
0.80
±0.29
0.95
±0.23
CD14
50.15
±4.30
63.13
±5.19
60.08
±3.83
41.65
±5.98
41.95
±13.83
52.43
±6.08
45.63
±3.42 ±2.72
21.20
±2.30
Table 5.7. Summary of the main findings using J774.2 cell experim ents (Figure 5.15 -  5.20). 
Each time core was normalized against PBS control. Values represent mean ±SD for each 
condition (n=4), stars with bold values show significant results.
Macrophage
surface
markers
PBS n-LDL Ox-LDL LPS Pepi Pep2 Pep3 Pep4 Pep5
TLR-2
0.40
±0.10
0.43
±0.11
0.70
±0.10
0.43
±0.11
7.0
±2.57*
0.93
±0.49
2.03
±0.32
1.23
±0.75
1.83
±0.20
TLR-4
0.233
±0.057
0.33
±0.11
1.43
±0.152
0.83
±0.11
2.83
±0.25*
0.433
±0.152
3.26
±0.45*
1.23
±0.416
0.933
±0.251
PD-Ll
15.83
±3.35
20.11
±1.91
21.68
±2.06
18.38
±1.48
21.97
±9.85
18.07
±8.75
17.63
±5.10
15.97
±6.80
9.72
±0.76
PD-1
1.86
±1.44
1.13
±0.63
3.33
±0.63
1.26
±0.75
2.96
±0.70
1.83
±0.25
2.73
±0.66
2.90
±0.20
2.16
±0.30
MHCII
0.266
±0.05
0.233
±0.11
0.46
±0.20
0.233
±0.05
1.40
±0.45
.016
±0.05
1.20
±0.10
0.50
±0.10
0.16
±0.05
CD14
19.53
±2.62
22.63
±1.51
22.23
±1.73
21.80
±1.25
27.60
±13.92
22.63
±10.06
20.67
±8.60
13.32
±2.04
14.21
±0.90
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5.16 The effect of macrophage-derived peptides on the activation o f macrophages by 
ox-LDL
These experiments were designed as pilot study to assess the effect of the peptides 
identified in the previous chapter on cells pre-exposed to ox-LDL. Flow cytometry was 
used to investigate this effect on J774.2 cells. As described in section 5.10, J774.2 cells 
were treated with 80pg/ml of ox-LDL and incubated for 72h. Peptides (Pep 1-5) were 
added separately at 80pg/ml post ox-LDL treatment and incubated for a further 72h 
before analysis. This experiment was repeated three times and the resulting cell pellets 
were pooled for flow cytometry analysis to show the general trend of Pep4 and Pep5 
immune responses on ox-LDL function.
In vitro exposure of macrophages to ox-LDL led to an up-regulation of TLR-2 
expression (Figure 5.21). This finding is different to the effect of ox-LDL on TLR-2 seen 
in Figure 5.15, and may due to differences in the experiment settings. The result in Figure 
5.15 presents the mean of four independent experiments, while cell pellets from three 
different experiments were pooled together as one sample in Figure 5.21 used as pilot 
study. Cells treated with ox-LDL and Pep5 showed a down-regulation of TLR-2 
expression suggesting that this peptide is a potent inhibitor of the pro-inflammatoiy effect 
of ox-LDL on macrophages. A moderate down-regulation was also observed with Pep4 
and Pep3. Interestingly, high levels of TLR-4 were noted in cells treated with ox-LDL 
and this was dramatically reduced after treatment with Pep5, Pep4 and Pep3 (Figure 
5.22).
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Figure 5.21. The effect of double treatm ent on the expression of TLR-2 in J774.2 cells. Cells 
were cultured for 24h and treated with SOpg/ml of ox-LDL and incubated for 72h (section 5.10). 
80pg/ml of Pepi, Pep2, Pep3, Pep4 and Pep5 were added separately on treated cells and 
incubate for 72h (section 5.10). Cell pellets from three different experiments were pool together 
and were labeled with different fluorescent antibodies and analysed by flow cytometry (section
5.10). Panel A shows a representative dot plot analysis. Panel B shows the complete analysis of 
four independent experiments for each treatment. Control samples are cells treated with ox-LDL 
only.
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Figure 5.22. The effect of double treatm ent on the expression of TLR-4 in J774.2 cells. Cells 
were cultured for 24h and treated with 80pg/ml of ox-LDL and incubated for 72h (section 5.10). 
80|jg/ml of Pepi, Pep2, Pep3, Pep4 and Pep5 were added separately on treated cells and 
incubate for 72h (section 5.10). Cell pellets from three different experiments were pool together 
and were labeled with different fluorescent antibodies and analysed by flow cytometry (section
5.10). Panel A shows a representative dot plot analysis. Panel B shows the complete analysis of 
four independent experiments for each treatment. Control samples are cells treated with ox-LDL 
only.
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Moderate levels of PD-Ll were induced by ox-LDL treatment (Figure 5.23), but 
this expression was decreased by half after treatment with Pep5. Moreover, we observed 
an approximately 3-fold up-regulation in the expression of PD-Ll in cells pre-treated 
with ox-LDL and with Pepi or Pep2. The exposure of macrophages to a mixture of ox- 
LDL and each peptide, led to the up-regulation of PD-1 expression when compared with 
the effect of ox-LDL treatment alone (Figure 5.24).
The expression of MHC class II molecules on macrophages was up-regulated by 
Pepi and Pep3 in cells pre-treated with ox-LDL (Figure 5.25). However, the expression 
of MHC class II was down-regulated by Pep2 and Pep4 treatments. A large increase in 
CD 14 expression levels was seen following treatment with Pepi and Pep2 in cells pre­
treated with ox-LDL (Figure 5.26). Additionally, Pep4 was able to suppress the effect of 
ox-LDL by approximately three quarters in J774.2 cells. From these results it appears that 
the peptides identified can have both stimulatory and inhibitory effects on ox-LDL 
action, depending on the specific target under regulation.
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Figure 5.23. The effect of double treatm ent on the expression of PD-L1 in J774.2 cells. Cells 
were cultured for 24h and treated with 80|jg/ml of ox-LDL and incubated for 72h (section 5.10). 
80|jg/ml of Pepi, Pep2, Pep3, Pep4 and Pep5 were added separately on treated cells and 
incubated for 72h (section 5.10). Cell pellets from three different experiments were pooled 
together and were labeled with different fluorescent antibodies and analysed by flow cytometry 
(section 5.10). Panel A shows a representative dot plot analysis. Panel B shows the analysis of 
four independent experiments for each treatment. Control samples are cells treated with ox-LDL 
only.
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Figure 5.24. The effect of double treatm ent on the expression of PD-1 in J774.2 cells. Cells 
were cultured for 24h and treated with 80pg/ml of ox-LDL and incubated for 72h (section 5.10). 
80|jg/ml of each peptide was added separately on treated cells and incubated for 72h. Cell pellets 
from three different experiments were pooled together and were labeled with different fluorescent 
antibodies and analysed by flow cytometry (section 5.10). Panel A shows a representative dot 
plot analysis. Panel B shows the analysis of four independent experiments for each treatment. 
Control samples are cells treated with ox-LDL only.
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Figure 5.25. The effect of double treatm ent on the expression of MHC ca iss II in J774.2 
cells. Cells were cultured for 24h and treated with 80|jg/ml of ox-LDL and incubated for 72h 
(section 5.10). SOpg/ml of Pepi, Pep2, Pep3, Pep4 and PepS were added separately to treated 
cells and incubate for 72h (section 5.10). Cell pellets from three different experiments were 
pooled together and were labeled with different fluorescent antibodies and analysed by flow 
cytometry. Panel A shows a representative dot plot analysis. Panel B shows the complete 
analysis of four independent experiments for each treatment. Control samples are cells treated 
with ox-LDL only.
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Figure 5,26, The effect of double treatm ent on the expression of CD14 in J774.2 cells. Cells 
were cultured for 24h and treated with 80pg/ml of ox-LDL and incubated for 72h (section 5.10). 
80pg/ml of each peptide was added separately to treated cells and incubated for 72h. Cell pellets 
from three different experiments were pooled together and analysed by flow cytometry (section
5.10). Panel A shows a representative dot plot analysis. Panel B shows the complete analysis of 
four independent experiments for each treatment. Control samples are cells treated with ox-LDL 
only.
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5.17 Discussion
Monocytes and macrophages are the main cellular components of atherosclerotic 
plaques. However, despite the vast amount of information published, there are still 
information gaps to be filled with regards to their activation, and physiological changes in 
response to atherogenic stimuli. In this chapter the characterisation of the response to pro- 
atherogenic agents such as ox-LDL and n-LDL is described using J774.2 cells and 
peritoneal macrophages as a model. The histological stain ORO was used to investigate 
the influence of ox-LDL and n-LDL on lipid accumulation in these cells.
Lipid accumulation in response to LDL, VLDL, AcLDL and other agents has 
been previously tested by different methods with different cell types including the human 
monocyte cell line THP-1, rat skeletal cells, J774.2 cells, U937 cells and peritoneal 
macrophages (Kosaka et al, 2001; Koopman et al, 2001; Brown et al, 2000; Yue et al, 
2009). Studies carried out by Kosaka and his group used ORO stain to study the 
formation of lipid droplets and the expression of the VLDL receptor. In their study THP- 
1 cells were treated with Phorbol-12-myristate-13-acetate (PMA) in the presence of IFN- 
y and two different techniques used to assess the effect, the ORO stain and ^^^1-P-VLDL 
degradation. The expression of the VLDL receptor was up-regulated during monocyte- 
macrophage differentiation and IFN-y suppressed this expression and suppressed foam 
cell formation in macrophages (Kosaka et al, 2001).
In this study foam cells derived from peritoneal macrophages and J774.2 cells 
were treated with n-LDL and ox-LDL. This was performed in the absence of any other 
effectors such as IFN-y or LPS, which have been used by others to assess similar effect 
on other macrophage-like cell types (Kosaka et al, 2001, Mori et al, 2001). The effect of 
different concentrations of ox-LDL and n-LDL were assessed in this study. The 
concentrations used were selected based on previous published studies and preliminary 
data from our laboratory. It has been found that a high concentration of ox-LDL 
(>100pg/ml) normally leads to cell death (Han and Pak, 1999), and therefore, low 
concentrations of ox-LDL (40, 50 or SOpg/ml) are typically used for in vitro studies to 
avoid any toxicity (Yang et al, 1996; Hamilton et al, 1999).
Matrix metalloproteinases are important components in the development of 
atherosclerotic plaques. They facilitate the migration of inflammatory cells into the sub-
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endothelial space and the formation of the neointimal layer responsible for the cell wall 
enlargement. MMP-2 and MMP-9 are both gelatinases that degrade collagen and play a 
crucial role in the physiological remodelling of tissues. In the atherosclerotic plaques, the 
degradation of the collagen of the fibrous cap, due to the action of these MMPs, may lead 
to plaque rupture (Libby, 2008; Yoon et al, 2002).
This study has shown that treatment with n-LDL and ox-LDL induces a 
differential pattern of MMP secretion in cultured macrophages. MMP expression was 
highly affected by ox-LDL treatment at different concentrations. Ox-LDL treatment of 
macrophage up-regulated the expression of MMP-9 in J774.2 cells at high and low 
concentrations (40, 80 and lOOpg/ml) with all incubation periods (48h, 72h and 6 days). 
Treatment with higher concentrations of ox-LDL (80 and lOOpg/ml) resulted in greater 
and significant expression of MMP-9 (Table 5.5).
Similar secretion patterns of MMP-2 were observed at similar concentrations with 
all incubation periods (48h, 72h and 6 days) after treatment with ox-LDL. A high 
concentration of ox-LDL produced a higher expression of MMP-2 and MMP-9 compared 
to the control sample at the same incubation period (Table 5.5). Furthermore, ox-LDL 
treatment activated macrophages at high and low concentrations with long and short 
incubation periods. These results demonstrate the role of ox-LDL in the expression of 
MMP-2 and MMP-9 by macrophages. It seems to be that this effect was not dependent on 
the duration of exposure to LDL. We hypothesize that the expression of MMP-2 and 
MMP-9 induced by ox-LDL treatment is concentration-dependent and long or short 
incubation periods are not determining factors. Similar work has been done by Yue et al 
(2009), using different types of cells but using similar treatment conditions (ox-LDL at 
different concentrations) within a short incubation time (48h). Yue and colleagues 
investigated the association between the secretion of MMP-2 and MMP-9 with foam cell 
formation using U937 cells treated with different concentrations of ox-LDL (0, 25, 50, 
100, 200 mg/1) for a 48h culture period (Yue et al, 2009). They reported that the 
expression of MMP-2 and MMP-9 was up-regulated depending on ox-LDL dose (Yue et 
al, 2009).
On the other hand, the effect of n-LDL on the secretion of both MMPs was 
different from that found using ox-LDL. The expression of MMP-9 was significantly up-
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regulated only at a high concentration (lOOpg/ml) of n-LDL after 72h incubation. In 
contrast with MMP-2, the secretion of MMP-2 was up-regulated only after a short 
incubation time (48h) and at higher concentration (lOOpg/ml) of n-LDL and the effect 
disappeared after 72h and 6 days incubation. The insignificant inhibition of MMP-2 
secretion was noted with 72h incubation at lower concentrations (40 & 80pg/ml). We 
hypothesize that specific concentrations of n-LDL may inhibit MMP-2 expression and 
that this effect may be related to the cell type and incubation periods which may inhibit 
plaque rupture.
The incubation period, but not the concentration of n-LDL, seems to play a role in 
MMP-9 expression. This effect may be related to the formation of other enzymes (e.g. 
Tissue Inhibitor Metalloprotease (TIMP)) in the culture medium after long incubation 
periods. The balance between MMP expression and their inhibitor (TIMP) plays a crucial 
role in directing the accumulation or degradation of MMPs in tissue (Libby et al, 2002; 
Libby, 2006), and therefore it has a massive relevance in atherosclerotic plaque research.
The expression of MMP-2 and MMP-9 by peritoneal macrophages exposed to 
different concentrations of ox-LDL during a 72h incubation period showed a similar 
trend to that seen in J774.2 cells treated under the same conditions. The up-regulation of 
both MMPs seems to be dependent on the concentration of ox-LDL used. No significant 
increase in the expression of either MMP was seen after 48h incubation in cells treated 
with 40pg/ml of ox-LDL. However, both MMPs were up-regulated at high concentration 
(lOOpg/ml) after 48h culture. MMP-9 expression was only up-regulated significantly in 
peritoneal macrophages after treatment with lOOpg/ml of n-LDL for 72h. The expression 
of MMP-2 (after 72h) decreased at 40 and 80pg/ml of n-LDl when compared to the 
control. n-LDL could be acting, as an inhibitory agent blocking the expression of MMP-2 
by macrophages in a time-dependent fashion. These findings suggest that ox-LDL is a 
pro-atherogenic agent that may be able to stimulate plaque rupture at different stages of 
atherosclerosis based on its concentration.
The possibility exists for the involvement of oxidative stress mechanisms as 
described in the study by Rajagopalan and colleagues should be taken in our 
consideration. They investigated the effects of reactive oxygen species (ROS) 
(superoxide, nitric oxide, and hydrogen peroxide) in vitro using metalloproteinases
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secreted by cultured human vascular smooth muscle cells. They found that the generation 
of the active forms of MMP-2 and MMP-9 relied on the release of ROS from 
macrophages or smooth muscle cells (Rajagopalan et ah, 1996). In addition, the activity 
of MMP-2 and MMP-9 is managed by reactive oxygen species derived from macrophage 
foam cells (Pasterkamp and Falk, 2000). Their results may explain our findings in 
relation to the increased levels of MMP-2 or MMP-9 induced by high concentrations of 
ox-LDL which may rely on the presence of ROS by activated macrophages in culture 
media. This needs to be investigated in future work.
Further investigation of the effect of each condition (ox-LDL, n-LDL, Pep 1-5) on 
macrophages was undertaken using flow cytometry analysis. The present study led to two 
parallel findings in J774.2 cells and peritoneal macrophage, allowing us to demonstrate 
that the effect of some treatments, under given conditions (ox-LDL, n-LDL, pepl-pep5), 
on macrophages may depend on cell type and this should be taken in to consideration 
when comparing results from different studies. In addition, the results obtained in this 
study show that some of the identified peptide (e.g. Pep5 and Pep4) were able to down- 
regulate the effect of ox-LDL on J774.2 cells as illustrated in results section in this 
chapter.
The effect of these treatments was assessed first on macrophage function. An 
increased level of TLR2 expression was seen in response to Pep3 on peritoneal 
macrophage and also in response to Pepi on J774.2 cells. In addition TLR-4 was up- 
regulated insignificantly after ox-LDL treatment by both macrophages and also increased 
in response to Pepi and Pep3 by J774.2. This finding may show that Pepi and Pep3 may 
possibly have pro-inflammatory effects on macrophage cells by triggering TLR-4 or 
TLR-2 expressions. This result cannot be compared with any other studies because this is 
the first time these peptides have been examined. Furthermore, it is well known that ox- 
LDL is a proatherogenic agent, in agreement with this study. The up-regulation of TLR-4 
expression on macrophages by ox-LDL in our study suggests that these TLRs may 
present a potential pathophysiological link between ox-LDL and infection/inflammation 
in atherosclerosis. The link between ox-LDL and TLR-4 has been reported by others. 
Apo-E' "^ mice and human plaques showed an up-regulation of TLR-4 expression, similar 
to our finding (Xu et al, 2001; Miller et al, 2005). Additionally, it has been shown that
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OX-LDL signals via TLR molecules (TLR-1, 2 and 4) to induce the modification of 
cytoskeletal cells and up-regulate the expression of inflammatory cytokines by 
macrophages and endothelial cells (Bjorkbacka, 2006; Miller et al, 2003; Miller et al,
2005). The ability of Pepi and Pep3 to activate macrophages may suggest a relationship 
between these peptides with the signaling pathway of TLRs as with ox-LDL condition 
(Bjorkbacka, 2006; Miller et al, 2003). This suggests that Pepi and Pep3 may play a 
similar role as ox-LDL and that they may use similar signaling pathways to enhance TLR 
expression in macrophages.
On the other hand, the lack of the effect of ox-LDL on the expression of TLR-2 
may be due to an insufficient incubation period or concentration of ox-LD and it may be 
that the activation of TLR-2 requires longer incubation periods or higher concentrations 
than those used in this study.
Surprisingly, LPS treatment resulted in an insignificant up-regulation of TLR-4 
and TLR-2 expressions by both cells. This result is different from previous published 
studies. It has been demonstrated that gram-positive bacteria and fungi are able to 
activate TLR-2, while gram-negative bacteria and LPS trigger TLR-4 (Paul-Clark et al,
2006). The explanation of our finding may be clarified by work by Cohly (2001). Cohly 
and co-worker reported that macrophage cells, especially J774.2 cell lines, are resistance 
to several effects of LPS when cultured in different types of media. They discovered that 
DMEM media inhibited the effect of LPS on J774.2 cells, whereas RPMI media did not 
(Cohly et al, 2001). Moreover, they found that the morphology of J774.2 cells, and their 
response to LPS, was different after culture in RPMI compared to DMEM media. DMEM 
media was used in the present study and it may block the effect of LPS on macrophages 
as reported in Cohly study.
Other surface markers were tested including PD-Ll and PD-1 using the same 
conditions and the same macrophages. The insignificant down-regulation of PD-Ll 
expression after Pep4 and Pep5 treatment by peritoneal macrophages (Pep5 only effect 
J774.2 cells) is evidence of the pro-inflammatory effect of these two peptides on 
macrophage functions. Other studies, have reported that the expression levels of PD- 
1/PD-Ll in patients with coronary artery disease is lower than in healthy people (Lee et 
al, 2009). In addition, they showed that the PD-1/PD-Ll pathway is crucial in the
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regulation of proatherogenic T cell immunity through the modulation of antigen 
presenting cells. Our findings demonstrate that Pep4 and Pep5 are play a similar role as 
ox-LDL on macrophages, and that their presence in vivo may support plaque formation 
and atherosclerosis development through suppression of PD-Ll/PD-1 pathway (Figure 
5.27). Although high expression of PD-Ll by all other treatments (ox-LDL, n-LDL, LPS, 
Pepi- Pep3), which were equal to negative control, were seen in this study. This may be 
explained by the fact that all macrophage cells are able to induce a certain amounts of 
PD-Ll ligand in a normal state (Loke and Allison, 2003).
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Figure 5.27. The effect of Pep4 and Pep5 on PD-L1 expression by m acrophages. Pep4 and 
PepS down-regulates PD-L1 leading to the activation of the Th1 pathway.
No significant change in the levels of PD-Ll, compared to negative control, was 
expressed following LPS treatment. Other studies reported that macrophage cells can 
express higher levels of PD-Ll after the classical activation (lipopolysaccharide (LPS) or 
IFN- y) (Loke and Allison, 2003). The limitations of LPS to trigger macrophages in the 
present study may due to the use of DMEM media as discussed earlier (Cohly et al, 
2001 ).
We detected an insignificant up-regulation of PD-1 expression only with ox-LDL 
treatment by peritoneal macrophages. Despite the fact that PD-1 is a T cell receptor it can 
be expressed by other activated cells. A recent study showed the ability of macrophage 
cells to express PD-1 after certain stimulations (Lee et al, 2009). Additionally, this result 
follows similar observations made by Huang and co-workers, who found peritoneal 
macrophages, express higher levels of PD-1 during inflammatory disease such as sepsis 
(Huang et al, 2009). Atherosclerosis therapy studies may possibly use the regulation of 
the PD-l/PD-Ll pathway. Generally, the differential roles of PD-1/PD-Ll molecules 
remain unclear and it is not well understood until now, and more effort needs to be made 
to understand the exact role of these molecules.
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Figure 5.28 shows, the effect of ox-LDL treatment on PD-1 expression on 
macrophages. This treatment may be responsible for the induction of two different 
interactions. First interaction between PD-1/PD-Ll that is expressed on the same cell 
surface, or second, the interactions that may occur between macrophages leading to cell 
death. This result demonstrates the role that ox-LDL may play in macrophage death in 
vitro and in the stimulation of Thl immune responses through the PD-1/PD-Ll pathway 
in vivo.
A pro-inflammatory effect was observed with ox-LDLon peritoneal macrophage 
via the up-regulation of MHC class II expression, while other treatments (Pepi and Pep3) 
showed no significant effect on MHC class II molecules. These treatments (ox-LDL, 
Pepi and Pep3) are able to enhance CD4 T cell proliferation and pro-inflammatory 
cytokine production (require more investigation in future work).
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Figure 5.28. The effect of ox-LDL on the expression of PD-1 by m acrophages.
CD 14 is normally expressed on the surface of macrophages and is up-regulated by 
stimulated macrophages. CD 14 is the main receptor for LPS on the macrophage surface 
(Dziarski et al, 2001). The implication of LPS in the development of the plaque in 
atherosclerosis has been well studied and reported (Plowden et al, 2004, Yi-jie et al, 
2009). Despite the high level of CD 14 that was expressed by all treatment on both 
macrophage cell types it was no greater than the negative control. This result may be 
explained by the fact that CD 14 is a macrophage phenotype marker expressed continually 
on the cell surface (Rudi et al, 2002). Insignificant down-regulation of CD 14 expression 
was detected with Pep4 and Pep5 treatments by both cells. This suggests that Pep4 and 
Pep5 may generate tolerogenic macrophages that suppress the inflammatory effect of 
LPS which may lead to a block in the formation of atherosclerotic plaques.
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The effect of each peptide on ox-LDL function was assessed as general 
characterisation for predicted peptide (Pep4 & Pep5) immune responses on ox-LDL 
function. The results showed that TLR-2 and TLR-4 are dramatically down-regulated in 
response to Pep3, Pep4 and Pep5. It should be taken into consideration that cells were 
incubated with ox-LDL for 72h before peptide treatment which allowed ox-LDL to 
activate cells. This finding suggests a possible inhibtion of the pro-atherogenic effect of 
ox-LDL on macrophage cells by these three peptides. This may indicate that they might 
possibly be used as therapeutic agents for atherosclerosis in the future. On the other hand, 
Pep5 acts as a pro-inflammatory agent via the down-regulation of PD-Ll and the up- 
regulation of PD-1 molecules. Moreover, Pep4 inhibits the expression of MHC class II 
and CD 14, which may lead to suppression of Thl responses. We hypothesize that Pep4 
and Pep5 may be act as an excellent anti-inflammatory agent that might be able to 
suppress the effects of ox-LDL through down-regulation of TLR-2, TLR-4, MHC class II 
and CD 14 and play an important role in the inhibition of atherosclerotic plaque 
formation.
All the peptides under investigation up-regulated PD-1 expression. This effect 
was similar to the effect of ox-LDL on PD-1 expression (Figure 5.28) indicating a 
possible role of these treatments in cell programmed death in vitro. Moreover, depending 
on previous studies by Huang (2009) and Lee (2009), Pep 1-5 are pro-inflammatory 
agents that activate macrophages (pre-treated with ox-LDL) to induce PD-1 on their 
surface (Huang et al, 2009; Lee et al, 2009).
Importantly, Pepl and Pep2 act as anti-inflammatory agents by up-regulating PD- 
Ll molecules (and MHC class II was down-regulated by Pep2 only). This finding 
suggests that Pep land 2 enhance the formation of tolerant macrophages that may 
suppress the development of the plaque at all stages of atherosclerosis. On the other hand, 
both peptides acted as pro-inflammatory agents by up-regulating CD 14 (and MHC class 
II by Pepl only) indicating two different effective roles of these peptides.
In summary, Pep3, 4 and 5 showed successful inhibition of ox-LDL function by 
down-regulating the expression of TLR-2, TLR-4, MHC class II and CD 14, which 
generates tolerant and regulatory macrophages. The possibility of generating tolerant and 
regulatory macrophages, and the ability of macrophage to induce T r in vivo and in vitro.
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has been reported previously (Zhen et al, 2008). Moreover, other studies demonstrated 
that three different types of activation of macrophages have been identified using IL-4, 
LPS or with classical activation in the presence of (IgG). The latter activation type 
(classical activation in the presence of (IgG)) was shown to induce IL-10 and TGF-p 
which reduces acute the inflammatory response (Mosser, 2003). These studies support 
our finding that Pep5, Pep4 and Pep3 may be able to generate tolerant macrophages that 
are able to decrease the inflammatory response in atherosclerosis. We hypothesize that 
Pep3, 4 and 5 may induce a different type of tolerant macrophage that may block foam 
cell formation and suppress plaque development.
On the other hand, their effect on macrophage function was different. Pepl and 
Pep3 were pro-inflammatory, through the activation of TLR-2, TLR-4 and MHC class II 
expression, whereas Pep4 and Pep5 showed pro-inflammatory effect via the down- 
regulation of PD-Ll expression. These completely opposing effects on macrophages and 
ox-LDL function might suggest a remarkable role of Pep 1-5 on Thl and Th2 balance 
which may regulate the proatherogenic T cell immunity by dominant antigen presenting 
cell dependent T cell activation.
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Chapter 6: Metabolomic Analysis
Abstract
Because atherosclerosis is one of the major causes of morbidity and mortality 
Worldwide, enormous efforts have been made by scientists to understand the underlying 
cause and to identify ways of preventing this disease. However, many questions remain 
unanswered. New technologies (i.e. ‘omics’) have provided the means of possibly 
increasing our understanding of disease mechanisms and may be able overcome the 
limitations of other methods. Metabolomics is one of the most important ‘omics’ that has 
been developed in recent years. The metabolite represents the final stage in a biological 
system and illustrates a clear function in the living system. Therefore, the identification 
of metabolites that exist in cells, or tissues, under specific conditions is an important issue 
in clinical and biological fields. It is a powerful technique that is used in drug 
development, biomarker discovery and for many other purposes in the clinical arena. This 
chapter aimed to identify lipid metabolite profiles that are induced by J774.2 mouse 
macrophages pre-treated with either ox-LDL or n-LDL components. To achieve this aim, 
LC/MS was performed for metabolomic analysis and the human metablomics database 
(HMDB) was used for metabolite identification purposes. Different lipid metabolite 
profiles were obtained from each condition studied, and different types of triglycerides 
and cholesterol were obtained from cells pre-treated with ox-LDL only. Various 
overlapping metabolites were identified that were induced in treated and untreated cells. 
Moreover, macrophages pre-treated with ox-LDL induced metabolites that are related to 
atherosclerosis and cardiovascular disease (e.g.7-ketocholesterol). These findings show 
the role of LDL treatment on lipid metabolism profiles in macrophages. Furthermore, 
these metabolites can be use as markers for the activation of macrophage cells and/or for 
the formation of atherosclerotic plaques.
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6.1 Introduction
The assessment of lipid metabolism induced by macrophages pre-treated with ox- 
LDL or n-LDL was one of the important steps for this study. A metabolomic approach 
plays a crucial role in the improvement of our understanding of biological systems and 
the underling mechanisms for several diseases. More importantly, it is also an aid to the 
development of different new therapies and drugs. For these reasons, it was decided to 
investigate the differences between metabolite profiles for three different culture 
conditions: ox-LDL, n-LDL and untreated cells.
6.2 Metabolomics and cardiovascular disease
The use of ‘omics’ technologies have increased our understanding of most 
biological systems and disease mechanisms. Genomics and proteomics define the 
proteins and genes expressed in a cell, whereas metabolomics defines the relationship 
between gene, protein and cell function through metabolome molecules. Researchers 
have focused on all metabolites in a given system but not on single metabolites, because 
it is difficult to connect any pathological condition to any one metabolite (Weckwerth, 
2003).
Many metabolic products and substrates such as sugars, lipids and organic acids, 
are significantly associated with heart diseases (Lewis et al, 2008). The metabolomic 
approach has been employed in cardiovascular research through different types of 
investigation. Several studies have focussed on biomarkers and the mechanism associated 
with statin treatment, others have tested the association between diabetes and heart 
disease and some attempted to understand the molecular mechanisms of whole-organ 
function in health and disease conditions (Glisic et al, 2008; Kola et al, 2008; Zhang et 
al, 2009). Metabolomic analysis has played an important role in the diagnosis of 
cardiovascular diseases because different metabolic components in the pathogenesis of 
CAD have been identified. Two different studies, using different patients, were able to 
distinguish severely diseased from normal coronary arteries using NMR-derived 
metabolic profiles (Grainger et al, 2005; Brindle et al, 2002; Grainger et al, 1995). Sun 
and bis group successfully discovered and profiled, 285 metabolites from murine 
myocardium (Sun et al, 2007). Furthermore, the metabolomic technique has increased
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our ability to discover new metabolites which can then be used as biomarkers for the 
study of atherosclerosis (Leo and Darrow, 2009; Zhang et al, 2009). Adipose tissue has 
been shown to play an important role in the homeostasis of non-esterified fatty acids, and 
the accumulation of this tissue increases the risk of developing metabolic diseases and 
CVD (Summers, 2006, Bays et al, 2008).
Despite this progress in the diagnosis and treatment of CVD using the 
metabolomic method, this area is still growing and requires more attention. In the near 
future, metabolomics is expected to become more widely applied to the study of heart 
diseases. The technique is so powerful that it may be used to clinically control coronary 
artery disease, and may provide a reasonable explanation of the metabolic mechanisms 
underlying the disease (Giovane et al, 2008).
6.3 Lipid metabolomics
The study of lipid metabolism was an important aspect of this project. The 
enhanced uptake of modified LDL by monocytes/macrophage is triggered during the 
formation of atherosclerotic lesions and during plaque formation. The accumulation of 
modified LDL in the cytoplasm of the macrophage is the main pathological feature of this 
disease (Glass and Witztum, 2001; Kharbanda and MacAllister, 2005). Moreover, 
alterations in lipid metabolism are a signature of this disease and the assessment of these 
metabolites will provide fundamental information which may be used to diagnose the 
development of atherosclerosis. Lipids make up the main core of the lipoprotein particle 
(chapter I, section 1.10). The implication of altered lipid metabolism in several diseases 
such as cancer, cardiovascular disease, diabetes and obesity demonstrate the importance 
of studying this molecule (Hu et al, 2009).
Lipidomics is a branch of metabolomics that tests and analyses a systems-based 
study of all lipids within the cell and tissue, especially in cardiovascular diseases. 
Lipidomics provides detailed information about cellular lipidomes and biochemical 
mechanisms of lipid metabolism, lipid-lipid and lipid-protein interactions. A number of 
investigations have focused on lipidomic analysis as a stand-alone ‘omics’ (German et 
al, 2007), and have performed this technique as a single step using mass spectrometry 
alone or linked to HPLC (Han and Gross, 2005b; Han and Gross, 2005a). It is possible
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that the combination of well assessed classical CAD risk factors and these techniques 
may enhance the early prediction of coronary and atherosclerosis events and/or may also 
help in the development of new drug treatments.
6.4 The components of lipids
Lipid molecules contain various classes of components that are soluble in organic 
solvents (e.g. ether, chloroform, acetone and benzene) but are insoluble in water. Each 
lipid molecule is biochemically divided in to two clusters based on its components: The 
ketoacyl and isoprene groups. The ketoacyl group contains saccharolipids, polyketides, 
fatty acyls, glycerolipids, sphingolipids and glycerophospholipids.On the other hand, the 
isoprene group contains only prenol lipids and sterol lipids (Fahy et al, 2005). In 
addition, these lipids consist of other subgroups such as triglycerides (fats) and fatty acids 
(e.g. phospholipids and monoglycerides, tri- and diglycerides) (Michelle et al, 1993). 
The main metabolites of lipids in mammalian bodies are membrane phospholipids, sterols 
and triglycerides.
The classification of lipids in to different subgroups was completed by scientists 
using the lipid library (www.lipidlibrary.co.uk) and lipid maps (Nature; 
http://www.lipidmaps.org) software. According to these databases, the main lipid groups 
are as follows:
• Polyketides have two types of metabolites involved in this lipid 
group;secondary metabolites and natural molecules derived from animal, 
plant, bacterial and fungal cells (Caffrey et al., 2008).
• Glycerophospholipids are also known as phospholipids and play a central role
in cell metabolism and signalling (Farooqui et al., 2000).
• Fatty acids are also known as fatty acyls and are the main components of lipid 
molecules (Fezza et al., 2008).
• Sphingolipids play a role in the development and metabolic mechanisms of
different diseases such as cancer and apoptosis (Morales et al., 2007; Modrak
et al., 2006).
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• Ceramide is a main subset of sphingolipid that is usually responsible for 
disease development and cell death (Ogretmen and Hannun, 2004; Modrak et 
al, 2006; Daum et al, 2009).
Focusing on the lipid complex as an example, high and low abundant molecules 
can be detected by metabolomic analysis. Fatty acids, triglycerides and phospholipids are 
abundant molecules, whereas important regulatory molecules such as eicosanoids, 
derived from arachidonic acid, are found at trace levels (Dettmer et al, 2006).
6.5 Macrophages and lipid metabolism
Several studies have focused on lipid metabolism within foam cells. Lipid Maps 
(lipidomicsgateway by Nature) published a comprehensive dataset of lipid metabolites 
derived from foam cells (www.lipidmaps.org/data/results/foam/foam.html). They utilized 
peritoneal macrophages from wild-type and LDL receptor knockout (LDLR '^^ "^ ) mice to 
achieve their aim. The dataset was completed by MS analysis for triplicate technical and 
biological repeats. The outcome of this investigation is shown in Table 6.1
Table 6.1. Foam cell lipid m etabolites: studied by The Nature Group and presented in 
lipidomicsgateway software (www.lipidmaps.org/data/resuits/foam/foam).
Lipid name Lipid numbers Main class Subclass
Fatty Acids (FA), from culture media Three different FA Eicosanoids [FA03] Other Eicosanoids [FA0300]
Fatty Acids (FA), from cells Three different FA Fatty acids and conjugates 
[FAOl]
Unsaturated fatty acids 
[FA0103]
Sterol lipids (ST) Three different ST Sterols [STOl] Cholysterol [STOl01]
Cholesterol ester (ST) Three different ST Sterol [STOl] Cholesteryl ester [STOl02]
Sphingolipids (SP) Three different SF Ceramides [SF02] N-acysphingosines 
(ceramides) [SF0201]
Glycerophospholipids (OF) Two different OF Not available Not available
Cardiolipins (OF) Three different GF Not available Not available
Frenol lipids (FR) Three different FR Quinones and 
hydroquinones [FR02]
Ubiquinones [FR0201]
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6.6 Metabolomics database searching tools
The necessity to generate and build up a metabolomic database is a consequence 
of the need to identify and detect different and new metabolites. In the plant kingdom, 
around 200,000 metabolites have been reported (Weckwerth, 2003) and 2,000 main 
metabolites have been identified in humans (Beecher, 2003). Within the mammalian 
species cellular metabolic pathways are extremely highly conserved, demonstrating their 
essential nature. Several metabolomic databases are available nowadays. Biological 
Magnetic Resonance Data Bank
(www.bmrb.wisc.edu/metabolomics/extemal_metab_links.html) contains most of these 
databases such as the Fiehn metabolomics database, the human database (HMDB) and 
the Madison Metabolomics Consortium Database (MMCD). This website offers 
researchers all metabolomic data that have been generated from NMR and MS studies. 
Some websites focus in particular on NMR data (www.liu.se/hu/mdFmain/) and others, 
such as HMDB, are a mixture of MS and NMR studies (http://www.hmdb.ca/).
The HMDB (http://www.hmdb.ca/) includes more than 2180 endogenous 
metabolites that have been collected from different research sources. More than a 
hundred publications and electronic databases have been by this software to populate the 
database, as well as the results from the investigation by the Human Metabolome Project 
(HMP) in 2004, which looked at human metabolites from different body fluids (Wishart 
et al, 2007). This database can be used to identify human, mouse and rat metabolites that 
rely on the same basic metabolic pathways. HMDB is normally updated every two 
months and around 100 new molecules are added per update. This indicates how 
powerful and current this database is.
6.7 Aims and objectives
6.7.1 Aims
To identify metabolite profiles for macrophages pre-treated with ox-LDL and n-LDL
6.7.2 Objectives
• To rupture cell membranes using different lysis reagents
• To analyse and identify metabolites using LC/MS and the HMDB
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6.8 Materials and Methods
6.8.1 Cell culture
J774.2 mouse macrophages (-2x10^ cells/ml ) were cultured in twelve well plates 
(Nunclon^™  ^delta surface) with 2ml serum-free medium (HyQ® ADCF-MAb™ without 
L-glutamine; Gibco-Invitrogen, UK) containing 5ml PSG [lOOu/ml penicillin; lOOpg/ml 
streptomycin; 2mM glutamine]. Cells were maintained at 37°C in a 5% CO2 atmosphere. 
After 24h incubation, SOpg/ml of n-LDL and ox-LDL were added and incubated for a 
further 72h. Cells were collected by scraping (Fisher Scientific) and centrifugation at 
400xg for 5min. Pellets were immediately ‘snap’ frozen in liquid nitrogen for 10 min and 
then stored at -80°C for LC/MS analysis.
6.8.2 Sample preparation
Cells were thawed and then cell membranes ruptured for LC/MS analysis. Three 
different methods were tested to assess the best outcome:
1. Acetonitrile (1ml) was added to cell pellets and sonicated (KERRY, model NO. 
PUL 55, volts: 20/240) for lOmin and then dried for 45min using an oxygen 
pump. Samples were reconstituted in 1ml Millipore water, to wash all cell 
membranes, and vortexed for 5min. Cells were centrifuged at 400xg for 5min and 
the supernatants discarded. Samples were again reconstituted in 1ml Millipore 
water and vortexed for 5 min. Each sample (200pl) was placed into polyproplyn 
vials (Phenomenex ®) and then analysed by LC-MS system.
2. Saponin buffer (1ml of a 3% solution) was added to each cell pellet and vortexed 
for 5min. Cells were centrifuged at 400xg for 5min, and cell pellets were 
reconstituted in 1ml Millipore water. 200pl of each sample was placed into 
polyproplyn vials (Phenomenex ®) and then analysed by LC-MS system.
Millipore water (1ml) was added to each cell pellet, vortexed for 5min and then 
sonicated for lOmin. Samples were centrifuged at 400xg for 5min and pellets 
reconstituted in 1ml Millipore water. Each sample (200pl) was placed into 
polyproplyn vials (Phenomenex ®) and then analysed by LC-MS system.
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6.9 Metabolomics system conditions and database
The UltiMate 3000 Intelligent LC/MS System (Dionex, USA) was connected to 
ACQUITY UPLC™ BEH columns. BEH columns were used for metabolomics analysis 
(as described in section 2.7). An injection volume of 5pi was used on a Cig BEH column 
at 40°C, while sample temperature was kept at 4°C. Both positive and negative modes 
were assessed with a lOmin run for each sample. Sample separation was achieved by 
gradient elution of two solvents of mobile phase:
A) (100% water + 0.1%FA) B) (100% ACN + 0.1 %FA)
The chromatographic profile used in the run was as follows: Initial conditions of 
100% solvent A, Linear gradient 0-0.5min (100% solvent A), Linear gradient 0.5 - 9mins 
(from 100% solvent A to 100% solvent B) and then back to 100% solvent A maintained 
for Imin for reconditioning
6.10 Data analysis
Metabolite peaks were captured and detected using Masslynx software (Ver 4.1, 
Waters, UK), and the presence of peaks in chromatogram analysis are presented in the 
main datasheet (Table 6.2). The presence of each metabolite (corresponding to their MW) 
in the main datasheet was compared manually for the three conditions. MS/MS analysis 
was completed to determine the differences between metabolites of interest in each 
sample. The HMDB was used (www.hmdb.ca. Version 2.0) to identify and distinguish 
metabolites.
190
6.11 Results
The assessment of protein patterns from three different culture conditions of 
J774.2 cells was completed in chapter four. Cells treated with ox-LDL expressed the 
highest number of proteins and peptides compared to n-LDL treated and untreated culture 
conditions. This altered protein expression pattern may be the result of different 
metabolism inside the cells, induced by treatment. In particular, different lipid 
metabolism may occur within the three culture conditions.
To assess and study these possibilities, metabolomics analysis was performed and 
presented in this chapter to form preliminary results for future evaluation. The 
metabolomics work was divided into three stages:
• The evaluation of cell rupture methods
• LC/MS and metabolite analysis
• Human metabolmics database and metabolite identification.
6.11.1. The evaluation of cell disruption methods
The process for releasing biological molecules from inside a cell is called cell 
rupture or the cell disruption method. Cell disruption is necessary to identify metabolite 
profiles (especially those based on lipid and cholesterol) under different culture 
conditions. Cell viability can be easily determined using Trypan blue stain, which is the 
method used herein to evaluate each cell disruption method. The membrane of living 
cells is semi-permeable in nature and shows negative stain with Trypan dye, while dead 
cells present a positive blue stain. In this study, LC/MS analysis was also used to evaluate 
cell disruption methods for consistency when comparing the main findings of each 
condition under investigation.
The first method for cell rupture using acetonitrile and sonication (section 6.8.2) 
failed to fully rupture the cells. No noticeable differences were seen between untreated 
cells, treated cells (ox-LDL) and MDME medium in chromatogram and spectrum 
analysis Figure 6.1, whereas they were when other methods were used. This indicates that 
acetonitrile and sonication is not a suitable method to achieve cell rupture. 
Chromatogram analyses for three different samples produced almost the same pattern 
(Figure 6.1A). Treated and untreated cells presented the same pattern and peaks (581, 186
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and 263) as culture medium Figure 6. IB. Although there is one peak expressed only in 
the ox-LDL treated condition (392) (Figure 6.IB), this differenee is not sufficient to 
justify the use of acetonitrile for cell rupture. More importantly, MDME medium showed 
a high background in chromatogram analysis which may interfere with cell 
metabolomics.
Cell extract after treatm ent for Sam a 
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t r e a t e d _ p o s 1 :T O F M S E S +
A. ox-LDL
1 :T O F M S E S +c o n t r o l j i o s
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9.506 .5 0 7.00 7.50 8.50 9.000.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 5.50 6.00 8.00
m e d i a j x j s 1 T O F M S E S +  
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C. Culture medium
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Figure 6.1 A. Chromatogram produced using acetonitrile and sonication to rupture cells.
J 7 7 4 .2  c e l ls  w e re  cultured in MDME m edium  for 2 4 h and  th en  trea ted  with SOpg/m l ox-LDL  
(sec tio n  6 .8 .1 ) . Cell p e lle ts  w e re  reconstitu ted  in 1ml aceton itrile  and  then  so n ic a te d  (se c t io n  
6 .8 .2 ) . 2 0 0 p l o f e a c h  sa m p le  w e r e  u se d  to perform  LC/M S a n a ly s is  (n=2). T h e  pattern for 
m edium  a lo n e  (C) is m ore or l e s s  th e  s a m e  a s  in p an el A  (treated  c e lls )  and  B (un treated  c e lls )  
with s o m e  d ifferen ces  in p ea k  d e n s it ie s . T h e Y a x is  s h o w s  th e  relative intensity in p e r c e n ta g e  and  
th e  X a x is  is th e  tim e o f a n a ly s is  in m ins.
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Figure 6.1 B. Spectrum analysis for the chromatogram in Figure 6.1 A. M S a n a ly s is  r e v e a ls  
th e  sim ilarities o f  m e ta b o lite s  in th e  th ree  s a m p le s . C e lls  trea ted  with ox-LDL (A) sh o w  p e a k s  
(5 8 1 , 18 6  an d  2 6 3 )  o b ta in ed  by un treated  c e lls  (B) and  by m ed ium  sa m p le  a lso  (C). O n e  p e a k  is 
p r e se n ted  by ox-LDL only (3 9 2 ) sh o w n  in th e  red circle. A x is Y s h o w s  relative in tensity  p r e se n te d  
a s  a p e r c e n ta g e  and  th e  X a x is  s h o w s  th e  m a s s  to c h a r g e  ratio (m /z).
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Selection of the most appropriate cell disruption method was a challenge in this 
work because the main aim at this stage was to identify the correct metabolites expressed 
by each condition without any non-specific effects from the cell rupture method itself. 
Further attempts at cell rupture were carried out using 3% saponin buffer and Millipore 
water respectively. In these experiments MDME medium was replaced with serum-free 
medium in all culture conditions. The purity o f rupture solutions was evaluated by 
LC/MS as shown in Figure 6.2A. The purity o f Millipore water was higher than the 
saponin buffer, and the purity o f serum-free medium is almost the same as Millipore 
water Figure 6.2B.
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Figure 6.2A. Evaluation of the purity of water, saponin and serum-free medium. S a m p le s  
(1 0 0 p l) w e re  p la ced  into polyproplyn v ia ls and  a n a ly se d  by LC/M S (n= 2). T h e  h ig h e st  b ack grou n d  
w a s  prod u ced  by sa p o n in  (A). Millipore w a ter  (0 )  an d  seru m -free  m edium  (B) p rod u ced  high  
purity with l e s s  b ackgroun d  in ch rom atogram  a n a ly s is .
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Figure 6.2B. Spectrum analysis for the chromatogram in Figure 6.2A. Millipore w a ter  
prod u ced  a higher quality o f  sp ectru m  a n a ly s is  co m p a red  to  sa p o n in . A xis Y s h o w s  th e  relative  
intensity  p r e se n ted  by p e r c e n ta g e  and th e  X a x is  s h o w s  m a s s  to c h a r g e  ratio (m /z).
To evaluate the suitability of saponin and water as cell rupture methods, cell 
pellets were reconstituted in 1ml water (section 6.8.2). Two different culture conditions 
(ox-LDL treatment and untreated) were used. Millipore water and sonication revealed a 
better quality of chromatogram and spectrum analysis for both treated and untreated 
conditions (Figure 6.3A and B). The appearance of peak 496 and 524 in cells treated with 
ox-LDL and disrupted using saponin and water methods, that are absent in untreated 
cells, confirmed the ability of both methods for cell rupture purposes. Despite this.
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saponin showed a poor quality of chromatogram (Figure 6.3A) and spectrum analysis 
(Figure 6.3B). Based on this finding, Millipore water and sonication proved to be the 
most suitable and appropriate system to achieve cell rupture in the present study.
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Figure 6.3A. A ssessm ent of the effects of saponin and water on cell rupture. J 7 7 4 .2  c e l ls  
w e r e  cultured in seru m -free  m edium  for 2 4 h  and  th en  trea ted  with 8 0 p g /m l ox-LDL (se c t io n  
6 .8 .1 ) . Cell p e lle ts  w e re  recon stitu ted  in 1ml Millipore w a ter  and  th en  so n ic a te d  (se c t io n  6 .8 .2 ) .  
2 0 0 p l o f e a c h  sa m p le  w a s  u se d  for LC/M S a n a ly s is  (n= 2). S a p o n in  buffer (p a n e ls  A and  C) 
sh o w e d  h ig h est  backgroun d in th e  a n a ly s is . Millipore w a ter  (p a n el B and  D) p rod u ced  a c lea rer  
chrom atogram  for both trea ted  and  un treated  co n d itio n s . P e a k s  4 9 6  and  5 2 4  w e r e  d e te c te d  in 
trea ted  c e lls  only (circled in red).
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Figure 6.3B. Spectrum analysis for the chromatogram in Figure 6.3A. T h e d iffe r e n c e s  
b e tw e e n  trea ted  and  un treated  sp ectru m  pattern s is o b v io u s:p e a k s  4 9 6 , 5 2 4  an d  4 0 1 , c ircled  in 
red in p an el A are m issin g  in p a n el B. T h is sh o w s  th e  s u c c e s s  o f u sin g  w a ter  a s  a  cell rupture  
m eth od . A xis Y s h o w s  th e  relative intensity  p r e se n te d  by p e r c e n ta g e  and  th e  X a x is  s h o w s  th e  
m a s s  to c h a r g e  ratio (m /z).
197
6.11.2 LC/MS and metabolite analysis
The investigation of lipid metabolism in three different culture conditions was 
completed using a LC/MS/MS system. Cells were cultured in serum-free medium and 
incubated for 24h, before treating with 80pg/ml of n-LDL or ox-LDL and incubating for 
72h (section 6.8.1). Millipore water was used as the cell rupture method as described in 
section 6.8.2.
Chromatogram analysis shows the complete metabolite pattern for each condition 
including untreated cells and blank samples (media and water) (Figures 6.4 A and B). 
Each condition was reanalysed three times, as technical repeats, to test the reliability of 
the analysis method, and two of these repeats are presented in Figure 6.4A. The third 
injection is presented in Figure 6.4B. The results obtained from these technical repeats 
are comparable, showing that the technique is reliable and robust. It can be seen that 
untreated conditions produce a different metabolite pattern compared to both LDL 
treatments. Some peaks are expressed by both treatments (n-LDL and ox-LDL), such as 
peaks 496 and 524, but the intensity of these peaks is higher with ox-LDL than with n- 
LDL, suggesting that they are produced in greater quantity. In addition, each condition 
expresses different metabolites that are absent in the other conditions. For example, peaks 
401 and 703 are produced by ox-LDL (red arrows), and peak 760 (blue arrow) is 
expressed in n-LDL treated cells at two different time points of analysis (at 9 and 9.50 
min).
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Figure 6.4A. Chromatogram analysis for three culture conditions (first and second  
injections). J 7 7 4 .2  c e lls  w e re  cultured in seru m -free  m ed ium  for 2 4 h  and  th en  trea ted  with  
80 |jg /m l o f ox-LDL or n-LDL (sec tio n  6 .8 .1 ) . C e lls  w e r e  ruptured u sin g  M illipore w a ter  and  
son ica tio n  (sec tio n  6 .8 .2 ) . 2 0 0 p l o f e a c h  sa m p le  w a s  u se d  for LC/M S a n a ly sis . T w o se p a r a te  
tech n ica l in jections w e r e  perform ed, 5pl o f sa m p le  for e a c h  injection. P a n e l A, B an d  C 
r ep re se n ts  first injection, pan el D and E th e  s e c o n d  injection. R ed  c irc le s  indicte th e  s a m e  p e a k s  
p r e se n ted  in n-LDL and  ox-LDL con d ition s, and  red (ox-LDL) and  b lue (n-LDL) arrow s s h o w  
different p e a k s  in both trea tm en ts.
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Figure 6.4B. Chromatogram analysis for three culture conditions (third injection). J 7 7 4 .2  
c e lls  w e re  cultured in seru m -free  m edium  for 2 4 h and  th en  trea ted  with SOpg/ml o f ox-LD L or n- 
LDL (se c tio n  6 .8 .1 ) . C e lls  w e re  ruptured u sin g  M illipore w a ter  and  so n ica tio n  (se c t io n  6 .8 .2 ) .  
2 0 0 p l o f e a c h  sa m p le  w a s  u se d  for LC/M S a n a ly s is . T h e third in jections for n-LDL an d  ox-LDL  
co n d itio n s are rep re se n te d  in p a n e ls  A and  B. P a n e l D and  E sh o w  blank sa m p le  a n a ly s is . R ed  
circ les  ind icate  p e a k s  p r e se n ted  in both n-LDL and  ox-LDL co n d ition s, and red (ox-LDL) an d  b lu e  
(n-LDL) arrow s sh o w  different p e a k s  in both trea tm en ts.
In the MS spectrum analysis o f the chromatogram presented in figure 6.4, clear, 
sharp spectrum peaks at 496 and 524 are indentified in the ox-LDL condition and not in 
the n-LDL condition (Figure 6.5). In addition, a peak at 760 (panel B) is detected in the 
n-LDL condition but not in the ox-LDL condition.
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Figure 6.5A. Spectrum pattern for the chromatogram analysis in Figure 6.4. C lear, sh a rp  
p e a k s  identified in th e  ch rom atogram  resulting from trea tm en t with n-LDL and  ox-LDL w e r e  
d e te c te d  by M S a n a ly s is  in th e  ox-LDL condition  only (p e a k s  4 9 6  and  5 2 4 ) p a n e l A (circled  in 
red). R ed  arrow s ind icate  m eta b o lite s  that are  e x p r e s s e d  in th e  ox-LDL cond ition  but not in in th e  
n-LDL condition . B lue arrow s ind icate  a p e a k  7 6 0  (p a n el B) that is not d e te c te d  in ox-LDL and  
u n treated  co n d ition s. Thr untreated  sa m p le  (C) provided a different sp ectru m  pattern to  trea ted  
c e lls . T h e  Y a x is  s h o w s  th e  relative intensity  p r e se n ted  a s  a  p e r c e n ta g e  and  th e  X a x is  s h o w s  
m a s s  to c h a r g e  ratio (m /z).
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To focus more on the metabolism of ox-LDL within macrophage cells, MS and 
MS/MS analysis were carried out to specify the major metabolite peaks after treatment 
with ox-LDL. Figure 6.5B shows the first MS analysis for peaks 401, 524 and 496 that 
are expressed by foam cells. The second MS analyses (tandem MS) for the same peaks 
are illustrated in Figures 6.6 A, B and C. Tandem MS identified the parent analyte 
(eircled in red) and the daughter ions (circled in green) for all speeies analysed. The 
detection of these parent and daughter metabolites will be presented in the next section of 
the results.
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Figure 6.5B. MS analysis for peaks 496, 524 and 401 from Figure 6.5A expressed by the ox- 
LDL culture condition. H um an M etab olom ic  D a ta b a se  (HM DB) w a s  u s e d  to identify p e a k s  5 2 4 ,  
4 9 6  and  4 0 1 . T h e  Y a x is  s h o w s  th e  relative intensity  p r e se n te d  a s  a  p e r c e n ta g e  and  th e  X a x is  
sh o w s  th e  m a s s  to ch a r g e  ratio (m /z).
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th e  g r ee n  circle s h o w s  th e  d a u g h ter  ion. T h e  Y a x is  s h o w s  th e  relative in tensity  p r e se n te d  a s  a  
p e r c e n ta g e  and  th e  X a x is  s h o w s  th e  n m a s s  to c h a r g e  ratio (m /z).
203
I d .m
w
SB5G
>0506
msæ80D800 700 75] 8304D 45] 900 55]200 253 330 35)
Figure 6.6B. MS/MS analysis for peak 524. T h e red circle in d ic a tes  th e  parent m eta b o lite  and  
th e  g r ee n  circle s h o w s  th e  d a u g h ter  ion. T h e  Y a x is  s h o w s  th e  relative intensity  p r e se n te d  a s  a 
p e r c e n ta g e  and th e  X a x is  s h o w s  th e  m a s s  to c h a r g e  ratio (m /z).
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6.11.3 The identification of lipid metabolites and The Human Metablomics 
Database (HMDB)
Detection of lipid metabolites from previous experiments was the biggest 
challenge due to the lack of available data in the mouse metabolomics database and the 
fact that J774.2 cells are a mouse macrophage cell line. No mouse metabolomics database 
was found to enable this aim to be completed. Therefore as an alternative, the Human 
metabolomics database was used, since it was found to be the most suitable and powerful 
database with which to identify mouse metabolites.
The Human Metabolomics Database (http://www.hmdb.ca/) is a powerful and 
fundamental source for all human metabolites and can also be applied to mouse 
metabolomic analysis. This is because the basis of the mammalian metabolic system is 
almost the same across multiple species and several previous studies have shown the
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similarity between human and mouse metabolism. Pennacchio and his colleagues 
reported that mice express the same apolipoprotein gene (APOAV) as humans, which is 
implicated in coronary artery disease (Pennacchio et al, 2001). These results show that 
APOAV is an essential factor determining plasma triglyceride levels, which is a major 
risk factor for coronary artery disease. In addition, the identification of an iron-regulated 
protein involved in intracellular iron metabolism has been found in both human and 
mouse metabolic systems (Abboud and Haile, 2000). Even within cancer research, 
scientists have found that carcinogenesis in humans and mice are similar (Balmain and 
Harris, 2000), suggesting that it is suitable to use a human database for identification of 
mouse metabolites. Other investigations have also reported similarities between specific 
metabolites in humans and mice such as the metabolites produced by deoxynucleoside 
phosphorylating enzymes involved in reseveratrol metabolism (Habteyesus et al, 1991; 
Yu et al, 2002). Though, proteins in mammalian metabolic pathways may often have the 
same function, they may display different affinities for their substrates, explaining 
observed differences in metabolic activity (Habteyesus et al, 1991).
The main datasheet of MS/MS analysis obtained from Figures 6.5 and 6.6 
isshown in Table 6.2. This datasheet summarises all spectrum MS peaks obtained by the 
main parent peaks in the chromatogram analysis. Numbers on the left indicate the 
molecular weights in Daltons (Da), red numbers show metabolites that are only expressed 
after ox-LDL treatment, blue numbers indicate metabolites expressed only after n-LDL 
treatment while green numbers show metabolites produced by untreated cells. All 
molecules listed in table 6.2 were manually compared to identify the species uniquely 
related to each species. All numbers in black are metabolites that are distributed and 
overlap in all three conditions (e.g. 102, 123 and 111 Da).
206
T a b le  6 .2 . M S/M S a n a ly s i s  d a t a s h e e t .  C oloured  n u m b ers in th e  m o lecu la r  w e ig h t (MW) co lu m n  
(red , b lu e and  g r ee n ) point to  m e ta b o lite s  that a re  e x p r e s s e d  by o n e  condition  (ox-LDL, n-LDL, 
un treated  r esp ectiv e ly ) but no in th e  o th er  co n d itio n s . All b lack  n u m b ers s h o w  overlap p in g  
m eta b o lite s .
Ox-LDL 
MW (Da) Ion count MW (Da)
n-LDL
Ion count MW (Da)
Control
Ion count
102.0269 2.800e4 102.0267 2.70464 102.0268 2.63564
107.9574 2.07164 111.9799 3.76764 169.9772 3.49164
111.9798 3.70904 113.9629 1.99965 174.9556 2.47664
113.9628 1.956e5 115.9624 2.65364 177.1107 2.62464
115.9622 2.600e4 186.9565 2.95164 178.1331 1.34165
118.0745 2.08364 327.2010 3.00664 182.9844 2.34464
120.0793 8.34264 367.3355 3.00064 184.0728 5.73864
158.9639 5.47864 369.3525 4.29364 203.0520 7.86064
160.0416 2.14064 371.1020 3.06764 283.1744 2.67764
164.9293 2.23064 383.3304 1.09665 309.2784 2.32264
165.9887 2.07664 384.3345 3.40264 327.2010 2.87164
167.0123 9.03564 522.5980 3.47364 339.2896 2.91064
169.9771 3.27464 550.6266 2.47564 634.6514 2.06365
172.9561 1.97164 575.5039 2.94164 635.6567 9.79264
174.9553 2.60064 577.5194 3.26664 636.6586 2.72864
178.1331 1.39565 603.5375 3.07964 663.4568 8.12864
179.1368 2.16564 607,3928 2.75064 664.4606 3.68364
182.9842 2.29864 608.6361 7.00364 699.5988 7.99064
184.0730 6.09964 609.6390 3.19164 700.6017 3.79364
187.2244 5.99964 634.6520 1.05165 701.5659 2.99764
195.1263 2.04864 635.6564 4.95164 702.5458 3.32664
203.0521 7.16664 663.4558 3.17765 703.5566 2.89964
214.9144 2.17764 664.4601 1.45365 715.5270 2.34964
239.1485 2.08064 665.4632 4.03964 717.5466 2.74964
283.1748 2.88164 699.5984 8.30864 718.5736 1.18765
371.2278 2.29164 700.6027 3.91264 733.5863 2.38864
383.3310 9.12564 701.5714 3.07064 734.5905 2.30464
384.3352 2.83264 702.5483 2.78664 740.5561 2.46864
401.3410 3.92964 717.5443 2.41764 744.5936 4.75464
445.1215 2.06164 718.5605 2.42064 745.6014 2.64264
496.3392 1.09065 721.5826 6.33864 746.6062 3.11565
497.3445 3.22964 731.6064 3.29564 747.6117 1.44165
518.3239 2.50964 732.5958 4.59664 761.5961 7.44464
524.3716 1.19665 747.6130 1.04165 768.5894 1.07065
525.3732 3.70364 748.6156 3.20764 769.5930 4.38464
546.3548 3.08164 759.6387 2.44764 770.6027 2.48964
549.4858 2.01964 760.5912 3.06065 772.6244 1.20865
575.5051 3.94264 761.5952 1.46865 773.6306 6.90064
663.4568 5.17664 762.6009 4.20464 774.6353 6.19064
664.4608 2.33364 768.5909 5.16864 782.5683 4.01064
682.6373 2.96664 772.6267 8.94264 784.5738 2.50664
699.5984 8.25064 773.6314 5.31764 785.6445 2.72264
700.6036 3.94564 774.6389 7.68964 786.6093 1.03665
703.5745 1.01365 775.6441 3.14664 787.6176 5.10964
704.5781 4.63764 782.5697 8.47064 788.6221 4.75264
207
705 .5808 2 .865e4 783.5731 3 .80164 794.6151 7 .64064
717.5525 2.13804 785.6558 3 .02664 795.6171 3.14364
789.6371 4 .2 4 2 e4 786.6085 1.54465 796.6204 3 .03464
799.6624 2 .304e4 787.6231 9 .03964 808 .5795 2 .68864
800.6683 2 .925e4 788.6239 1.07765 810 .5932 3 .94664
810.5989 2 .2 39e4 789 .6310 4 .28664 812.6246 2 .25364
815.6981 5 .62764
To confirm the detection (name and structure) of the metabolites identified using 
the HMDB, the search was repeated using other resources, for example, the Biological 
Magnetic Resonance Data Bank (BMDB;
www.bmrb.wisc.edu/metabolomics/extemal_metab_links.html), which provide same 
finding.
Table 6.3 demonstrates the identification of all metabolites indentified from 
J774.2 cells treated with ox-LDL that were not detected as a result of other treatments. 
Under ox-LDL conditions, 25 metabolites were identified as indicated in the HMDB 
database. n-LDL treated cells yielded the identification of fewer peaks corresponding to 7 
different metabolites (Table 6.4).
Table 6.3. The Identification of unique metabolites expressed by ox-LDL treated cells.
Human Metabolomics DataBase, Version 1.0 and 2.0 (http://www.hmdb.ca/).
Metabolites 
molecular 
weight 
(MW) Da
Metabolite identification HMDB ID
496.34 Triglycerides (TGs) HMDB 10541
383.33
• 5a-Cholesta-8,24-dien-3-one is an intermediate in the 
cholesterol synthesis pathway
• Cholesta-4,6-dien-3 -one is a produet of the oxidation of 
eholesterol C2 7H4 2O
HMDB01093
HMDB02394
525.38 
instead of 
525.37
TG(22:5(7Z,10Z,13Z) Triglycerides C69H102O6 HMDB 10554
384.33 (R)-3-Hydroxy-Octadecanoie acid, In humans fatty acids CisHseOa HMDB 10737
160.04 N-Acetylgalactosamine 4-sulphate CgHieNOgS HMDB02817
118.07 N-a-Acetyleitrulline CgHisNgO^ HMDB00856
107.9 [Cu]2+ Copper, The catalytic activity of copper is used by the enzymes that it is associated with
HMDB00657
195.12 • Dihydropteridine C6H6N4• 2,3-Dihydroxyvaleric acid C5H1 0O4
HMDB01441
HMDB00421
179.13 Nandrolone is a CIS steroid with androgenic C1 8H2 6O2 HMDB02725
165.9 Sareosine is a natural amino acid found in muscles and other body tissues C3H7NO2
HMDB00271
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172.9 Malic acid is a tart-tasting organic dicarboxylic acid C^HgOg HMDB00744
239.14 PA is a phosphatidic acid. It is a glycerophospholipid CsgHggOgP HMDB00674
214.9144 Dodecanoic acid is the main fatty aeid in coconut oil C1 2H2 4O2 HMDB00638
401.34
7-Ketocholesterol is a major oxidation product of cholesterol 
found in human atherosclerotic plaque and is more atherogenic 
than cholesterol in some animal studies C2 7H4 4O2
• 7a-Hydroxy-eholestene-3-one: 7a-Hydroxy-cholestene-3-one
• CerP is a eeramide 1-phosphate belonging to the sphingolipid
• DG (22:l(13Z)/24:0/0:0) is a diglyceride
HMDB00501 
HMDB01993 
HMDB 10707 
HMDB07644
497.34 TG is a didocosahexaenoic acid triglyceride CoHggOg HMDB 10555
518.32 • LysoPC is a lysophospholipid (LyP). C2 6H4 8NO7P HMDB 10388 HMDB06710
524.37 • LysoPC [C2 6H5 4NO7P]• TG C6 7H1 0 2O6
HMDB 103 84 
HMDB 10550
546.35 LysoPC is a lysophospholipid (LyP) C2 8H5 2NO7P
546.35 Ganglioside GA2 is a glycosphingolipid (eeramide and oligosaccharide) C5 0H9 2N2O1 8
HMDB04888
549.44 DG (15:0/14:0) is a diglyceride consisting of two fatty aeid C3 2H6 2O5 HMDB07066
704.57
Dodeeanoyleamitine is present in fatty acid oxidation disorders 
C1 9H3 7NO4
• DG(20:5(5Z,8Z,11Z,14Z,17Z) C4 5H6 6O5
HMDB02250
HMDB07585
705.58 DG is a diglyeeride, or a diacylglycerol (DAG) C4 2H8 2O5 HMDB07793
682.63 DG is a diglyceride, or a diacylglycerol (DAG) C4 2H8 0O5 HMDB07094
799.66
• PC is a phosphatidylcholine (PC or GPCho). C44H88N06P
• CerP is a eeramide 1-phosphate belonging to the sphingolipid 
class of molecules C44H88N06P
HMDB 11266 
HMDB 10706
800.67 • PC(22:l(13Z)/dml6:0) is a phosphatidylcholine C4 6H9 0NO7P HMDB11314
Table 6.4. The identification of unique metabolites expressed by n-LDL treated cells.
H um an M eta b o lo m ics D a ta B a se , V ersion  1 .0  an d  2 .0  (h ttp ://w w w .h m d b .ca /).
Metabolites 
molecular 
weight 
(MW) Da
Metabolite identification HMDB ID
575.50 Stéaraldéhyde or oetadecanal is a normal long chain fatty aldehyde that can be found in total lipid extracts of muscle tissue C18H360
HMDB02384
522.59 CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z) is a cardiolipin (CL) C8sHi4 4 0 ,7P2 HMDB 10299
550.68 instead 
of 550.62
Eieosanoyl-CoA is an intermediate metabolite in the synthesis of 
phosphatidic acid C4 1H7 4N7O1 7P3S
HMDB04258
607.39 (3R,3'R,6'R,9'-cis)-Carotene-3,3'-diol is a carotenoid found in human fluids C4 0H5 6O2
HMDB02950
665.48 instead 
of 665.46
• DG (14:0/20:5(5Z,8Z,llZ,14Z,17Z)/0:0) C37H6205
• PE (14:1(9Z)) is a phosphatidylethanolamine C3 4H6 6NO8P
HMDB07027
HMDB08856
762.60 • DG (22:5(7Z,10Z,13Z,16Z,19Z)/20:0/0:0) C45H7805• PC (20:0/14:0) is a phosphatidylcholine C4 2H8 4NO8P
HMDB07745
HMDB08262
783.57 • MG (20:3 (8 Z, 11Z, 14Z) is a monoacyIglyeeride C2 3H4 0O4• DG(24:0/18:l(9Z)/0:0)) C45H8605
HMDB 11577 
HMDB07798
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Untreated cells produced a different pattern of metabolites compared to treated 
cells. The metabolites produced by untreated cells but not from other conditions are listed 
in Table 6.5. Fifteen different metabolites were induced by untreated cells, which is a 
higher number compared to the nLDL treated cells.
Table 6.5. The Identification of metabolites expressed by untreated cells. U sin g  H um an  
M eta b o lo m ics D a ta B a se , V ersio n  1 .0  an d  2 .0  (h ttp ://w w w .hm db .ca /).
Metabolites 
molecular 
weight 
(MW) Da
Metabolite identification HMDB ID
177.11
• Isobutyric acid is a carboxylic or short chain fatty acid
• Levulinic acid is a crystalline keto CgHgOa
HMDB01873
HMDB00720
309.27
• Eieosadienoie aeid is an omega 6  fatty aeid found in 
human milk (PMID: 15256803) CzoHggOz
• Geraniol, also called rhodinol, is a monoterpenoid and 
an alcohol CioHigO
HMDB05060
HMDB05812
715.52 DG(22:5(4Z,7Z,10Z,13Z,16Z)/18:0/0:0) C4 3H7 4O5 HMDB07709
636.65 Tridemorph is a fungicide their trade name Calixin C1 9H3 9NO HMDB01334
740.55 • PC(P-18:0/14:0) is a phosphatidyleholine (PC or GPCho) C40H80N07P
HMDB 1123 6
744.59 PC (18:l(9Z)/dml6:0) is a phosphatidylcholine C42H82N07P HMDB08126
769.59 PE (dml6:0/dm) is a phosphatidylethanolamine C39H76N06P HMDB 11367
770.60 PC (18:2(9Z,12Z) is a phosphatidylcholine C44H84N07P HMDB08160
745.60
• SM Sphingomyelin is a sphingomyelin is a type of 
sphingolipid found in animal cell C3 9H8 0N2O6P
• DG is a diglyeeride with two fatty acid C4 5H8 6O5
HMDB 10169 
HMDB07798
795.61 PE (dm 18:1 (9Z)/dm 18:1 (9Z)) is a phosphatidylethanolamine (PE or GPEtn) C4iH7gN0 6 P
HMDB 11466
820.64 PC (20:0/16:l(9Z)) is a phosphatidylcholine (PC or GPCho). C4 4H8 6NO8P
HMDB08266
812.62 PE (20:1(11Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn) C41H80NO7P
HMDB09279
785.56 
instead of
784.57
PC (18:0/P-16:0) is a phosphatidylcholine (PC or GPCho) 
C42H84N07P
HMDB08060
925.27 
instead of
925.28
Dihydrofolic aeid is a folie acid Ci9H2iN7 0 6 HMDB01056
926.27 Hexanoyl-CoA is a fatty acid coenzyme A derivative that ean be 
involved in the biosynthesis and oxidation of fatty aeids as well 
as in eeramide formation C2 7H4 6N7O1 7P3S
HMDB02845
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Figure 6.7 shows the number of identified metabolites induced by each condition. 
This figure shows clearly that ox-LDL treatment yields the identification of many more 
metabolites than n-LDL treatment, and that untreated cells produce an intermediate 
number of metabolites. It is important to realise that the metabolomic work conducted in 
this chapter is to be considered as preliminary data only, and is not a rigorous analysis. 
Further analysis will need to be carried out in the future to determine the validity and 
biological relevance of these findings.
25
20 <
i 15 4
10
1/
OX-LDL n-LDL Untreated cells
Figure 6.7. The number of uniquely identified metabolites for each condition. T h e u n treated  
condition  sh o w e d  15 different m eta b o lite s , th e  ox-LDL condition  2 5  and  th e  n-LDL s h o w e d  th e  
lo w e st nu m ber o f m eta b o lite s  (only 7).
21
6.12 Discussion
Lipid metabolism is one of the best studied biological processes with respect to 
cardiovascular disease, and more specifically in relationship to the development of 
atherosclerosis. The discovery of lipids, and molecules related to fatty acids in 
cardiovascular disease and the atherosclerotic plaque made lipids an important agent to 
investigate. The study of metabolite patterns in biological samples is a fundamental way 
to understand and explain the biological systems. Several previous studies have focused 
on lipid metabolism within cardiovascular diseases, especially atherosclerosis (Watson, 
2006; Glisic et al, 2008; Leo et al, 2009). The present study focused on the effect of ox- 
LDL and n-LDL treatments on lipid metabolism in J774.2 cells. This chapter looks at the 
assessment of metabolite profiles in the three culture conditions in order to better 
understand the effect of lipoproteins on macrophage metabolism.
Before attempting to determine these patterns, various experiments were 
undertaken to test different cell rupture methods. Different types of cell disruption 
systems are available these days such as Niro Soavi VHP and the Stansted Fluid Power 
high pressure homogenizing system (Stansted Homogenizer Systems), but these systems 
are not available in our laboratory. In addition, several cell rupture kits are also available 
commercially, but to avoid any interference with the metabolomic results these kits were 
not applied in this study. The aim of the metabolomic study in this chapter was to 
determine and compare the metabolite profiles for each condition in the absence of any 
other effects that may be derived from the kit reagents. Because of this, three different 
cell rupture methods were tested: acetonitrile, Millipore water and saponin buffer with 
sonication. The ability of these three agents to remove and rupture cell membranes was 
almost the same (Figure 6.1-6.3). Peaks 496 and 524 appeared within treated conditions 
and were missing in untreated cells. However, the purity of these agents was completely 
different, and therefore this parameter was used to decide which method was best for cell 
rupture. Acetonitrile with sonication and saponin showed lower purity with high 
chromatogram background compared to Millipore water (Figure 6.1 and 6.2). Millipore 
water with sonication resulted in the highest purity with the least chromatogram 
background. Serum-free media also showed similar purity to Millipore water.
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The next stage in the study was to use the most appropriate cell rupture method, in 
this case Millipore water with sonication, to determine metabolite patterns for n-LDL, ox- 
LDL and untreated conditions followed by identification of these metabolites. 
Chromatogram analysis showed clear, differences between all conditions under 
investigation. The analysis was achieved within lOmin and all different peaks were 
obtained between 6.5 to lOmin. Some metabolites were produced by both culture 
conditions (ox and n-LDL) including 469 and 524 peaks in the chromatogram analysis 
(Figure 6.4). These metabolites may have developed from LDL particles in both 
conditions as normal untreated cells lack these metabolites. Interestingly, these 
metabolites were expressed with high intensity with ox-LDL treatment compared to n- 
LDL treatment in all technical repeats. This may be because of the strong effect of 
oxidation on lipid metabolism. In addition, spectrum analyses of the peaks derived from 
ox-LDLwere detected, while both peaks were missing in the spectrum of the n-LDL 
condition. Using HMDB software, peak 524 was identified as triglyceride (TG) or 
lysophospholipid, and peak 496 was identified as another isoform of TG (Table 6.3). 
These metabolites are possibly processed by the LDL particle with higher intensity after 
ox-LDL treatment but not as a part of normal cell metabolism.
In addition, each condition expressed specific metabolites that were not expressed 
in the other conditions. For example, peaks 401 and 703 were only expressed in the ox- 
LDL treated samples. In the n-LDL treated samples, two different peaks at two different 
analysis times resulted from one metabolite with two isotypes (760.59 and 760.60) 
(Figures 6.4 and 6.5). These differences in metabolism between n-LDL and ox-LDL 
were expected. Different metabolite patterns for these treatments may occur because of 
the chemical differences between native and oxidised LDL. Also, the ability of ox-LDL, 
but not n-LDL to accumulate in macrophage cells may be a factor too (Lougheed et al, 
1991). Although very high eoncentrations of n-LDL can accumulate in macrophage 
cells, these droplets are chemically different from those obtained after ox-LDL treatment 
as published previously (Kruth et al, 2002; Brown et al, 2000), which also suggests that 
different metabolism may occur.
Several overlapping metabolites were expressed by all the three conditions but 
with different intensities and at different analysis times (e.g. peak 139.9 and 203) (Figure
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6.5). These overlapping metabolites are likely to have been developed and processed by 
the main cell metabolic system and were not a result of LDL treatment. Cells normally 
contain lipids and fat which are used for essential cell function, signalling and 
differentiation and are implicated in normal cell metabolism (Feng et al, 2007). 
Moreover, there were several peaks (746,177 and others in Table 6.2) that were present in 
untreated cells only. The absence of these metabolites in treated cells may be due to the 
negative effect of these treatments on cell function. The inhibition or alteration of these 
metabolites by LDL particles may occur, leading to the absence of these metabolites 
following treatment (Figures 6.5 and 6.6).
To conclude, treatment with LDL alters lipid metabolism in the J774.2 cell line. 
Treatment with ox-LDL induces some metabolites that are also expressed after n-LDL 
treatment, but with higher intensities. In addition, ox-LDL treatment resulted in a higher 
number of lipid and fatty acid metabolites (25) compared to n-LDL treatment (7) (Figure 
6.7). Importantly, untreated cells resulted in a higher number of lipid and fatty acid 
metabolites (15) than cells pre-treated with n-LDL. These findings demonstrate that both 
ox- and n-LDL treatments effect cell metabolism and may even degrade or inhibit the 
formation of some metabolites that are normally expressed by untreated cells.
The abundance of TGs within samples derived from ox-LDL treated cells 
suggests that ox-LDL may be the main source of lipid detected metabolites. Four 
different isotypes of TG were detected in ox-LDL samples; peaks 496, 525,524 and 497, 
whereas TG was missing in n-LDL treated and untreated conditions. Diglyeeride (DG), 
also called diacylglycerol (DAG), was identified in all three conditions with different 
isoforms. Five isoforms of DG were expressed after ox-LDL treatment at different 
analysis times (peaks 401, 549, 704, 705 and 682), and three types were found in n-LDL 
treated cells at peaks 665, 762 and 783. However, untreated cells expressed only one type 
of DG at peak 715 and 745. More importantly, lysophospholipids (LysoPC) were 
presented at high levels in ox-LDL treatment but were completely absent in the other two 
other conditions. A phosphatidic acid (PA) metabolite was expressed within ox-LDL 
samples with very low abundance (peak 239) but was absent in the other two conditions. 
This may be because of the large influence of ox-LDL on J774.2 general cell metabolism, 
or may be directly related to atherogenic processes. For instance, the presence of PA and
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LysoPC may indicate the activation of the phospholipase A2 (PLA2) enzyme or 
lipoprotein-associated PLA2 (IP-PLA2) that is implicated with the development of cardiac 
atherosclerosis (Wilensky et al, 2008; Shirai et al, 2000).
Interestingly, cholesterol metabolites were identified only after ox-LDL treatment. 
Peak 401, which showed a major difference in ox-LDL treatment compared with the 
other conditions, resulted from different types of cholesterol such as 7a-Hydroxy- 
cholestene-3-one and 7-Ketocholesterol metabolites (Table 6.3). 7-Ketocholesterol is 
implicated in atherosclerosis plaque formation and has a higher atherogenic effect than 
normal cholesterol (Lyons and Brown, 1999; Brown et al, 2000). The molecule 7a- 
Hydroxy-cholestene-3-one has been also identified in severe atherosclerotic tissue 
(Shibamoto, 1993). An important comment should be highlighted in Table 6.3; the 
identification of copper in peak 107 indicates the presence of a small amount of copper in 
our samples. It is evident that copper has been carried over from the dialysis of ox-LDL 
in PBS using a cellulose membrane (Chapter 2, section 2.3). A 48 hour dialysis period 
may not be sufficient to remove all copper from the sample, and therefore a longer 
dialysis period would be recommended in future preparations of ox-LDL.
The identification of eeramide 1-phosphate (CerP) amongst the metabolites 
derived from ox-LDL treated cells (peaks 401, 799 and 546) provided more evidence for 
for different metabolism mechanisms within ox-LDL treated cells compared to n-LDL 
treated cells and untreated conditions. The involvement of sphingomyelin and eeramide 
in lipoprotein metabolism within atherosclerosis was reported in 2004 (Tabas, 2004). In 
addition sphingomyelin can be use as an independent risk factor for coronary artery 
disease in humans (Jiang et al, 2000).
In summary, the main aim of this chapter to analyze and identify all metabolites 
produced from each treatment condition has been acheived. The secretion of different 
cholesterol isotypes associated with atherosclerosis and coronary disease, specifically 
from cells treated with ox-LDL was observed. This finding has the potential to shed light 
on the different roles of ox-LDL and n-LDL on macrophage metabolism and may help in 
the early detection of coronary artery and atherosclerosis. As mentioned previously, 
future work is required to confirm the findings of this metabolomic study, but the 
preliminary findings offer a promising start.
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Chapter 7: General Discussion and 
Future Work
7.1 General Discussion
Despite the fact that macrophages are the cell type with the most involvement and 
control in atherosclerosis, many aspects of their biology, in relation to immunity and 
inflammation, are still not clear. Thus, in order to understand the disease and its 
pathological mechanisms it is extremely important to understand their exact role. One of 
the key roles of macrophages in general inflammatory responses is the antigen 
presentation process, which triggers T cell immunity. Since T cell responses are specific 
to the type of antigen that is presented, the characterization of the peptide profile that this 
macrophage presents is also important to determine. The work presented in this study 
focused on role of T cell epitopes extracted from the surface of macrophages pre-treated 
with ox-LDL, on immune responses potentially involved in atherosclerosis.
Acid elution methodology was used for the first time herein, to extract MHC class 
I and Il-associated peptides from the surface of macrophages treated with ox-LDL.This 
method extracted novel MHC class I and Il-associated peptide profiles that were 
identified using LC/MS with the intent to further investigate the effect of these peptides 
on some macrophage functions. The results obtained prompted a study to evaluate the 
effect of LDL on cell metabolism. The identification of peptides for their use as 
biomarkers or therapeutics (is a field that has received considerable attention (Robertson 
and Hansson, 2006). For example, some studies have focused on the development of 
vaccines derived from ox-LDL particles or HSP65 (Robertson and Hansson, 2006; 
Habets et al, 2010). The importance of the present study is that for the first time, T cell 
epitopes derived from a range of macrophage-derived proteins potentially involved in the 
stimulation of anti-infiammatoiy responses, and consequently athero-protective immune 
responses, have been identified.
Prior to extracting and identifying peptides, it was necessary to optimize the 
methodology for the identification of MHC-derived peptides from macrophages. The 
isolation of MHC-derived peptides by the acid elution method has been successfully used
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in previous studies for MHC class I- associated peptides, especially in relation to cancer 
diagnosis and/or immunotherapy (Storkus et al, 1993; Torabi-Pour et al, 2001). 
However, this is the first time that this methodology has been used to isolate MHC - 
associated peptides from macrophage cells in the context of atherosclerosis. This study 
successfully identified 135 peptides derived from 100 proteins, of which 22 peptides 
were shown to bind MHC class 1 alleles, 24 to MHC class 11 alleles and 43 were 
promiscuous peptides. Compared to previous results (Storkus et al, 1993), we were able 
to identify a larger number of peptides, which is likely to be the result of the specific 
analysis techniques used in our experimental setting. Most importantly, our study clearly 
showed a differential protein expression profile derived from each culture condition with 
a particularly large number of proteins and peptides derived from ox-LDL-treated cells.
In addition, differential metabolite profiles were also derived from ox-LDL and n- 
LDL conditions, with more lipid metabolites induced by ox-LDL treatment (25 
metabolites) than with n-LDL treatment (7 metabolites). With regards to proteomics, 
some of the proteins identified in our study have been previously reported as being 
involved in macrophage activation (16 proteins) or implicated in the development of 
atherosclerosis and other diseases (13 proteins) such as cancer and asthma (Smart et al, 
2002; Wang et al, 2008). In a similar manner, the metabolomic analysis for macrophages 
showed that treatment with ox-LDL induced four different types of triglycerides, while 
no triglyceride-related compounds were detected from cells treated with n-LDL or from 
untreated cells. In addition, we found that several phospholipid products such as 
lysophospholipid (LysoPC) were induced by ox-LDL treatment. We also identified 7a- 
Hydroxy-cholestene-3-one, 7-ketocholesterol and (eeramide 1-phosphate (CerP); 
components that have been previously reported to be associated with the development of 
atherosclerotic plaques (Shibamoto, 1993; Brown et al, 2000; Jiang et al, 2002; Ichi et 
al, 2006). These compounds were exclusively detected in our study from cells treated 
with ox-LDL, suggesting that only this form of lipoprotein induces such cholesterol 
pathways.
It has been suggested that ox-LDL triggers eeramide induction via the acidic 
sphingomyelinase (ASM) pathway and that these ceramides may play an important role 
in protein phosphatase-dependent signaling pathways, leading to the inhibition of cell
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growth or stimulation of programmed cell death (Grandi et al, 2006). We also found 
from our metabolomic study that ox-LDL treatment stimulated eeramide production, 
whereas other conditions did not. These observations could explain the up-regulation of 
PDl that was seen by flow cytometry analysis of cells treated with ox-LDL. However, 
further studies are needed to confirm this hypothesis.
Activation of J774.2 cells by ox-LDL induced the expression of a differential 
range of proteins including those related to B cell activation, lipid and lipoprotein 
metabolism, and matrix metalloproteinases (MMPs). These results show the direct 
contribution of ox-LDL to immune responses by acting as a pro-inflammatory agent. 
Together with the results obtained from the ORO staining, these protein inductions link 
the pro-inflammatory effect of ox-LDL with its role in foam cell formation. The pro- 
atherogenic effect of ox-LDL was further evaluated by measuring the expression and 
activity of MMPs. Our results confirm previous findings that the synthesis of these 
enzymes is a pathophysiologically relevant index of inflammation and that they play a 
crucial role in plaque rupture (Deguchi et al, 2006; Gough et al, 2006; Morishige et al, 
2003). More importantly, it has been reported that increased levels of MMP-2 expression 
stimulates eeramide production (Bismuth et al, 2008), which could explain and link our 
findings from the metabolomic study with the levels of MMP-2 detected in our proteomic 
study. We identified eeramide within the metabolite profile derived from cells treated 
with ox-LDL, suggesting that ox-LDL stimulated eeramide production via the activation 
of MMP-2 signaling, which then lead to downstream activation of pathways that induced 
PDl expression
Interestingly, we observed an inhibition of MMP-2 expression by treatment of 
cells with n-LDL, compared to the levels observed in both ox-LDL treated cells and 
untreated controls. This effect could be related to anti-inflammatory properties of this 
lipoprotein when used at eertain concentrations and incubation periods in vitro. However, 
the effect of n-LDL on MMP-2 expression has not been previously reported, so this 
theory cannot as yet be substantiated. Further investigation into the effect of n-LDL may 
therefore shed light on some of the physiological mechanisms that occur in vivo that are 
linked to the expression of MMP-2.
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An important and novel part of this study was to assess the effect of apo-BlOO- 
derived peptides (Pepl, 2 and 3) on macrophage functions. A clear pro-inflammatory 
effect of Pepl and Pep3 was seen via the induction of foam cells and the expression of 
surface macrophage markers. Peptide concentration could play a role in cell pathology, 
but this possibility requires further investigation as herein, the peptides were used at a 
single dose, to identify potential immunomodulatory molecules. Three important pro- 
inflammatory markers were assessed in this context: TLR-2, TLR-4 and MHC class II, 
which were all found to be up-regulated by the effect of Pepl and Pep3. Previous studies 
have shown that TLRs are pro-inflammatory molecules expressed by monocyte-derived 
macrophages or other cells such as endothelial cells, to initiate the immune response 
(Satta et al, 2008; Yi-jie et al, 2009; Plowden et al, 2004). We hypothesized that Pepl 
and Pep3 would trigger macrophages to express TLR molecules and that this may be 
associated with the expression of other inflammatory cytokines, including TNF-a, IL-6, 
and IL-8. This hypothesis was founded on previous research that has reported the same 
effect for other compounds in the context of atherosclerosis (Stein et al, 1992; 
Mantovani et al, 2005).
Apo-B 100-derived peptides also have an effect on cells previously exposed to ox- 
LDL, changing their behaviour in relation to ox-LDL induced inflammatoiy response. 
Pepl and Pep2 highly up-regulate the expression of PD-Ll, which is a potential anti­
inflammatory effect. Pepl, Pep 2 and Pep3 also increased the levels of MHC class II and 
CD 14 molecules; markers traditionally associated with pro-inflammatory effects 
(Shashkin et al, 2005). The mechanisms underlying the effect of these peptides are still 
unclear, as markers involved in antagonistic pathways are induced simultaneously. 
However, the role of nuclear factor kappaB (NFkB) signalling in inflammatory pathways 
especially in atherosclerosis has previously been reported (Xanthoulea et al, 2005). This 
mechanism may help to explain the response of macrophages to treatment with these 
peptides. For instance, our findings suggest that up-regulation of PD-Ll, in response to 
these peptides could increase the possibility that maerophages suppress T cells responses 
while blocking Thi immune responses.
Interestingly, Pep3 stimulated both anti- and pro-inflammatory effects on ox-LDL 
conditioned cells by suppressing the expression of TLR-2, TLR-4 and MHC class II, and
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by up-regulating the synthesis of PD-1 on the macrophage surface. The contradictory 
effects of Pep3 on macrophages indicate that this effect may not be sequence specific. 
We suggest that Pepl, 2 and 3 elicit these effects through the activation of different 
immune response pathways depending on the experimental conditions (cell type or 
incubation periods) used. To confirm the exact role and mechanisms of these peptides on 
macrophages, further studies are needed. Nevertheless, these preliminary results have 
raised some interesting theories to be tested in the future. Further work is also needed to 
assess the expression of several cytokines, including TNF-a, IL-6, and IL-10, to identify 
the specific role of each peptide on cytokine release from ox-LDL pre-treated 
macrophages.
Similar experiments were carried out with the peptides, Pep4 and Pep5 that were 
identified in this study using LC/MS analysis. Pep5 stimulated a pro-inflammatory effect 
on macrophages, observed through the increased level of TLR-4 expression and the 
down-regulation of PD-Ll molecules. On the contrary, Pep4 and Pep5 also down- 
regulated the expression of CD 14 molecules, indicating an anti-inflammatory 
mechanism. These findings suggest a complex role for Pep4 and Pep5 in inflammatory 
responses. Nonetheless, these results suggest that Pep4 and Pep5 could be used to 
suppress the effect of LPS (a prototypical inducer) on macrophages due to their 
suppression effect on LPS receptors on the macrophage surface.
In contrast to the above findings, macrophages pre-treated with ox-LDL showed 
different responses to treatment with these two peptides. The expression of TLR-2, TLR- 
4, MHC class II and CD 14 was down-regulated by Pep4 and Pep5 indicating anti­
inflammatory effects. In addition, the expression of PD-Ll was down-regulated by Pep5, 
indicating an opposite pro-inflammatory effect on cells pre-treated with ox-LDL. We 
therefore hypothesize that Pep4 and Pep5 may play an important role in suppressing the 
effect of ox-LDL on macrophages by stimulating the expression of molecules that are 
linked to Th] immune responses, which in the context of atherosclerosis are known to 
inhibit inflammation.
Pep4 is a peptide derived from Profilin 1 protein which has been implicated in 
vascular and atherosclerotic diseases (Bayoumi et al, 2007; Romeo et al, 2007). It has 
been reported that Profilin 1 protein is over expressed in vascular hypertrophy and
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hypertension, and that low levels o f Profilin 1 can protect against atherosclerosis in LDL 
Receptor-Null Mice (Romeo et a l, 2007). Based on this, we hypothesize that Pep4 may 
elicit different effects on macrophages (anti and pro-inflammatory) depending on the 
concentration used. On the other hand, Pep5 is a peptide derived from pulmonary 
surfactant-associated protein D (Sftpd). Sftpd protein has been found to be involved in 
the regulation o f pulmonary macrophage stimulation and air space remodelling (Kingma 
et a l, 2006). These are processes that could relate the effect o f Pep5 as a potential 
modulator o f atheroselerosis in the suppression o f macrophage activation.
Pep4 and Pep5 were chosen to investigate based on the roles o f the parent proteins 
(sftpd and profilin 1 respectively) from which the peptides are derived (section 5.7). We 
speculated that if  the parent proteins had roles in immunomodulation, that the derived 
peptides would also. The findings o f this study support our preliminary assumptions, but 
further investigation is required to determine whether this theory holds true for a wider 
selection o f proteins and related peptides. In essence, the results obtained with these 
peptides are novel, meaning that future validation and deeper investigation into the 
effects o f these peptides is required.
7.2 Conclusion
The present study provided an alternative method to affinity chromatography for 
peptide analysis and was used successfully to extract 135 peptides from macrophage 
surfaces for the first time. The identified peptides may contribute to the field o f 
atherosclerosis treatment or prevention as potential immunomodulatory roles for these 
peptides have been suggested. The findings also related to the effects o f Pep4 and Pep5 
and/or the proteins from which they are derived, to the development o f atherosclerosis, 
which may help to elucidate the disease mechanism.
7.3 Project limitations
Several limitations that were associated with this study are listed below:
1. Two different types o f LC/MS systems were used in this study (at the beginning 
of the research and then at the identification stage), which may have resulted in 
sensitivity differences.
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2. More o f the LC/MS analysis needs to be repeated with respect to peptide 
identification in order to increase the reproducibility o f these results. However, 
this was not possible due to time and funding limitations.
3. It is normally required that more than one type o f metabolomic analysis is 
performed. However, again due to time and funding limitations this was not 
possible. The metabolomics data is only considered as preliminary
7.4 Future work
Suggested directions for future work;
1. For a more detailed picture o f macrophage response to ox-LDL, it is necessary to 
investigate the role o f more o f the predicted peptides and to assess their effects in 
vivo and in vitro. This can be carried out using animal models (e.g. apoE-/- mice) 
and analytical methods such as flow cytometry and ELISA.
2. Confirmation o f the exact roles o f Pep4 and Pep5 on macrophages as pro- or anti­
inflammatory agents should be undertaken, in relation to peptide concentration. 
The formation o f foam cells potentially induced by Pep4 and Pep5 treatment 
should be tested, and the secretion o f pro- and anti-inflammatory cytokines (i.e. 
IL-1, IL-12, IL-10 and INF-y) by macrophages should also be assessed using 
ELISA, flow cytometry or PCR.
3. The metabolite profile derived from cells treated with Pep4 and Pep5 should be 
evalulated using a second database and compared to the profile generated by ox- 
LDL treated cells. This may provide more information to better understand the 
exact role o f these two peptides.
4. Cells should be treated with ox-LDL or Pep4 and Pep5 to induce foam cell 
formation and the contents o f the foam cells analysed to determine differences 
between the treatment conditions.
5. Investigate how different concentrations o f ox-LDL and n-LDL modulate the 
expression levels o f MMPs and regulate the expression o f their natural inhibitors 
(TIMPs).
6. Finally, more rigorous analysis is required to confirm our findings. This analysis 
may include study repetition using more biological repeats for LC/MS detection, 
the use o f principle components analysis to demonstrate the driving factors in the 
metabolomics pathways and the presentation o f loading plots, pattern recognition 
and cluster analysis.
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Appendices
Appendix 1
Proteins a n a ly sis  by: The gene ontology.org (GO) and iHOP. An example for this detection: ox-LDL 
condition (pH3)
This T able con ta ins the protein type, function & organism  a s  p resen ted  in th e se  tw o w e b s ite s . T h e c o d e  for
Protein name The gene ontology.org iHOP
(3oxl). LOC633468 No information similar to H3 histone, family 3B 
protein coding 
Mus musculus
(3ox2). Accession 00:0003677 histone cluster 1, H3c
Histlh3c Ontology molecular function unknown 
Synonyms related: microtubule/chromatin 
interaction
Mus musculus
(3ox3).
Histlhlb!
Prosecc: nucleosome assembly 
Function DNA binding 
Accession 00:0006334 
Ontology biological process 
Synonyms exact: nucleosome modeling
histone cluster 1, H2bl
(3ox4).
Pfnl Profilin-1
Similar information as iHOP Actin binding protein
Function: Binds to actin and affects the structure 
of the cytoskeleton. At high concentrations, 
profil in prevents the polymerization of actin, 
whereas it enhances it at low concentrations. By 
binding to PIP2, it inhibits the formation of IP3 
and DG..
Appendix 2
W ave len g th  
n-LDL
Wave length 
(ox-LDL)
Ox-LDL and n-LDL absorbance. Human p lasm a u sed  to iso la te  LDL using 2ml o f 60%  Optiprep with 8ml 
of p lasm a (12%  Optiprep) (M aterials and M ethods chapter). In B eckm an tube tw o different layers w ere  
prepared: 6  ml of 6% Optiprep and then 5ml of the 12%. S a m p le s  w ere  centrifuged at 2 0 0  OOOxg for 4h at 
16°C, and LDL w a s iso la ted  (oran ge colour). N ano-drop sp ectrop h otom eter  perform ed to m ea su re  the  
a b sorb a n ce . n-LDL sh o w s a clear peak  b etw een  3 0 0 -4 5 0  of w a v e  length, this peak  flattened  after the  
oxidation indicate to the m odification of LDL to ox-LDL .
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Appendix 3
Peptide dilutions from 750-24000ng (standard curve)
^PeptideTwieghtf^^
Volume for peptides 
(Pep2)
Pep2 Volume
1500 1500ng^ 1500ng/ |il= I gl ISOOng 1700ng/ pl= O.SSpl
3000 3000ng ^ 1500ng/ gl= 2pl SOOOng ^ 1700ng/ pl= 1.7 pi
6000 6000ng - ISOOng/ pl= 4 pi 6000ng 1700ng/ pl= 3.S pi
12000 12000ng ^ ISOOng/ pl= 8 pi 12000ng ^ 1700ng/ pl= 7 pi
24000 24000ng^ ISOOng/ pl= 16 pi 24000ng ^ 1700ng/ pl= 14.1 pi
750 750ng ISOOng/ pl= O.S pi 7S0ng 1700ng/ pl= 0.41pl
LC-M S p e p tid e  s ta n d a rd  cu rv e
c\j 600
IP 400
100 150
P e p 2  (ng/ul)
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Appendix 4
C h ro m a to g ra m  a n d  sp e c tru m  a n a ly s is  of c itra te  p h o s p h a te  b u ffer a n d  s e ru m  fre e  m e d ia  a s  n e g a tiv e  con tro l
for LC/M S a n a ly s is .
2 4 - A u g - 2 0 0 7
1. T O F  MS E S I
1
(A) Citrate phosphate
250
82-pos 550 (4.475) Cm (415:553) 1:T0FMSES+
1.83e5.125.9851
(B) Citrate phosphate
167.0139
214.9201 255.9458
416.8448
500 600 700 1000200 300 400100
rofepœ 1 T O E ©
(c) Serum free media
92
730
4GB06
0 g D l Q D ' i æ 2 Q D 2 3 D 3 G D 3 æ 4 ( ï ) 4 3 Û 5 Q D 5 æ e Q D 6 3 D 7 Q D 7 g D 8 a D 8 3 D 9 G D 9 3 D
tD ÆaSB
(D) Serum free media
18KBB
1C0tB
1 1  r - i  I  r  Î 1 1  r  I  p  1 ,  1 1 . ,  I  r ]  I  T i  T I  I Î I I  1 1  Î  t  Î
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